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Clostridium perfringens, a Gram-positive and spore-forming anaerobe, is a significant pathogen 
of both humans and domestic animals.  Among the many toxins produced by this bacterium, the 
C. perfringens enterotoxin (CPE) is one of the principal contributors to C. perfringens human 
disease via its role in both foodborne and non-foodborne gastrointestinal illness.  Produced in 
massive quantities during sporulation in the intestine, CPE begins its action by binding to host 
cells and forming an SDS-sensitive small complex.  At physiologic conditions, CPE then 
associates with additional proteins to form large SDS-resistant complexes in the plasma 
membrane, the formation of which coincide with membrane permeability alterations of the cell.  
The two species of large complex have been reported to have molecular masses of ~155 and 
~200 kDa, and recent compositional analysis of the complexes has shown that the former 
complex contains both CPE and claudin, while the latter contains CPE, claudin, and occludin.  
Prior structure-function analysis of CPE has defined regions at the N- and C-termini involved 
with cytotoxic and binding activities of the toxin, respectively.  Despite the important findings 
contributed from previous studies of CPE, several significant questions remain regarding the 
molecular aspects of CPE’s mechanism of action.  In this thesis dissertation, research is 
presented aimed to answer three specific structure-function and mechanistic questions about 
CPE action.  Site-directed mutagenesis enabled the identification of two residues in the N-
terminal cytotoxicity region of CPE that were crucial for the formation of the CPE large 
complexes, and likely function in oligomerization of the toxin.  In addition, a novel pre-pore step 
was defined by deletion mutagenesis of a 25 amino acid region of CPE proposed to be involved 
in membrane insertion.  Lastly, CPE was determined to have hexameric stoichiometry in both of 
the large complexes, prompting a reevaluation of their molecular masses.  Several new insights 
into CPE activity have been gained by the work presented here within, and models for the 
molecular mechanism of action and structure-function relationships of CPE are updated. 
 
INVESTIGATING THE MOLECULAR MECHANISM OF ACTION  
OF Clostridium perfringens ENTEROTOXIN USING  
STRUCTURE-FUNCTION AND OLIGOMERIC ANALYSES 
 
James Gilbert Smedley, III, M.S. 
University of Pittsburgh, 2007
 v 
 
TABLE OF CONTENTS 
LIST OF TABLES........................................................................................................................... xii 
LIST OF FIGURES ......................................................................................................................... xiii 
PREFACE....................................................................................................................................... xvi 
1.0      INTRODUCTION ................................................................................................................. 1 
1.1      Clostridium perfringens ........................................................................................... 1 
1.1.1      General bacteriology..................................................................................... 1 
1.1.2      Genomic analysis of C. perfringens ............................................................ 2 
1.1.3      C. perfringens toxins and associated diseases ......................................... 2 
1.1.3.1      Typing toxins of C. perfringens ....................................................... 3 
1.1.3.2      Non-typing toxins of C. perfringens ................................................ 4 
1.2      C. perfringens ENTEROTOXIN................................................................................. 5 
1.2.1      C. perfringens type A food poisoning and the discovery of CPE............. 5 
1.2.2      Association of CPE with non-foodborne diarrheas ................................... 8 
1.2.3      Beta2 toxin: an AAD/SD accessory toxin? ................................................. 8 
1.2.4     CPE Genetics.................................................................................................. 9 
1.2.4.1      Gene structure and transcriptional regulation of cpe.................... 9 
1.2.4.2      Genetic locus of cpe ......................................................................... 11 
1.2.4.3      Molecular Koch’s postulates and cpe ............................................. 11 
1.3      MECHANISM OF ACTION OF CPE........................................................................... 12 
1.3.1      The enterotoxic consequences of CPE delivery in the small intestine.... 12 
 vi 
 
1.3.2      Cellular toxicity induced by CPE ................................................................. 14 
1.3.2.1      Cell culture models of CPE cytotoxicity.......................................... 15 
1.3.2.2      Cellular mechanism of death............................................................ 17 
1.3.3      Membranes and complexes: the molecular action of CPE ....................... 18 
1.3.3.1      Receptor binding ............................................................................... 19 
1.3.3.2      Small complex formation by CPE .................................................... 21 
1.3.3.3      Large complex formation by CPE .................................................... 22 
1.3.3.4      Exploiting CPE:claudin interactions: clinical and therapeutic 
applications......................................................................................................... 24 
1.4      CORRELATING CPE STRUCTURE WITH ACTIVITY............................................... 26 
1.4.1      CPE biochemistry.......................................................................................... 26 
1.4.2      Current knowledge of structure-function relationships within CPE ........ 29 
1.4.2.1      N-terminal activation region ............................................................. 29 
1.4.2.2      N-terminal cytotoxicity region.......................................................... 31 
1.4.2.3      C-terminal binding domain ............................................................... 33 
1.5      THE β-BARREL PORE-FORMING TOXINS.............................................................. 36 
1.5.1      Membrane-damaging proteins ..................................................................... 36 
1.5.2      β-PFTs: from water-soluble proteins to membrane-penetrating pores.... 37 
1.5.2.1      Structural attributes of the β-PFTs .................................................. 38 
1.6      QUESTIONS ADDRESSED IN THIS THESIS............................................................ 41 
1.6.1      Specific question #1 – Why is the N-terminal cytotoxicity region of CPE 
essential for its post-binding cytotoxicity activity?................................................. 41 
1.6.2      Specific question #2 – Is there a region of CPE that is important for 
membrane insertion or pore formation?................................................................... 42 
 vii 
 
1.6.3      Specific question #3 – What is the oligomeric state of CPE within the 
large complexes?........................................................................................................ 43 
2.0      MATERIALS AND METHODS ............................................................................................ 45 
2.1      BACTERIAL CULTURING ......................................................................................... 45 
2.1.1      Bacterial strains, growth media, and media supplements ........................ 45 
2.2      DNA PREPARATION AND MANIPULATION............................................................ 45 
2.2.1      Site-directed mutagenesis of cpe ................................................................ 45 
2.2.2      Deletion mutagenesis of cpe........................................................................ 47 
2.2.3      DNA Sequencing ........................................................................................... 47 
2.3      PROTEIN BIOCHEMISTRY AND CHROMATOGRAPHY ......................................... 49 
2.3.1      Preparation of CPE........................................................................................ 49 
2.3.2      Enterokinase digestions of rCPE37-319 ......................................................... 50 
2.3.3      Limited trypsin proteolysis assay ............................................................... 50 
2.3.3      Size exclusion chromatography .................................................................. 51 
2.3.3      Ferguson plot analysis ................................................................................. 52 
2.4      CPE ACTIVITY CHARACTERIZATION ..................................................................... 53 
2.4.1      Morphologic damage assay ......................................................................... 53 
2.4.2      Competitive binding analysis....................................................................... 53 
2.4.3      Small complex formation.............................................................................. 54 
2.4.4      Large complex formation ............................................................................. 54 
2.4.5      Heteromer gel shift assay with CPE large complexes............................... 55 
2.4.6      86Rb release experiments ............................................................................. 56 
2.4.7      Pronase resistance of large complex.......................................................... 56 
2.4.8      Dissociation of CPE large complex from membranes............................... 57 
2.4.9      Heat denaturation of CPE large complex.................................................... 57 
 viii 
 
2.5      IN VIVO ANALYSIS OF CPE ACTIVITY .................................................................... 58 
2.5.1      Fluid accumulation in rabbit ileal loops...................................................... 58 
2.5.2      Histopathological analysis of CPE-treated ileal tissues............................ 58 
3.0      RESULTS ............................................................................................................................ 59 
3.1      FINE-MAPPING OF THE N-TERMINAL CYTOTOXICITY REGION OF CPE ........... 59 
3.1.1      Alanine-scanning mutagenesis ................................................................... 59 
3.1.1.1      Introduction of amino acid substitutions........................................ 59 
3.1.1.2      Morphologic damage of Caco-2 cells by alanine variants of 
rCPE..................................................................................................................... 60 
3.1.1.3      Analysis pore-formation by the alanine-substituted rCPE 
variants................................................................................................................ 61 
3.1.1.4      Competitive binding ability of the rCPE alanine variants.............. 63 
3.1.1.5      Small complex formation by the rCPE alanine variants ................ 65 
3.1.1.6      Large complex formation by the rCPE alanine variants ................ 66 
3.1.1.7      Analysis of gross conformational changes in rCPE alanine 
variants................................................................................................................ 67 
3.1.2      Saturation mutagenesis of residues important for CPE action ................ 68 
3.1.2.1      Non-alanine substitutions at D48..................................................... 69 
3.1.2.2      Non-alanine substitutions at I51 ...................................................... 70 
3.1.2.3      Non-alanine substitutions at W50.................................................... 70 
3.1.3     Correlation between in vitro cytotoxicity and in vivo enterotoxicity ........ 71 
3.1.3.1      Fluid accumulation in the rabbit ileal loop model .......................... 71 
3.2      SEARCH FOR A MEMBRANE INSERTION DOMAIN OF CPE ................................ 75 
3.2.1      Amino acids 81-106 of CPE: a transmembrane stem domain? ................ 75 
3.2.1.1      Deletion mutagenesis of the putative TMD of CPE ........................ 76 
 ix 
 
3.2.1.2      Competitive binding analysis of the TM1 deletion variant ............ 77 
3.2.1.3      Cytotoxicity of the TM1 deletion variant ......................................... 77 
3.2.1.4      Pore-formation of the TM1 variant ................................................... 78 
3.2.1.5      Formation of SDS-resistant large complexes by the TM1 variant 80 
3.2.1.6      Analysis of the TM1 pre-pore large complex .................................. 81 
3.2.1.6.1      Pronase resistance of the TM1 large complex.................... 81 
3.2.1.6.2      Membrane dissociation of the TM1 large complex............. 82 
3.2.1.6.3      Heat Denaturation of the TM1 Large Complex.................... 84 
3.2.2      Temporal questions regarding functional regions of CPE........................ 85 
3.2.2.1      Activity characterization of TM1-D48A............................................ 86 
3.3      INVESTIGATING THE OLIGOMERIZATION OF CPE IN THE LARGE 
COMPLEXES......................................................................................................................... 87 
3.3.1      Generation of rCPE molecular mass variants ............................................ 87 
3.3.2     Characterization of large complexes made by rCPE molecular mass 
variants......................................................................................................................... 88 
3.3.3     Heteromeric CPE large complex gel shift analysis..................................... 90 
3.3.4     Reassessment of the molecular mass of the CPE large complexes......... 92 
3.3.4.1      Ferguson plot analysis of the CPE large complexes ..................... 94 
3.3.4.2      Analysis of the large CPE complexes by size exclusion 
chromatography ................................................................................................. 98 
3.3.5     Exploration of dominant negative phenotypes from rCPE variants.......... 100 
3.3.5.1      Dominant negative effects of CPE oligomerization ....................... 101 
3.3.5.2      Blocking of pore-formation by dominant negative variants.......... 103 
4.0      DISCUSSION....................................................................................................................... 105 
 x 
 
4.1      WHY IS THE N-TERMINAL CYTOTOXICITY REGION ESSENTIAL FOR POST-
BINDING CYTOTOXIC ACTIVITY OF CPE? ........................................................................ 107 
4.1.1      Explanation of mutagenesis and rCPE variant phenotypes ..................... 107 
4.1.1.1      D48 and I51: crucial for CPE cytotoxicity........................................ 107 
4.1.1.2      Glycine to alanine: loss of flexibility ............................................... 108 
4.1.1.3      W50 is plays a structural role for CPE............................................. 109 
4.1.2      N-terminal core cytotoxicity sequence: the latch hypothesis .................. 110 
4.1.3      In vivo validation of in vitro phenotypes..................................................... 112 
4.2      SEARCH FOR A REGION OF CPE INVOLVED IN MEMBRANE INSERTION......... 113 
4.2.1      Identification of a pre-pore large complex state ........................................ 113 
4.2.2      Possible functions of CPE amino acids 81-106.......................................... 114 
4.2.2.1      Transmembrane stem domain ......................................................... 114 
4.2.2.1.1      Probing the environment of residues in the putative TMD 
of CPE......................................................................................................... 118 
4.2.2.2      Rim interactions with the membrane............................................... 122 
4.2.2.3      Protein-protein interactions ............................................................. 123 
4.2.3      Order of involvement of CPE functional regions ....................................... 123 
4.3      EXAMINATION OF THE OLIGOMERIC STATE OF CPE IN THE LARGE 
COMPLEXES......................................................................................................................... 124 
4.3.1      Determination the stoichiometry of CPE in the large complexes............. 125 
4.3.2      Molecular mass and composition of the “~155 kDa” large complex ....... 126 
4.3.3      Molecular mass and composition of the “~200 kDa” large complex ....... 127 
4.3.4      Nomenclature change................................................................................... 128 
4.3.5      Dominant negative variants of rCPE ........................................................... 129 
4.3.5.1      Inhibition by blocking membrane insertion .................................... 129 
 xi 
 
4.3.5.2      Inhibition by chain termination ........................................................ 130 
4.4      UPDATING STRUCTURE-FUNCTION RELATIONSHIPS OF CPE.......................... 131 
4.4.1      N-terminal activation region......................................................................... 131 
4.4.2      N-terminal core cytotoxicity sequence ....................................................... 132 
4.4.3      Putative transmembrane domain................................................................. 132 
4.4.4      Tight junction modulator region .................................................................. 133 
4.4.5      C-terminal binding domain........................................................................... 133 
4.4.6      Latch binding site.......................................................................................... 133 
4.5      UPDATED MODEL FOR THE MOLECULAR MECHANISM OF ACTION OF CPE..134 
4.5.1      Step 1 – Receptor binding and formation of the small complex .............. 134 
4.5.2      Step 2 – Oligomerization of CPE and formation of the pre-pore .............. 135 
4.5.3      Step 3 – Pore-formation by membrane insertion ....................................... 135 
4.6      FUTURE INVESTIGATIONS ...................................................................................... 137 
4.6.1      NTCCS latch and binding site ...................................................................... 137 
4.6.2      Confirming the putative TMD of CPE .......................................................... 137 
4.6.3      Additional dominant negative analysis....................................................... 138 
4.6.4      Solving the three-dimensional structure of CPE........................................ 139 
4.7      FINAL SUMMATION .................................................................................................. 141 
4.8      ORIGINAL KNOWLEDGE CONTRIBUTED............................................................... 142 
BIBLIOGRAPHY ............................................................................................................................ 143 
 xii 
 
LIST OF TABLES 
Table 1.1  Classic toxinotypes of C. perfringens............................................................................. 3 
Table 1.2  Some members of the β-PFT family of toxins................................................................ 38 
Table 2.1  Bacterial strains used in this study................................................................................. 46 
Table 2.2  DNA primers used in this study for mutagenesis or sequencing ................................... 48 
Table 3.1  Summary of rCPE variant phenotypes........................................................................... 63 
Table 3.2  Gross histology scores of rabbit ileal loops treated with the indicated constructs ......... 73 
Table 3.3  Binding analysis of constructs in this study.................................................................... 77 
Table 3.4  Ferguson plot calculations for CPE large complexes .................................................... 96 
 
 xiii 
 
LIST OF FIGURES 
Figure 1.1  Ligated rabbit ileal loops ............................................................................................... 5 
Figure 1.2  Gastrointestinal diseases caused by cpe+ C. perfringens............................................. 7 
Figure 1.3  Map of cpe gene ........................................................................................................... 10 
Figure 1.4  Two-stage effects of CPE treatment of the mammalian small intestine ....................... 14 
Figure 1.5  Cellular death pathways induced by CPE treatment .................................................... 18 
Figure 1.6  Membrane topology and domain structure of claudin and occludin.............................. 20 
Figure 1.7  Model for molecular action of CPE prior to start of present study ................................ 22 
Figure 1.8  Primary amino acid structure of CPE............................................................................ 27 
Figure 1.9  Kyte-Doolittle hydrophobicity analysis of CPE.............................................................. 28 
Figure 1.10  Secondary amino acid structure predictions of CPE................................................... 29 
Figure 1.11  Enzymatic, chemical, and cloning fragments of CPE ................................................. 30 
Figure 1.12  Deletion mutagenesis of rCPE using molecular cloning ............................................. 32 
Figure 1.13  Random point mutagenesis of rCPE .......................................................................... 33 
Figure 1.14  Deletion mutagenesis of the C-CPE fragment of CPE ............................................... 34 
Figure 1.15  Three dimensional crystal structure of the S. aureus alpha hemolysin monomer ...... 39 
Figure 1.16  Three dimensional crystal structure of the S. aureus alpha hemolysin heptamer ...... 40 
Figure 1.17  Alignment of TMDs of several β-PFTs and CPE amino acids 81-110 ........................ 43 
Figure 3.1  Map of the N-terminal cytotoxicity region...................................................................... 60 
Figure 3.2  Caco-2 morphologic damage assay ............................................................................. 61 
 xiv 
 
Figure 3.3  Assessment of pore-formation by rCPE variants.......................................................... 62 
Figure 3.4  Competitive binding analysis of rCPE variants ............................................................. 64 
Figure 3.5  Small complex formation by rCPE variants .................................................................. 65 
Figure 3.6  Formation of the SDS-resistant large complexes by rCPE variants ............................. 67 
Figure 3.7  Limited trypsin proteolysis of rCPE variants ................................................................. 68 
Figure 3.8  Fluid accumulation by rCPE constructs ........................................................................ 72 
Figure 3.9  Histology of rabbit ileal loops ........................................................................................ 74 
Figure 3.10  Structure-function map of CPE depicting the putative TMD ....................................... 75 
Figure 3.11  Constructs used to investigate membrane insertion................................................... 76 
Figure 3.12  Caco-2 morphologic damage assay ........................................................................... 78 
Figure 3.13  Assessment of pore-formation by rCPE variants........................................................ 79 
Figure 3.14  Formation of SDS-resistant large complexes by rCPE variants ................................. 80 
Figure 3.15  Comparative pronase susceptibility of large complexes formed by rCPE and TM1 ... 82 
Figure 3.16  Dissociation of the large complexes formed by rCPE and TM1.................................. 84 
Figure 3.17  Heat denaturation of the CPE large complex ............................................................. 85 
Figure 3.18  Constructs used to investigate the oligomerization of CPE ........................................ 88 
Figure 3.19  Western blots of constructs before and after large complex formation....................... 89 
Figure 3.20  Heteromer gel shift analysis of the “~155 kDa” CPE large complex........................... 91 
Figure 3.21  Heteromer gel shift analysis of the “~200 kDa” CPE large complex........................... 92 
Figure 3.22  Effect of altering acrylamide concentration in large complex gels .............................. 94 
Figure 3.23  Ferguson plot analysis of CPE ................................................................................... 95 
Figure 3.24  Ferguson plot analysis of CPE large complexes ........................................................ 97 
Figure 3.25  Size exclusion chromatography of the CPE large complexes .................................... 99 
Figure 3.26  Dominant negative effects on oligomerization by some rCPE variants ...................... 102 
Figure 3.27  Dominant negative effects on pore-formation by some rCPE variants ....................... 104 
 xv 
 
Figure 4.1  Current structure-function map of CPE with predicted secondary structure................. 106 
Figure 4.2  Membrane topology model of TMDs of β-PFTs............................................................ 115 
Figure 4.3  Kyte-Doolittle hydrophobicity analysis of two β-PFTs................................................... 116 
Figure 4.4  Crystal structure of perfringolysin O ............................................................................. 117 
Figure 4.5  Small-scale fluorescence study of the putative TMD of CPE........................................ 120 
Figure 4.6  Possible configurations of the CH1 and CH-2 complexes ............................................ 127 
Figure 4.7  Model for the molecular mechanism of action of CPE.................................................. 136 
Figure 4.8  Montage of various crystal morphologies formed by CPE............................................ 140 
 
 xvi 
 
PREFACE 
It is a sheer impossibility that this thesis dissertation could have been produced without the advice, 
fellowship, and encouragement of so many people.  I must foremost thank God for the opportunities and 
blessings which I am provided on a daily basis.  My faith in Jesus Christ has provided a great deal of inner 
strength and personal confidence during some of life’s hardest times, and this relationship is one that is truly 
invaluable.  I owe the faculty of the Department of Biological Sciences of Duquesne University thanks for my 
development as a student of the sciences.  Despite an unremarkable undergraduate career, my attitude toward 
academic achievement quickly matured after being given a chance by Duquesne to earn a Master’s degree.  I 
must specifically thank my Master’s thesis advisor, Dr. Peter Castric, who provided exceptional mentorship during 
my time at Duquesne, enabling and inspiring me to continue on for my doctorate.  I would like to thank Drs. 
Steven Phillips and Joanne Flynn who played key advisory roles to me during my early years at the University of 
Pittsburgh.  Also deserving thanks are members of my thesis committee consisting of Drs. Mike Cascio, Jay 
Carroll, Tim Mietzner and Mike Parniak, and I am especially grateful to Drs. Carroll and Parniak for their helpful 
personal and scientific mentorship.  I also wish to thank my scientific twin brother, Dr. Derek Fisher, for his sincere 
fellowship both in and out of the laboratory.  I also wish to acknowledge my friendship with former lab-mate Dr. 
Qiyi Wen.  Though Dr. Wen has left this world for a better place, his light-hearted spirit and dedication to family 
has left an indelible mark in my heart.   
I also wish to acknowledge my thesis advisor, Dr. Bruce McClane, for his contributions to my scientific 
development.  Dr. McClane has provided me with an appropriate balance of freedom and supervision that has 
been vital for my achievements and growth into an independent scientist.  While being the recipient of excellent 
training on protein biochemistry and eukaryotic cell culturing in his laboratory, I have also learned important 
aspects of the ‘business end’ of science which will no doubt be of value as I continue my scientific career.  
Lastly, I have to acknowledge my family for their constant encouragement and support.  My parents Jim 
and Becky have deeply impressed the value of education into me, and without their support (both emotional and 
financial), I would be unable to attain the goals I have set forth.  It is my wife, Kelly, who deserves my deepest 
gratitude.  Even though the road leading to my academic endeavors can be seemingly endless, Kelly’s 
unwavering support and encouragement has been an irreplaceable aspect of my drive to continue forward.  I am 
truly blessed by God to have her as my loving wife, the mother of my son, and my best friend. 
 1 
1.0 INTRODUCTION 
 
 
Bacterial toxins have had a significant negative impact on their eukaryotic hosts throughout 
evolution, and unfortunately humans are no exception.  In order to mitigate the effects of these 
toxic proteins, we must first understand, at the molecular level, how toxins execute their 
activities to cause disease.  This thesis dissertation describes a detailed examination of the 
mechanism of action of the Clostridium perfringens enterotoxin using analysis which correlates 
its structural attributes to its molecular activities.  Findings from this work regarding the 
functional domains and oligomeric state of the enterotoxin have contributed extensively to the 
understanding of the molecular events occurring between this protein and the host cell.  It is the 
ultimate hope that this work will advance both basic and applied research approaches to further 
appreciate the activities and potential remedies for this dynamic toxin. 
 
 
1.1 Clostridium perfringens 
 
 
1.1.1 General bacteriology 
 
The Gram-positive bacterium Clostridium perfringens is a notorious human and veterinary 
pathogen, and is most appreciated for its tremendous toxin-producing capability (168).  As a 
member of the Clostridium genus, C. perfringens is a spore-forming anaerobe with a rod-
shaped cellular morphology and a pilus-based motility (219).  First isolated as Bacterium welchii 
by the American physician William Henry Welch in 1892, C. perfringens is thought to have been 
responsible for the deaths of hundreds of thousands of soldiers suffering from wound-induced 
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gas gangrene in World War I (183).  C. perfringens is believed to be the most wide-spread 
bacterial pathogen in nature (120), as it can be found in water, soil sediments, and also part of 
the normal intestinal flora of humans and other animals.  Its genetic manipulability, fast growth 
rate, and relative tolerance to oxygen has enabled C. perfringens to be a genetic model 
organism for the entire Clostridium genus (167).  
 
1.1.2 Genomic analysis of C. perfringens 
 
As typical of the Firmicutes, C. perfringens maintains an exceptionally low G+C content of ~28% 
(149, 183).  The genomes of several C. perfringens strains have recently been sequenced, 
revealing an average ~3.0 Mbp genome size between the 3 strains (149, 183).    A considerable 
amount of variation exists not only between the three completely sequenced C. perfringens 
strains, but also between many other C. perfringens human and animal disease isolates (149).  
These genomic differences cluster to over 300 different genomic islands and can encode genes 
involved with metabolism, capsule synthesis, toxin production, and mobile genetic elements.  
This finding undoubtedly reflects the phenotypic diversity required for the wide array of human 
and veterinary diseases which this bacterium can cause.  In addition to its chromosome, C. 
perfringens can harbor several large plasmids, many of which contain toxins and other virulence 
factors vital for the establishment and maintenance of infections (90, 141, 168).   
 
1.1.3 C. perfringens toxins and associated diseases 
 
The Clostridium genus has evolved an extreme expertise for producing many highly potent 
toxins.  The tetanus toxin from Clostridium tetani is responsible for one of the most dramatic and 
devastating diseases worldwide (5), while the botulinum toxin produced by Clostridium 
botulinum has been acknowledged as the most poisonous substance ever identified (54).  In 
 3 
this regard, C. perfringens itself contains a potent arsenal of up to 14 different protein toxins 
(168).  Since any one C. perfringens isolate produces only a small repertoire of these toxins, a 
classic typing scheme is commonly used to categorize C. perfringens isolates based on the 
presence of four “major lethal” toxins (Table 1.1). 
 
 
Table 1.1  Classic toxinotypes of C. perfringens 
 Toxins produced: 
Toxinotype alpha toxin beta toxin epsilon toxin iota toxin 
A + - - - 
B + + + - 
C + + - - 
D + - + - 
E + - - + 
 
 
1.1.3.1 Typing toxins of C. perfringens 
 
The C. perfringens alpha toxin is carried by all types and has hemolytic, phospholipase C, 
sphingomyelinase, and lethal activities (172).  This toxin has been shown to be the primary 
mediator of gas gangrene caused by C. perfringens (7).  C. perfringens types B and C can 
produce beta toxin, a pore-forming toxin (150) shown to be the primary lethal toxin in a mouse 
intravascular injection model (43).  Type C isolates of C. perfringens are a cause of necrotic 
enteritis in humans, the symptoms of which beta toxin is thought to be the principal mediator 
(43, 193).  Epsilon toxin, produced by type B and D isolates of C. perfringens, is another pore-
forming toxin (144, 159, 160) which localizes to nasal, brain, and kidney tissues once absorbed 
into the blood stream (205).  Though epsilon toxin has not been experimentally shown to affect 
humans, its extreme potency (trumped only by the previously-mentioned tetanus and botulinum 
toxins) has led to its classification by the Centers for Disease Control as a Class B Select Toxin.  
Type E isolates of C. perfringens express the iota toxin, a classic binary toxin with ADP-
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ribosyltransferase activity (163).  Though iota toxin has homology both in structure and function 
to several other bacterial binary toxins affecting humans (Clostridium difficile transferase, C. 
botulinum C2 toxin, and Salmonella enterica SpvB toxin; (104)), type E C. perfringens isolates 
have only been associated with veterinary enteritises (193).   
 
1.1.3.2  Non-typing toxins of C. perfringens 
 
C. perfringens  also produces several other toxins not used in the typing scheme.  Theta toxin, 
or perfringolysin O, is a member of the cholesterol-dependent cytolysin family of pore-forming 
toxins, and is reported to act in synergy with alpha toxin in a mouse model of myonecrosis (7).  
The beta2 toxin can be produced by all C. perfringens types (17) and has been associated with 
both veterinary enteric disease (9, 194) and with some human non-foodborne diarrheas (44).  
Several other non-typing toxins have been identified but are incompletely characterized with 
regard to their pathogenic contribution, including proteases (lambda and kappa toxins), 
glycolytic enzymes (nanI, nanH, nagH, mu toxin), and a collagenase (colA) (168). 
In addition to the multitude of aforementioned toxins, the C. perfringens enterotoxin, or 
CPE, could be currently considered the most medically significant C. perfringens toxin.  As will 
be illustrated below, CPE is responsible for the symptoms of C. perfringens type A food 
poisoning, as well as non-foodborne gastrointestinal illnesses in humans. 
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1.2 C. perfringens ENTEROTOXIN 
 
 
1.2.1 C. perfringens type A food poisoning and the discovery of CPE 
 
C. perfringens has been linked with food poisoning since the 1940’s and 1950’s, and institutions 
such as military bases and hospitals in both the U.S.A. and Europe were frequent sites of 
reported C. perfringens food poisoning outbreaks (24, 25, 91, 128).  While attempts have been 
made to construct mouse, monkey, lamb, chicken, and even pigeon models for the food 
poisoning caused by this bacterium (74, 153, 211, 212, 224, 239), a rabbit ileal loop model (Fig. 
1.1) established by Duncan and colleagues in 1968 remains, nearly 40 years later, as the 
standard in vivo assay for C. perfringens type A enterotoxicity (33).  A human volunteer study 
later verified this rabbit ileal loop model, since enteropathogenic cultures of C. perfringens which 
could elicit fluid accumulation in rabbit ileal loops were able to cause diarrhea 61% of the time 
when administered orally to human volunteers (199).  
 
 
 
Figure 1.1  Ligated rabbit ileal loops.  Arrows indicate individual 
loops treated for 3 h with 50 µg of CPE (photograph courtesy of 
Francisco Uzal, CAHFS Laboratory). 
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Evidence that C. perfringens food poisoning may be caused by a factor released or 
secreted from the bacterial cell first came from a key study demonstrating fluid accumulation in 
rabbit ileal loops after treatment with cell-free extracts of C. perfringens (31).  Early 
characterization studies of crude preparations of enterotoxic C. perfringens suggested the 
enterotoxic factor was a single protein of approximately 35,000 Da (73, 196).  Purified CPE 
(127) was later shown to be the primary enterotoxic factor for the experimental disease in many 
animal enteric models (reviewed in (122)), and diarrhea could be experimentally induced in 
healthy human volunteers after ingestion of highly purified CPE (189).  Confirming this notion 
was the finding that C. perfringens strains containing a knock-out mutation of the gene encoding 
CPE could not elicit fluid accumulation or histopathologic damage like their isogenic parent 
strains (175).  Currently, CPE-producing isolates of C. perfringens are ranked as the second 
and third most common cause of foodborne illness in the U.K. and U.S.A, respectively (155).  In 
addition, C. perfringens type A food poisoning (Fig. 1.2A) has been estimated to have a $187 
million/year effect on the economy (adjusted for today’s dollars) (209). 
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Figure 1.2  Gastrointestinal diseases caused by cpe+ C. perfringens.  A, Model for the cycle of C. 
perfringens type A food poisoning.  B, Model for the cycle of non-foodborne diarrheas caused by cpe+ C. 
perfringens. 
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1.2.2 Association of CPE with non-foodborne diarrheas 
 
While C. perfringens (and later, CPE) has been implicated in foodborne (FB) disease for over 
five decades, only within the last 20 years have CPE-producing strains of C. perfringens been 
recognized as a legitimate source of non-foodborne (NFB) diarrheas (18).  One such illness, 
antibiotic-associated diarrhea (AAD), has predominantly thought to be caused by a C. 
perfringens relative, C. difficile.  However, a study in 1984 (14) described the detection of CPE 
in the stools of 11 patients receiving antibiotics who were suffering from prolonged and severe 
diarrhea (symptoms distinct from the rather short-lived diarrhea associated with C. perfringens 
type A food poisoning).  Not only was C. perfringens also isolated from these stools samples, 
but C. difficile was absent, indicating that CPE-producing C. perfringens isolates could be 
responsible for these AAD infections (12, 14).  A more recent comparative analysis determined 
that CPE-positive C. perfringens accounted for 21% of the known AAD pathogens in an over 
700 sample AAD survey (6).  In addition to contributing to diarrheas associated with antibiotic 
use, CPE-producing C. perfringens isolates have also been implicated in sporadic diarrhea (SD) 
episodes, particularly in the elderly population (18).  While detection rates of CPE-positive C. 
perfringens in cases of SD range from 18% (148) to 6.8% (15), it is clear that enterotoxic type A 
isolates of C. perfringens appear to be an emerging etiology for SD as well as AAD (Fig. 1.2B). 
 
1.2.3 Beta2 toxin: an AAD/SD accessory toxin? 
 
As mentioned above, the symptoms witnessed in AAD and SD have been reported to be more 
prolonged and severe than seen in cases of C. perfringens type A food poisoning (18).  While 
the basis for this difference is not entirely clear, one possible explanation could be the action of 
an additional toxin.  The beta2 toxin, mention above, is frequently found associated with cpe+ C. 
perfringens isolates which cause AAD/SD (>75% of tested isolates) and infrequently with cpe+ 
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C. perfringens food poisoning isolates (<15% of tested isolates) (44).  In addition, beta2 toxin 
itself has been associated with many serious veterinary enteric diseases, including in horses, 
piglets, and cattle (17, 37, 51, 53, 103).  Although there are currently no reports of human 
disease where beta2 toxin was identified as the single causative agent, purified beta2 toxin has 
been shown to be cytotoxic for Caco-2 cells (44), a human colon carcinoma cell line (described 
in detail below).  Collectively these findings suggest that beta2 toxin, because of its genetic 
associations with CPE and its own cytotoxic/enterotoxic activities, could contribute in an 
accessory fashion to CPE and be responsible for the more intense gastrointestinal symptoms 
seen during AAD/SD (Fig. 1.2B; (42)).   
 
1.2.4 CPE genetics 
 
1.2.4.1  Gene structure and transcriptional regulation of cpe 
 
The gene for CPE (cpe) is roughly 1.3 kbp in length and encodes a 319 amino acid protein with 
a molecular mass of 35,346 Da (29).  The cpe gene contains no significant DNA or amino acid 
homology to any other bacterial toxins.   However, it does have 27% identity and 46% similarity 
at the amino acid level to the non-toxic hemagglutinin components of the type C botulinum toxin 
(45).  Remarkable sequence conservation of the cpe gene exists within C. perfringens, including 
cpe genes from both FB and NFB isolates (26).  
Early investigations of regulation of the enterotoxin established that, unlike the other C. 
perfringens toxins, CPE is produced only by sporulating cells (31, 32).  When induced to 
sporulate, cpe+ C. perfringens isolates produce massive amounts of the enterotoxin which 
accumulates in a large inclusion body inside the mother cell (101, 102).  Both the quantitative 
and temporal characteristics of cpe expression can be explained by the presence of three 
sporulation-associated promoters (two SigE-like and one SigK-like) upstream from the cpe ORF 
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(Fig. 1.3; (238)).  In addition, the distal SigE-like promoter of cpe is thought to be directly 
regulated by the SpoOA, an very early regulator of sporulation in both the Bacillus and 
Clostridium genera (81).  Termination of cpe transcription is thought to be Rho-independent, 
mediated instead by a putative step loop structure preceding an oligo-T tract located 
downstream of the stop codon (Fig. 1.3; (29)).  Although cpe is most commonly only carried by 
type A C. perfringens isolates, CPE can be produced by natively cpe-  type A, B, and C isolates 
transformed with a cpe-containing shuttle plasmid (28).  Also, cpe expression has been 
detected in sporulating cultures of natively cpe+ type B, C, and D isolates of C. perfringens (40, 
42, 177).  CPE can be produced (although in much lower quantities than from the cpe promoter) 
in an Escherichia coli background (28), an indication that sporulation is not required for cpe 
expression.  Production of recombinant CPE (rCPE) from highly active promoters in E. coli has 
allowed great strides to be taken in structure-function analysis of CPE, as will be illustrated 
below. 
 
 
 
Figure 1.3  Map of the cpe gene depicting its three sporulation-regulated promoters and 3’ transcription 
termination elements. 
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1.2.4.2  Genetic locus of cpe 
  
Despite the stringent sequence conservation in cpe sequence between FB and NFB isolates of 
C. perfringens (26), the genetic context of cpe in these two distinct etiologies is very different.  
Genetic analysis of NFB cpe+ C. perfringens isolates identified an episomal location of cpe, 
while FB enterotoxic C. perfringens isolates were found to harbor their cpe genes on the 
chromosome (27).  In both loci however, cpe is flanked by mobile genetic elements suggesting 
that plasmid cpe C. perfringens isolates have acquired this toxin gene via horizontal gene 
transfer from chromosomal cpe C. perfringens isolates (140).  The differences in cpe locus 
organization between chromosomal and plasmid cpe C. perfringens isolates has enabled 
development of a multiplex PCR assay that can be used to rapidly identify whether an 
enterotoxic C. perfringens isolate is of FB or NFB origin (142, 225).  Complete sequencing of 
two cpe plasmids has identified that these ~70-75 kbp plasmids carry genes for the conjugative 
transposon Tn916, suggesting a possible mechanism of plasmid transfer (141). 
 
1.2.4.3  Molecular Koch’s postulates and cpe 
 
Many lines of evidence presented in the above sections support the role of CPE in C. 
perfringens type A food poisoning.  In addition, CPE+ C. perfringens can cause NFB diarrheas 
such as AAD and SD, though the exact contribution of CPE in these diseases remains to be 
completely evaluated.  Robust confirmation of CPE’s role in both FB and NFB gastrointestinal 
illnesses came from molecular Koch’s postulates analysis of both plasmid and chromosomal 
cpe isolates (175).  Knockout mutations in both chromosomal and plasmid cpe genes were 
generated by homologous recombination and assayed for enterotoxicity in the rabbit ileal loop 
model.  Sporulating culture lysates from either the chromosomal or plasmid cpe knockout 
mutants were unable to induce fluid accumulation or the typical histopathology associated with 
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CPE treatment (villus blunting, epithelial desquamation, etc.).  When these same chromosomal 
and plasmid knockout mutants were complemented in trans with a plasmid copy of cpe, the 
enterotoxic phenotype was completely restored (175).  This careful analysis conclusively 
showed that CPE is necessary for C. perfringens type A  gastrointestinal diseases. 
 
 
 
1.3 MECHANISM OF ACTION OF CPE 
 
 
CPE mediates its toxicity through several distinct levels of action, ranging from the early 
molecular events occurring at cell membranes, to the cytotoxic effects leading to cell death, and 
finally culminating in enteropatholgy resulting in diarrhea and cramping.  Detailed below is a 
description of the enteric, cellular, and molecular facets of the mechanism of action of CPE. 
 
1.3.1 The enterotoxic consequences of CPE delivery in the small intestine 
 
The symptoms of C. perfringens type A food poisoning, diarrhea and cramping, begin within 8-
18 h after consumption of a food source contaminated with vegetative cultures of a cpe+ isolate 
of C. perfringens (Fig. 1.2A; (122)).  A relatively large dose of bacteria (107-108) is required to 
initiate C. perfringens type A food poisoning (98) since most of the bacteria perish in the acidity 
of the stomach.  C. perfringens cells surviving this challenge continue to the small intestine 
where the presence of bile salts is thought to cause the bacteria to sporulate (76).  As described 
above, the multiple sporulation-regulated cpe promoters (Fig. 1.3) allow for large amounts of 
CPE to be produced by the sporulating bacteria.  Instead of being secreted like other C. 
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perfringens toxins, CPE is released into the intestinal lumen by lysis of the mother cell at the 
end stages of sporulation. 
On the other hand, the details of CPE production in cases of AAD/SD is not so clear.  
Since the cpe plasmids have been shown to be conjugative (16), and since C. perfringens can 
exist commensally in the intestinal tract, one leading hypothesis is that cpe plasmids are 
transferred in the intestine from ingested cpe+ environmental C. perfringens isolates to cpe- C. 
perfringens isolates already acclimated to the intestinal tract (Fig. 1.2B).  A balance between 
colonization and sporulation of intestinal cpe+ C. perfringens isolates would be responsible for 
the more prolonged and severe symptoms experienced with AAD/SD.  Also, beta2 toxin has 
been shown to be produced by both sporulating and vegetative cpe+ cultures (44), so the 
possibility of beta2 acting as an accessory toxin must be considered (42). 
Regardless of the means by which CPE is produced, its presence has a devastating 
effect on the intestine.  An early rat ileum model of enterotoxin action found that CPE treatment 
led to a switch from absorption to secretion of fluid, sodium, and chloride (121).  In this study, 
histopathological changes of the intestine were also noted, including destruction of villus tips 
resulting in an exposed lamina propria.  Similar histopathology effects have been reported in the 
rabbit model of CPE action at doses that were sufficient to cause fluid accumulation, making an 
important link between these two events (124).  Scanning electron micrographs confirmed these 
findings by showing villus tip damage, with heavy blebbing occurring at villus tips after rabbit 
ileum was treated with CPE (123).  Later studies (182) described the two-phase effects of CPE 
on the intestine: i) inhibition of the absorption of fluid and ions occurs as epithelial cells are 
intoxicated by CPE, and ii) death of intestinal epithelial cells leads to progressive desquamation 
of the epithelium culminating in a net secretion of fluid into the intestinal lumen (Fig. 1.4).  
Recent studies have been performed on sections of human intestine examined ex vivo for their 
electrophysiological responses to CPE.  This work revealed that human ileal epithelium 
experiences a decrease in transepithelial resistance and water absorption after CPE-treatment, 
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and that these effects seemed to correlate with damage of the intestinal tissue (41).  Also, the 
abdominal cramping that is typically associated with C. perfringens type A gastrointestinal 
disease has been attributed (by one study) to the increased myoelectric activity seen in CPE-
treated small intestine (87). 
 
 
       
Figure 1.4  Two-stage effects of CPE treatment of the mammalian small intestine. 
 
 
1.3.2 Cellular toxicity induced by CPE 
 
Hints on how CPE acts at the cellular level came first from transmission electron microscopy 
studies of CPE-treated rabbit small intestine.  Ultrastructural analysis showed that microvilli of 
the columnar epithelial cells were partially or completely missing, and that the epithelial cells at 
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the tips of villi showed heavy amounts of blebbing (indicative of cellular death) (123).  The 
disruption of the brush border and loss of apical membrane explains the initial absorption 
inhibition effects described previously (Fig. 1.4).  It was also interesting to note in that electron 
microscopy study that cells which had succumbed to CPE toxicity contained organelles that 
were normal in appearance, indicating that the toxic effect was outside-in rather than the inverse 
(123).  Other studies showed that epithelial tissue pre-treated with protein synthesis inhibitors is 
not protected from fluid accumulation or tissue damage, signifying that CPE action is not 
dependent on the synthesis of new proteins after the toxin interacts with the cell (125).   
 
1.3.2.1  Cell culture models of CPE cytotoxicity 
 
The introduction of immortal cell lines to CPE research greatly aided in further analyzing CPE-
mediated cytotoxicity.  The green monkey kidney cell line, Vero, was the first cell line reported to 
be sensitive to CPE (63).  CPE treatment of these cells rapidly causes dramatic changes in 
cellular morphology (116), including the development of blebs similar to what is seen with CPE 
treated epithelial cells of the rabbit intestine (126).  Binding of CPE to Vero cells was shown to 
be a crucial first step in the cellular action of the toxin, as Vero cells selected for resistance to 
CPE demonstrated a 10-fold reduction in CPE binding (126).  Other cell lines have been shown 
to be naturally sensitive to the enterotoxin, including HeLa cells (108) and MDCK cells (55). 
The rapid cytotoxic response (63, 116) involving membrane blebbing (116, 123) without 
detectable organelle damage (126) gave clear indications that the cellular plasma membrane 
was the target for CPE action.  Plasma membrane permeability alterations of Vero cells were 
discovered initially using a marker-release assay (206) with various sized radio-labeled 
molecular mass markers.  It was shown in this work that nearly all of the 14C-amino-isobutyric 
acid (103 Da) and most of the 3H-uridine (244 Da) could pass freely out of Vero cells treated 
with CPE for 30 min.  However macromolecules such as 51Cr-protein complexes  (3,000 Da) 
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and 3H-RNA (25,000 Da) were greatly restricted in their cellular efflux after CPE treatment (115), 
presumably because these molecules could not fit through the CPE pore.  Osmotic protection 
studies of Vero cells showed that sucrose could prevent the CPE-induced cytotoxic response, 
however poly-ethylene glycol was unable to provide similar protection (114).  This work was 
later confirmed by determining that molecules such as Tris (120 Da) and arabinose (150 Da) 
could not osmotically protect Vero or HeLa cells, whereas glucuronic acid (185 Da) and N-
acetylglucosamine (225 Da) conveyed a partial or complete, respectively, protective effect from 
CPE-induced damage (107).  These observations collectively suggested that CPE treatment of 
cells induces the formation of a pore, through which these experimental molecules pass. 
While Vero and HeLa cells provided an important initial cytotoxic model for CPE action, 
more physiologically-relevant insights regarding the interactions between CPE and the intestinal 
epithelium were gained when the human colon carcinoma cell line, Caco-2, was employed.  
Isolated in the 1970’s from a colorectal adenocarcinoma, Caco-2 cells are like enterocytes in 
that they form tight junctions and can generate microvilli brush borders similar to those seen in 
native intestinal epithelial cells (reviewed in (133)).   
The CPE response of Caco-2 cells has been examined in great detail.  Initial studies 
involving CPE treatment of Caco-2 cells demonstrated that CPE binds and forms the SDS-
sensitive ‘small complex’ (see following sections on molecular action of CPE) similar to Vero 
cells (229).  CPE was found to elicit a 86Rb-release response from Caco-2 cells typical of that of 
CPE-sensitive cells (186), and when monolayers of Caco-2 cells were grown on Transwell® 
permeable supports, these cells were 2-3-fold more sensitive when challenged with CPE 
basolaterally rather than apically (185).  Electrophysiological analysis of Caco-2 monolayers has 
also been used to show that CPE can reduce the transepithelial resistance by increasing the 
paracellular flux of small cations such as sodium (70).  When single Caco-2 cells were patch-
clamped after CPE treatment, cationic currents were detected and were blockable by both zinc 
and barium (70).   
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1.3.2.2  Cellular mechanism of death 
 
The detection of cationic currents induced by CPE treatment of Caco-2 cells is significant 
because of previous findings regarding the involvement of Ca2+ in CPE action.  In the Vero and 
HeLa cell models of CPE action, Ca2+ was found to be required for the initiation of morphologic 
damage (108).  Interestingly, however, this same study showed that binding of CPE to these 
cells was independent of the presence of Ca2+ in treatment buffers.  Several other studies later 
showed that small molecule permeability alterations resulting from CPE action were also 
independent on the presence of Ca2+ (79, 108, 118, 203).   
Rather than being involved in early molecular events at the cell membrane, such as 
binding and pore formation, Ca2+ appears to have a direct role as a second messenger, driving 
cell death pathways (Fig. 1.5).  An investigation of the cell death pathways of CPE cytotoxicity 
demonstrated that treatment of Caco-2 cells with low doses (1.0 ug/ml) of CPE triggers 
apoptosis, since DNA damage and morphological changes were blocked by inhibition of the 
apoptosis-specific caspase-3 and -7 (20).  Conversely, high doses (10.0 ug/ml) of CPE seemed 
to induce oncosis because the cytotoxic response to CPE was blocked using oncosis-specific 
inhibitors glycine and YVAD-CHO (20).  It was later determined that the degree of Ca2+ influx is 
responsible for driving the CPE-treated cell to either apoptosis or oncosis, both of which are 
mediated through calpain- and calmodulin-dependent pathways (19). 
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Figure 1.5  Cellular death pathways induced by CPE treatment.  A small 
degree of Ca2+ influx by lower doses of CPE leads to an apoptotic 
response (left pathway).  High doses of CPE treatment induce large 
amounts of Ca2+ influx leading to oncosis (right pathway). 
 
 
1.3.3 Membranes and complexes: the molecular action of CPE 
 
The early molecular events occurring as a result of enterotoxin treatment of sensitive cells have 
garnered the interest of a wide array of scientific investigators, from toxinologists to cell 
biologists, and even oncologists.  CPE maintains some unique features in its molecular 
mechanism of action, however, as the present body of work proceeds it should be come clear 
that CPE has several mechanistic and structural characteristics reminiscent of a particular 
family of bacterial toxins (discussed later in this dissertation). 
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1.3.3.1  Receptor binding 
 
Specific binding of CPE to membranes was first recognized in 1979 as being essential for 
cytotoxicity (126) and remains to this day the necessary first step in molecular action of CPE.  
While CPE is able to bind to non-intestinal tissues such as liver and kidney (119), the 
physiological relevance to this capability is questionable and more likely a result of coincidental 
expression of CPE receptors (detailed below).  One interesting feature of CPE binding to the 
membrane surface of cells is that it is reported to be irreversible, even resistant to dissociation 
with chaotropic salts (119).  Since the association and dissociation rates of CPE with 
membranes are so different, it has been put forth in the literature that CPE undergoes a 
conformational change after receptor binding, thus not permitting escape of the toxin from the 
membrane after binding (122). 
Using a Vero cell expression library created in natively CPE-resistant L929 mouse cells, 
Katahira et al. discovered a functional receptor for CPE which they entitled “CPE-R” (88).  L929 
cells induced to express CPE-R bound high levels of the toxin and exhibited extensive 
morphologic damage (blebbing, cellular detachment) after CPE treatment (88).   Another 
functional receptor, androgen withdrawal apoptosis protein (RVP1), was later defined through 
analysis of human and mouse cDNAs homologous to the Vero CPE-R protein (89).  These CPE 
receptors were then determined to be part of a large multi-gene family of tetraspan integral 
membrane proteins, named claudins, found to be associated with tight junctions (Fig. 1.6A; 
(146)). 
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Figure 1.6  Cartoon model of the membrane topology and domain 
structure of claudin (A) and occludin (B). 
 
 
While the involvement of claudins in the structure and function of tight junctions is an 
incredibly active area of research (reviewed in (50, 216)), additional work on characterizing 
CPE:claudin interactions continues to put forth interesting findings regarding the molecular level 
CPE action.  Among the 24 claudins currently identified, six claudins (claudin-3 (RVP1), -4 
(CPE-R), -6, -7, -8 and -14) have been shown to be capable of CPE binding (47).  Conversely, 
four claudins (claudin-1, -2, -5, and -10) were identified in that same study to lack the ability to 
serve as a CPE receptor.  The second extracellular loop of claudins (Fig. 1.6A) has been 
determined to be the region responsible for CPE binding, as chimeric claudins constructed from 
claudin-1 and claudin-3 only could interact with CPE when the second extracellular loop of 
claudin-3 was present (47).   
The discovery of claudins as a cellular receptor for CPE is highly consistent with the 
location of the enterotoxin in natural disease.  While tight junctions are known for their ‘fence’ 
function of defining the apical and basolateral membrane compartments, they also provide a 
 21 
‘gate’ function in regulating paracellular permeability across epithelia (50, 216).  Since individual 
claudins contain differences in charged amino acid residues in the first extracellular loop (Fig. 
1.6A), its is thought that the differential expression of claudins in epithelial tissue directly 
regulates permeability of ions and other molecules paracellularly (23, 218).  Not only are the 
CPE receptors claudin-3, -4, -7, -8 expressed in the mammalian small intestine (46, 162), but 
each have been shown to be localized along the length of intestinal villi (as opposed to the 
crypts) suggesting they would be fully accessible to CPE during infection.  Thus, it appears that 
CPE has been perfectly selected to bind receptors which it is likely to encounter in its passage 
through the intestinal tract. 
  
1.3.3.2  Small complex formation by CPE 
 
When CPE initially binds to membranes containing functional CPE receptors, the toxin is 
localized in an SDS-sensitive complex of roughly ~90 kDa in size (Fig 1.7; (229)).  Referred to in 
the literature (and hereafter) as the ‘small complex’, this association of proteins has been shown 
to contain a ~50 kDa protein by CPE co-immunoprecipitation studies of CPE-treated Vero and 
Caco-2 cells (229).  The CPE small complex appears to not insert into membranes, since CPE 
in this complex is not protected from digestion by soluble proteases (228).  In addition, rabbit 
polyclonal antibodies against CPE could readily react with CPE in the small complex, indicating 
this complex is surfaced-exposed at this stage (94). 
One interpretation of the observation of the small complex is that it simply represents 
CPE bound to its receptor.  However, since some claudins (20-27 kDa) have been clearly 
shown to serve as functional receptors (47, 88, 89), whether the ~50 kDa protein (229) is a 
multimer of claudin (or some another protein altogether) is unknown at this time.  Evidence 
providing support for the ~50 kDa protein being a claudin multimer has come from recent results 
demonstrating that both receptor and non-receptor claudins can be located in the small complex 
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(166).  Since claudin self-association and multimerization has been previously reported (49, 
106, 139, 176, 217), the idea of the unknown ~50 kDa protein being comprised of two or more 
claudins (receptor and non-receptor) is particularly attractive.  
 
 
 
Figure 1.7  Model for the molecular action of CPE prior to start of the present 
study.  CPE binds to transmembrane cellular receptor proteins (claudins) to form 
the small complex.  At physiological conditions, CPE rapidly forms a large 
complex of ~155 kDa which is concomitant with membrane permeability changes 
of the cell.  A second large complex of ~200 kDa can also be formed by CPE and 
contains the tight junction protein occludin. 
 
 
1.3.3.3  Large complex formation by CPE 
 
After receptor binding and formation of the small complex, CPE associates with additional 
proteins to form an SDS-resistant complex of high molecular mass (Fig. 1.7).  This was first 
discovered when SDS-PAGE gels showed that the formation of high molecular mass radioactive 
material correlated with increasing treatment times of rabbit brush border membranes (BBMs) 
with 125I-CPE (118).  A follow-up study using size exclusion chromatography initially assessed 
the molecular mass of this CPE complex to be ~160,000 kDa, and a CPE-affinity 
chromatography column precipitated an ~70 kDa protein in similarly treated BBMs (232).  It was 
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presented in this preliminary work that one molecule of CPE, one ~50 kDa protein (described 
above (229)), and one ~70 kDa protein combined to form the ~160,000 kDa large complex 
which was resistant to SDS (232).   
The significance of the formation of large complex was established when it was found to 
precisely correlate with membrane permeability alterations of cells (117), suggesting that this 
complex functions as a pore (or a subunit thereof).  It was also determined that the large 
complex only is formed under physiological temperatures; Vero cells treated with CPE at 4°C 
only formed large complex after being warmed to 37°C (117).   Unlike the SDS-sensitive small 
complex, the SDS-resistant CPE large complex rapidly gains resistance to pronase when 
associated with membranes (228).  Since extraction of membranes leaves CPE sensitive to 
pronase, this implies that CPE acquires pronase resistance by insertion into the membrane, an 
concept consistent with the pore-forming action of CPE (108, 114, 116).  Despite its insertion 
into membranes, part of the CPE large complex must remain surface exposed, as anti-CPE 
polyclonal antibodies can react with CPE in the large complex (94). 
When Caco-2 cells were utilized in CPE action studies and characterized for their 
response to CPE, not one, but two SDS-resistant large complexes were detected after CPE 
treatment of isolated Caco-2 cells (186).  The first complex was reported to have a molecular 
mass of ~155 kDa and is believed to be the same large complex seen when BBMs and Vero 
cells are treated with CPE at 37°C (118, 232).  The second large complex is of higher molecular 
mass (~200 kDa) and was shown by immunoprecipitation, electroelution, and Western blotting 
analyses to contain the tight junction protein, occludin (186).  Although this ~65 kDa protein was 
initially thought to be the major structural constituent of tight junctions, the identification and 
functional characterization of claudins quickly usurped the importance of occludin in tight 
junction physiology.  Interestingly, CPE treatment of Caco-2 monolayers causes removal of 
occludin from the tight junction via internalization (185).  While it is currently unclear what role 
occludin plays in both tight junction composition or CPE-mediated cytotoxicity, rat fibroblast 
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transfectants expressing occludin (but no claudins) could not bind CPE and were not sensitive 
to the toxin (186).  This result indicates that CPE does not interact directly with occludin (at least 
initially), and though likely, it remains to be shown that association of occludin with these CPE 
large complexes is mediated through claudin. 
The specific involvement of claudins within the CPE large complexes has been recently 
evaluated (166).  Preliminary work demonstrating the association of CPE with claudin showed 
that when mouse L929 cells expressing claudin-4 were treated with the enterotoxin, high 
molecular mass material was formed that apparently contained claudin-4 (88).  Recent work has 
conclusively demonstrated that claudins are located in the small and both large complexes 
formed by CPE-treated Caco-2 cells (166).  One of the more interesting findings from this study 
is that claudin-1, previously determined to lack the ability to bind CPE (47), is also physically- 
associated with CPE in each of the complexes (166).  Since claudin-1 cannot directly interact 
with CPE, its presence must be a result of claudin:claudin reactions.  The association of multiple 
claudins with these complexes will be revisited later in this dissertation. 
 
1.3.3.4  Exploiting CPE:claudin interactions: clinical and therapeutic applications  
 
As mentioned above, the discovery that CPE specifically interacts with claudin has piqued the 
interest of not only those who study bacterial toxins, but also cell and cancer biologists.  Within 
the past five years, alterations in claudin expression have been detected in over ten different 
cancers, including breast, prostate, and ovarian cancers (reviewed in (95)).  Since claudin-3 and 
claudin-4 are overexpressed in many tumors (including some resistant to current 
chemotherapeutics (174, 197)), a novel CPE-based therapeutic has been pursued by several 
investigators.  One study demonstrating the tremendous potential for a CPE-based cancer 
therapy approach gave intraperitoneal injections of CPE to treat ovarian tumors explanted on 
the backs of severe combined immune deficiency mice (135).  All mice receiving these 
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injections had a significant inhibition of the growth of their explanted tumors with excellent 
survival rates. 
Other investigators have taken advantage of the remarkable effect of CPE on claudin-
expressing cells.  A binding, but non-cytotoxic recombinant fragment of CPE (C-CPE; see CPE 
structure-function section below) has been shown to remove claudin-4 from tight junctions, while 
leaving claudin-1, a non-receptor claudin, unaffected (195).  Tight junction functionality of C-
CPE-treated cells was also investigated in this study, showing that transepithelial resistance 
dramatically decreased when C-CPE was added to MDCK cell monolayers.  Several follow-up 
studies have shown that C-CPE treatment of rat intestinal loops enhances the absorption of 
dextrans, and structure-function studies of this claudin-modulating fragment are actively ongoing 
((34, 35, 69, 96, 105, 204); described in detail below).  While the botulinum toxin has 
established an incredible precedent for the application of bacterial toxin activity for clinical 
benefit (reviewed in (21)), CPE maintains impressive potential for both direct treatment of 
cancers and for enhancing small molecule absorption through paracellular permeability 
modulation. 
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1.4 CORRELATING CPE STRUCTURE WITH ACTIVITY 
 
 
1.4.1 CPE biochemistry 
 
As mentioned above, CPE is a single polypeptide of 319 amino acids (Fig. 1.8; (29)).  Though 
determined to be 35,346 Da in molecular mass, CPE undergoes anomalous aggregation in the 
presence of detergents, most notably with SDS (36, 188).  An isoelectric point near 4.3 indicates 
that CPE is a highly negatively-charged molecule with a net charge of approximately -9 at 
neutral pH.  CPE on average has normal hydrophobicity (Fig 1.9), however one significantly 
hydrophobic section appears to exists between residues 80-110.  Serine, leucine, asparagine, 
and isoleucine are among the most abundant amino acids within CPE’s primary amino acid 
structure.  Biological activity of CPE can be abolished after only 5 min at 60°C (151), and 
incubation in solutions with pH values of 1.0, 3.0, 5.0, and 12.0 can also readily inactivate the 
toxin (31). 
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Figure 1.8  Primary amino acid structure of CPE.  While a detailed discussion of the functional 
regions can be found below, residues in blue box represent the N-terminal cytotoxicity domain, 
residues in yellow box represent the putative TMD, and residues in the red box represent the C-
terminal binding domain. 
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Figure 1.9  Kyte-Doolittle hydrophobicity analysis of CPE (97).  A, Hydrophobicity plot using all 319 amino 
acids of CPE shows overall average hydrophobicity with the exception of a region between roughly amino 
acids 80-110 (dashed box).  B, In addition to overall increased hydrophobicity, amino acids in this 80-110 
region contain striking pattern of alternating hydrophobicity. 
 
 
Two circular dichroism studies examining the secondary structure of CPE observed very 
high beta sheet composition (60-80%) and low alpha helical content at physiological conditions 
(58, 173).  Both studies also noted a shift in secondary structure from sheet to helix at pH 
extremes or in the presence of SDS.  Current secondary structure prediction analysis is 
somewhat consistent with these early studies in that ~85% of the residues are in a beta sheet or 
loop structure and only ~15% in a helix (Fig. 1.10; (170)).  Additional correlations between 
elements of CPE’s predicted secondary structure and its structure-function relationships will be 
presented later in this dissertation. 
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Figure 1.10  Secondary amino acid structure prediction analysis of CPE using the PROF method (170). 
 
 
1.4.2 Current knowledge of structure-function relationships within CPE 
 
At the beginning of the present study, two major regions of CPE had been identified as 
important for activity: the N-terminal ~60 amino acids and the C-terminal 30 amino acids.  These 
regions were initially discovered by generating fragments of the toxin via enzymatic and 
chemical cleavage.  Molecular cloning with recombinant DNA techniques later confirmed and 
extended these early discoveries.  The identification and characterization of each of these 
functional regions will be discussed individually below. 
 
1.4.2.1  N-terminal activation sequences 
 
The ability to generate highly-purified preparations of CPE led to enzymatic and chemical 
cleavage approaches that delineated sections of the CPE protein important for its activity.  In 
one of the first such studies, treatment of purified CPE with trypsin increased its activity by ~3-
fold (Fig. 1.11; (60)).  These findings were later confirmed using Vero cells where trypsinization 
 30 
of CPE caused a 2-3 fold increase in 86Rb release from these cells, but not an increase in 
receptor binding (Fig. 1.11; (67)).  Limited digestion of CPE with another intestinal protease, 
chymotrypsin, also resulted in an ~3-fold increase of cytotoxicity toward Vero cells (Fig. 1.11; 
(59)).  The removal of these 25 or 36 amino acids from the N-terminus of CPE (164, 165) by 
treatment with trypsin or chymotrypsin (respectively) is believed to represent an activation step 
for the enterotoxin, since it is likely to encounter these enzymes while initiating disease in the 
small intestine.   
 
 
 
Figure 1.11  Enzymatic, chemical, and cloning fragments of CPE and their respective CPE activities. 
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A deletion mutagenesis study of rCPE confirmed the idea that some amino acids at the 
N-terminus are inhibitory since rCPE constructs lacking 36 or even 44 amino acids from the N-
terminus were ~2-fold more active than full length rCPE or native CPE (Fig. 1.12; (93)).  This 
same study also showed that rCPE (containing a 42 amino acid (His)6 tag fused to the N-
terminus) was less active that native CPE in the Vero 86Rb release assay.  These observations 
collectively suggest that amino acid sequences up to residue 44 at the N-terminus (whether 
existing natively or recombinantly engineered) seem to have an inhibitory effect on cytotoxicity, 
but not binding.  While the exact molecular basis for this effect is not currently known, results 
presented later in this dissertation provide a possible role for the N-terminus in the molecular 
mechanism of action of CPE.   
 
1.4.2.2  N-terminal cytotoxicity region  
 
While the several investigations mentioned above have shown the inhibitory nature of some 
amino acids at the N-terminus of CPE, removal of extensive portions of the N-terminal half of 
the toxin has a deleterious effect on cytotoxicity.  A purified 16 kDa trypsin fragment of CPE 
(containing roughly amino acids 165-319) maintained binding activity but was not cytotoxic (Fig. 
1.11; (57)).  Similar effects were seen when 2-nitro-5-thiocyanobenzoic acid was used to cleave 
CPE after its sole cysteine residue at position 186 (Fig. 1.11), as this purified C-terminal 
fragment of CPE could bind but was inactive (78).  Molecular cloning of amino acids 171-319 of 
CPE confirmed these results, as E. coli lysates expressing this recombinant construct could 
compete for CPE binding but were unable to elicit a cytotoxic response (Fig. 1.11; (68)).  It was 
also shown in this study that the 171-319 fragment of CPE could not insert into membrane like 
CPE, thus assigning a potential functional role for the missing 170 N-terminal amino acids (Fig. 
1.11). 
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Figure 1.12  Deletion mutagenesis of rCPE using molecular cloning (93). 
 
 
The aforementioned deletion mutagenesis study of rCPE more systematically truncated 
the N-terminus of CPE in efforts to define a region required for cytotoxicity.  It was found in this 
work that while deletion of 36 or 44 residues from the N-terminus appeared to activate the toxin,  
removal of 52 amino acids completely ablated large complex formation and cytotoxicity without 
affecting receptor binding (Fig. 1.12; (93)).  Also, deletion of 68, 102, or 167 residues from the 
N-terminus paralleled the binding-competent but non-cytotoxic phenotype of rCPE53-319 (Fig. 
1.12).  This result identified a specific region between D45 and G53 which is required for the 
formation of large complex and eliciting cytotoxicity.  Random mutagenesis of full length rCPE in 
an E. coli mutator strain generated several attenuated mutants, but two contained single point 
mutations near this N-terminal cytotoxicity region (Fig. 1.13; (92)).  The negative charge 
introduced with a G49D mutation in CPE was sufficient to eliminate large complex formation and 
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cytotoxicity, but did not affect binding or small complex formation.  A similar effect was seen 
when the S59L mutation was introduced, though this mutation lies outside of the N-terminal 
cytotoxicity region defined by deletion mutagenesis (Figs. 1.12 & 1.13). 
 
 
Figure 1.13  Random point mutants of rCPE deficient for one or more CPE activity (92). 
 
 
1.4.2.3  C-terminal binding domain 
 
It was discovered early on in investigations of CPE that the C-terminal half of the protein 
contained the receptor binding activity.  As mentioned above, C-terminal fragments of CPE 
generated by enzymatic digestion (57), chemical cleavage (78), or molecular cloning (68) were 
completely deficient in cytotoxicity.  Each of these fragments, however, could competitively 
inhibit binding of native CPE and protect cells from CPE-induced cytotoxicity (Fig 1.11).  While 
chymotrypsinization of CPE was shown to remove 36 N-terminal residues and enhance 
cytotoxicity, treatment with this enzyme also removed 3 amino acids from the C-terminus 
without functional consequence.  Another study determined that an even smaller C-terminal 
fragment (amino acids 290-319) could compete with CPE for receptor binding, and a synthetic 
peptide corresponding to these same amino acids functioned similarly (Fig. 1.11; (66)).  
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Interestingly, rabbit polyclonal antibodies derived against this 30 amino acid peptide could 
neutralize CPE activity (136), giving promise for a potential protective vaccine against CPE-
induced gastrointestinal disease. 
Deletion mutagenesis of the C-terminus of CPE (93) confirmed the above findings when 
it was shown that removal of the 30 C-terminal amino acids completely eliminated binding 
activity (Fig. 1.12).  Interestingly, deletion of only 5 or 10 amino acids had the same effect, 
suggesting that residues at the extreme C-terminus of CPE make up the essential components 
of the C-terminal binding domain.  Combined with the chymotrypsin cleavage results described 
above (59), these results suggest that L315 or F316 may be crucial for binding activity. 
The observation that the C-CPE fragment of rCPE (amino acids 184-319; Fig. 1.14) can 
remove claudins from tight junctions (195) has prompted several investigators to more carefully 
examine N- and C-terminal residues of this fragment and their contributions to tight junction 
modulation.  C-CPE has been demonstrated to enhance the intestinal absorption of small 
molecules by binding to claudins and disrupting the barrier function of tight junctions (34, 35, 
105, 195, 204).  A C-CPE fragment missing residues 184-219 is able to bind to claudins, 
however this fragment variant cannot modulate tight junction permeability (Fig. 1.14; (105)).  
This effect apparently suggests that disruption of tight junctions is mediated by N-terminal 
sequences in this C-terminal fragment of CPE.  Removal of 30 or 16 amino acids from the C-
terminus of C-CPE (Fig. 1.14) completely attenuates claudin binding activity (204), consistent 
with previous reports of the involvement of these residues in CPE binding (65-67, 93). 
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Figure 1.14  Deletion mutagenesis of the C-CPE fragment of CPE 
 
 
The aforementioned random mutagenesis study of rCPE generated a Y310C point 
mutant which was reduced in binding activity compared with wild type CPE (Fig. 1.13; (92)).  
This finding motivated some workers to investigate the role of three tyrosine residues at the C-
terminus of C-CPE.  While some reduction in claudin binding and tight junction modulation was 
seen when the single Y310A and Y312A mutations were introduced, a Y306A mutation seemed 
to be most severe (69).  Double mutations were also most detrimental when a Y306A mutation 
was included, and a triple mutant of Y106A/Y310A/Y312A completely inhibited the ability of this 
variant C-CPE construct to interact with claudins (69).  When non-alanine substitutions were 
introduced at Y106 of C-CPE, replacing this residue with aromatic residues (tryptophan and 
phenylalanine) did not inhibit claudin binding or tight junction modulation as a lysine at this 
position did (34).  While it is still unclear precisely how these residues interact with the second 
extracellular loop of claudin (47), the fragmentation and mutagenesis studies carried out to date 
have helped define essential components of the C-terminal binding domain of CPE. 
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1.5 THE β-BARREL PORE-FORMING TOXINS 
 
 
As mentioned above, CPE contains significant DNA and amino acid homology with only one 
other known protein (a non-toxic hemagglutinin component of the botulinum toxin, (45)).  In 
addition, CPE is not homologous to any toxins, bacterial or otherwise.  Despite this, CPE has 
several structural and functional attributes similar to a particular family of bacterial pore-forming 
toxins.  While these comparisons will discussed in detail later, it is prudent to briefly review the 
mechanisms of action and structural characteristics of this well-studied group of toxins. 
 
1.5.1 Membrane-damaging proteins 
 
The cellular plasma membrane is target for the action of several toxic proteins produced by 
prokaryotes and eukaryotes alike, and membrane attack is even an important constituent of the 
innate immune system (complement).  Bacterial membrane-active toxins can be broken down 
into three groups, i.) small peptides with surfactant-like activity, ii.) toxins which enzymatically 
cleave components of the phospholipid bilayer, and iii.) toxins which insert into the membrane 
form water-filled pores or channels (2).  The latter category of pore-forming toxins (PFTs) can 
further be classified into toxins which use either alpha helices or beta-barrels to penetrate the 
membrane.  Many Gram-positive bacteria (including C. perfringens) produce toxins in this 
second category, and thus the β-barrel pore-forming toxins (β-PFTs) is the subject of the review 
provided below. 
 
 37 
1.5.2 β-PFTs: from water soluble proteins to membrane-penetrating pores 
 
While many investigators examine the β-PFT family from a bacterial pathogenesis standpoint, 
β-PFTs have been also heavily studied based purely on their unique biochemical activities.  
Over 30 different β-PFTs have been identified in both Gram-positive and Gram-negative 
bacteria (Table 1.2; (3)).  Two divisions exist within the β-PFT family, the small-pore β-PFTs and 
the cholesterol-dependent cytolysins.  While the small-pore β-PFTs form smaller oligomeric 
pores containing 5-8 toxin protomers (Table 1.2), the cholesterol-dependent cytolysin pores are 
very large oligomers of up to 50 protomers.  Though variations in their mechanisms exist, these 
toxins form membrane pores by performing the following steps (2).  First, localization to the cell 
membrane occurs by binding to either glycosyl-phosphatidyl-anchored proteins, cholesterol, or 
integral membrane proteins.  Second, membrane-bound protomers undergo significant 
conformational changes and/or proteolytic cleavage to form an oligomeric pre-pore.  Last, 
additional changes in protomer tertiary structure allow the cooperative insertion of one or more 
beta-sheet hairpins from each monomer to form a membrane-penetrating beta-barrel.   
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Table 1.2  Some members of the β-PFT family of toxins 
β-PFT 
Amino 
acids* 
Molecular 
mass (Da)* 
Stoichiometry 
of Oligomer 
Internal Pore 
Diameter (nm) References 
Vibrio cholerae cytolysin 
 
583 64,864 pentamer 1.2-1.6 (83, 234, 240) 
Clostridium perfringens beta toxin 
 
309 34,000 heptamer 1.2 (82, 150, 179) 
Staphylococcus aureus alpha hemolysin 
 
267 33,200 heptamer 1.4 (61, 192) 
Aeromonas hydrophilia aerolysin 470 52,000 heptamer 1.7 (62, 145, 157, 
213, 230) 
Bacillus anthracis protective antigen 
 
735 83,000 heptamer 1.1 (99, 100, 187) 
Clostridium perfringens epsilon toxin 
 
296 32,500 heptamer 2 (122, 144, 
160) 
Bacillus cereus hemolysin II 
 
412 45,600 heptamer ? (103, 132, 
134) 
Bacillus cereus cytotoxin K 
 
304 34,000 heptamer 0.7 (38, 71) 
Staphylococcus aureus  
Panton-Valentine leukocidin (LukS/LukF) 
286/301 31,000/ 
34,000 
octamer 1.9-2.1 (8, 137, 161, 
202) 
Clostridium septicum alpha toxin 
 
412 46,550 ? 1.5 (10, 11, 130) 
Vibrio vulnificus vulnificolysin 
 
481 50,851 ? ~3 (235, 236) 
* Indicates the amino acid count and molecular mass of the secreted monomeric toxin 
 
 
1.5.2.1  Structural attributes of the β-PFTs 
 
The β-PFTs typically have high beta sheet compositions, and the monomeric proteins generally 
range in size from ~300 to 500 amino acids.  Many of these toxins, such as Aeromonas 
hydrophilia aerolysin, Bacillus anthracis protective antigen, and C. perfringens epsilon toxin, 
require proteolytic activation in order to oligomerize (62, 99, 143).  The crystal structure of the S. 
aureus alpha hemolysin, solved in 1996, shed tremendous amounts of light on structure-
function relationships that exist within these proteins (192).  Four structural elements are 
apparent in the S. aureus alpha hemolysin monomer structure (depicted in Fig. 1.15).  First, the 
extreme N-terminus of the protein extends out to make contact with a neighboring monomer in 
the heptamer.  This N-terminal ‘latch’ domain has been shown to be important for 
oligomerization and serves to join monomers together in the oligomeric form (215, 222, 223).  
 39 
The second structural element, the cap region, is essentially the core of the protein and consists 
of a nine-strand β-sandwich.  Upon heptamerization, this region serves as the top of the ring-
shaped pore structure, thus the ‘cap’ demarcation (Figs. 1.15 & 1.16).  A second globular 
domain serves as the third structural element in this protein and is referred to as the ‘rim’ 
domain.  Loops in this largely beta sheet domain make peripheral contact with the membrane 
and serve to anchor the oligomer.  Last, the central stem domain protrudes as a beta hairpin 
from the globular body of the protein inserting into the membrane.  This transmembrane stem 
domain (TMD) is the hallmark of the β-PFTs, and is comprised of amino acids of alternating 
hydrophobicity (Fig 1.15).  Numerous examinations of the β-PFTs have established that the 
hydrophobic residues in these stems face and insert into the membrane, while the hydrophilic 
side chains face the water-filled channel formed by the oligomer (reviewed in (2)). 
 
 
 
Figure 1.15  Three dimensional crystal structure of the S. aureus alpha 
hemolysin monomer (192). 
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The crystal structure of the S. aureus alpha hemolysin heptameric pore has an overall 
mushroom shape, with the stem spanning the phospholipid bilayer (Fig. 1.16; (192)).  In total, 
the oligomer is 10 nm tall and 10 nm across the face of the cap.  Its minimum internal diameter 
of 1.4 nm is typical for the β-PFTs, as most pore diameters have been measured to be between 
1-3 nm (Table 1.2).  The heptameric stoichiometry of S. aureus alpha hemolysin is shared by 
many of the β-PFTs, including the C. perfringens epsilon toxin (Table 1.2).  Hexameric 
stoichiometries have been reported for both the S. aureus alpha (13, 84, 208) and gamma (152) 
hemolysins, however the heptameric form of each of these toxins is regarded in the literature as 
the functional and more physiologically-relevant oligomeric conformation.  The Vibrio cholerae 
cytolysin is the lone example of a β-PFT which has a pentameric stoichiometry (240), and the S. 
aureus Panton-Valentine leukocidin the only toxin shown to be a octomer in its pore (137). 
 
 
 
Figure 1.16  Top (A) and side (B) views of the three dimensional crystal structure of the S. aureus alpha 
hemolysin heptamer (192). 
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1.6 QUESTIONS ADDRESSED IN THIS THESIS 
 
 
As highlighted above, investigations correlating structural elements of CPE with its various 
activities have provided important first steps in understanding how this toxin works.  However, 
the many unanswered questions that remain regarding the molecular mechanism of action of 
CPE warrant a closer look at known and putative functional regions of the toxin.  This 
dissertation describes a protein/membrane biochemistry based approach directed at answering 
three specific questions about the molecular events of CPE action.  First, why is the N-terminal 
cytotoxicity domain essential for post-binding cytotoxic activity of CPE?  Second, is there a 
region of CPE that is important for membrane insertion or pore formation?  Third, what is the 
oligomeric state of CPE within large complexes?  Pursuit of answers to these questions has not 
only furthered the knowledge of CPE action, but has also generated several unforeseen 
advancements in the understanding of how this toxin acts at the molecular level.  Found below 
is a brief description of the background and rationale for each specific question asked in this 
study. 
 
1.6.1 Specific question #1 – Why is the N-terminal cytotoxicity domain of CPE essential 
for its post-binding cytotoxic activity?   
 
As described in detail above, fragmentation of the enterotoxin using enzymatic (57), chemical 
(78), or molecular cloning (68) methods demonstrated that some part of the N-terminal half of 
CPE is essential for cytotoxicity (Fig. 1.11).  However a previous deletion mutagenesis study of 
CPE isolated a stretch of essential amino acids (residues D45 to G53) that, when missing, 
resulted in a variant unaffected in receptor binding but unable to form large complex or elicit a 
cytotoxic response (Fig. 1.12; (93)).  A similar phenotype was noted from a G49D point mutant 
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of CPE generated by random mutagenesis, giving additional evidence that this region is 
somehow important cytotoxicity (Fig. 1.13; (92)). 
While deletion mutagenesis and generation of loss-of-function variants can be an 
important start to defining functional regions of a protein, site-directed mutagenesis provides a 
much more detailed analysis of the contributions of specific amino acids in the targeted region.  
To this end, site-directed mutagenesis was used in the present study to make single alanine 
substitutions of every amino acid in the N-terminal cytotoxicity region of CPE.  The resultant 
rCPE variants were characterized for their CPE activities, and additional non-alanine 
substitutions were then engineered into sites found to crucial for CPE.  Also, structure-function 
relationships defined in in vitro cell culture systems were verified in an in vivo model of CPE 
action, the rabbit ileal loop model. 
 
1.6.2 Specific question #2 – Is there a region of CPE that is important for membrane 
insertion or pore formation? 
 
Previous structure-function studies of the enterotoxin have concentrated on two major functional 
regions, the N-terminal cytotoxicity region and the C-terminal receptor binding domain.  Despite 
this, it is possible (if not likely) that other distinct functional regions exist within the structure of 
the CPE protein.  For example, the enterotoxin has been shown to insert into membranes since 
CPE in the large complex is protected from proteolytic degradation (228).  As reviewed above, 
members of the β-PFT family have very characteristic membrane insertion domains consisting 
of a beta-strand hairpin (Figs. 1.15 and 1.16) that alternates in amino acid hydrophobicity.  
Although CPE lacks sequence homology with this family of toxins, the high beta sheet content 
(58, 173) and pore-forming activity (115) of CPE suggests that it may act in a similar manner 
using a TMD.  Secondary structure predictions only reveal one major hydrophobic patch in CPE 
between amino acids 80-110 (Fig. 1.9).  In addition, when aligned with the TMDs of several 
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members of the β-PFT family, amino acids 81-106 in CPE appear to closely resemble a TMD 
beta hairpin (Fig. 1.17).  Thus, this putative TMD of CPE serves as an ideal candidate for a 
region of CPE involved with membrane insertion. 
To ascertain whether or not amino acids 81-106 could be important for membrane 
insertion, internal deletion mutagenesis was used to delete this region from rCPE.  The resultant 
deletion variant was subsequently characterized for its CPE activity. Additional mutagenesis 
was performed taking into account information learned from Specific Question #1 in efforts to 
gain temporal insights about CPE functional regions. 
 
 
 
Figure 1.17  Alignment of the TMDs of several β-PFTs and CPE amino acids 80-110.  In the TMDs, 
hydrophobic residues (boxed) alternate with hydrophilic residues to form a beta hairpin.  A similar 
pattern can be seen between amino acids 81-106 of CPE. 
 
 
1.6.3 Specific question #3 – What is the oligomeric state of CPE within the large 
complexes? 
 
Many models of the CPE large complex composition have been put forth over the past two 
decades.  The discovery that two unknown proteins (of ~50 and ~70 kDa) physically associate 
with CPE sparked the first model for large complex formation, where one CPE molecule (~35 
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kDa) and one molecule of each of the ~50 and ~70 kDa proteins associate to form an SDS-
resistant large complex of ~160 kDa (232).  Later, the discovery of a second SDS-resistant 
large complex containing occludin in CPE-treated Caco-2 cells led to the idea that the ~160 kDa 
large complex, plus one occludin molecule (~65 kDa), would lead to the formation of the ~200 
kDa large complex (186). 
Despite these findings, it has yet to be directly determined whether or not CPE is a 
monomer or an oligomer in these complexes.  Several anecdotal lines of evidence suggest that 
CPE oligomerizes during cytotoxic action.  First, (as illustrated in Section 1.6.2) the presence of 
a putative TMD (Fig. 1.17), along with other structural similarities, suggests that CPE maintains 
a mechanism of action akin to the β-PFT family by forming an oligomeric membrane-penetrating 
pore.  Second, in the absence of other proteins, CPE has been shown to form ion-permeable 
pores in artificial membranes (72), suggesting that CPE has an inherit ability to form pores 
(presumably by oligomerization).  Last, a previous study has shown that large complex formed 
by native CPE (~35 kDa) and rCPE (~40 kDa) differ in apparent molecular mass by more than 
the ~5 kDa which separates the two toxins alone (186).  This finding is consistent with the idea 
that CPE in present in more than one copy in the SDS-resistant large complexes. 
To directly address whether CPE is an oligomer in its two SDS-resistant large 
complexes, a heteromer gel shift assay was used that has defined the stoichiometries of several 
oligomeric pore-forming toxins (56, 143, 144, 240).  Findings from these experiments prompted 
the reassessment of the molecular masses of complexes formed by CPE, as well as exploration 
of dominant negative phenotypes of several rCPE variants already in existence.   
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2.0 MATERIALS AND METHODS  
 
 
2.1 BACTERIAL CULTURING 
 
 
2.1.1 Bacterial strains, growth media, and media supplements 
  
All plasmids used or generated in this study (Table 2.1) were harbored by the XL-1 Blue strain 
of E. coli.  Solid and/or liquid Luria-Bertani media was to culture bacteria for all molecular 
cloning methods.  Where protein production was desired, liquid SOB media was used.  All 
plated cultures of bacteria were incubated overnight at 37°C.  Liquid cultures of rCPE-
expressing E. coli were subjected to constant shaking at 245 rpm at 37°C overnight.  Ampicillin 
(100 µg/ml) was used when selection for E. coli harboring any of the Table 2.1 constructs was 
required.  When production of rCPE (or its derivatives) was desired, culturing media was 
brought to 5 mM isopropyl-beta-D-thiogalactopyranoside at inoculation (unless otherwise 
noted).  Stocks of bacterial strains were prepared by bringing 1.0 ml of the culture to 20% 
glycerol, then stored at -80°C. 
 
 
2.2 DNA PREPARATION AND MANIPULATION 
 
2.2.1 Site-directed mutagenesis of cpe 
 
Single point mutations were introduced into the cpe gene of pJKFLt-1 using the QuikChange® 
site-directed mutagenesis kit (Stratagene, La Jolla, CA), as instructed by the manufacturer.  
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DNA oligos used for mutagenesis (Table 2.2) were synthesized by Integrated DNA 
Technologies (Coralville, IA).  To generate the mutant plasmids, mutagenesis primers were 
added to a thermocycling reaction permitted in vitro synthesis of the plasmid DNA using the 
high-fidelity polymerase, PfuTurbo.  Parental template DNA was digested away by the 
methylase-specific DNase, Dpn I, and the resultant mutated plasmid mixture was used to 
transform XL-1 Blue Supercompetant E. coli cells.   
 
Table 2.1  Bacterial strains used in this study 
Plasmid harbored Description Reference 
pTrcHis A Protein expression vector used for all constructs made in this 
study.  Encodes a 42 N-terminal (His)6-tag. 
Invitrogen 
(Carlsbad, CA) 
pJKFLt-1  Complete cpe ORF cloned into pTrcHis A. With the 42 amino 
acid (His)6-tag, produces a 40.0 kDa protein of 361 total amino 
acids. 
(93) 
pJSD45A pJKFLt-1 with D45A single point mutation in cpe This study; (190) 
pJSK46A pJKFLt-1 with K46A single point mutation in cpe “ 
pJSG47A pJKFLt-1 with G47A single point mutation in cpe “ 
pJSD48A pJKFLt-1 with D48A single point mutation in cpe “ 
pJSG49A pJKFLt-1 with G49A single point mutation in cpe “ 
pJSW50A pJKFLt-1 with W50A single point mutation in cpe “ 
pJSI51A pJKFLt-1 with I51A single point mutation in cpe “ 
pJSL52A pJKFLt-1 with L52A single point mutation in cpe “ 
pJSG53A pJKFLt-1 with G53A single point mutation in cpe “ 
pJSE54A pJKFLt-1 with E54A single point mutation in cpe “ 
pJSD48E pJKFLt-1 with D48E single point mutation in cpe “ 
pJSD48N pJKFLt-1 with D48N single point mutation in cpe “ 
pJSW50F pJKFLt-1 with W50F single point mutation in cpe “ 
pJSW50Y pJKFLt-1 with W50Y single point mutation in cpe “ 
pJSI51L pJKFLt-1 with I51L single point mutation in cpe “ 
pJSI51V pJKFLt-1 with I51V single point mutation in cpe “ 
pJSTM1 pJKFLt-1 with deletion of amino acids 81-106 in cpe This study; (191) 
pJSTM1-D48A pJSTM1 with D48A single point mutation in cpe This study; (191) 
pJK22 pJKFLt-1 with deletion of amino acids 1-36 in cpe (rCPE37-319) (93) 
pJK19 pJKFLt-1 with deletion of amino acids 1-167 in cpe (rCPE168-319) (93) 
pJKW266Stop pJKFLt-1 with W266Stop stop mutation in cpe (92) 
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 2.2.2 Deletion mutagenesis of cpe 
 
Splicing by overlap extension (80) was used to generate the internal deletion variant of CPE in 
this study.  Regions upstream and downstream from the cpe sequence to be deleted were 
amplified by PCR, with the 3’ upstream reaction primer having complementarity with the 5’ 
downstream reaction primer.  Products from these two PCR reactions were then used as the 
template in a third PCR reaction, adding the 5’ upstream reaction and 3’ downstream reaction 
primers after 3 cycles to allow the amplification of the entire cpe gene (minus the sequence to 
be deleted).  The product from the third PCR reaction was excised from an agarose gel and 
purified with Freeze n’ Squeeze™ Spin Columns (Bio-Rad, Hercules, CA).  After simultaneous 
digestion with BamHI and EcoRI, the DNA was again gel-purified before precipitation using 0.1 
volumes of sodium acetate and 2.0 volumes of cold ethanol for 30 min at -20°C.  The DNA was 
pelleted by centrifugation at 4°C for 30 min, washed once with 70% ethanol, re-centrifuged, and 
resuspended in the desired volume.  This DNA was then ligated into a BamHI and EcoRI-
digested pTrcHis A vector, and this ligation mixture was used to transform XL-1 
Supercompetent Blue E. coli.   
 
2.2.3 DNA Sequencing 
 
The presence of all mutations in the cpe gene of the Table 2.1 constructs were confirmed by 
nucleotide sequencing.  Plasmids containing the mutated cpe gene were isolated from overnight 
E. coli cultures with the QIAGEN Plasmid Mini Kit (QIAGEN, Valencia, CA).  Primers used for 
sequencing can be found in Table 2.2, and sequencing reactions were performed by the 
University of Pittsburgh Genomics and Proteomics Core Laboratories. The BioEdit DNA 
analysis software (64) was used to confirm the presence of the desired mutation and the 
absence of unintended mutations. 
 48 
Table 2.2  DNA primers used in this study for mutagenesis or nucleotide sequencing 
Name Sequence (5’-3’)* Purpose; Reference 
D45A-F GGATTATATGTAATAGCTAAAGGAGATGGTTGGATATTAGGGGAACCC 
D45A-R GGGTTCCCCTAATATCCAACCATCTCCTTTAGCTATTACATATAATCC 
D45A point mutation; (190) 
K46A-F GGATTATATGTAATAGATGCAGGAGATGGTTGGATATTAGGGGAACCC 
K46A-R GGGTTCCCCTAATATCCAACCATCTCCTGCATCTATTACATATAATCC K46A point mutation; (190) 
G47A-F GGATTATATGTAATAGATAAAGCAGATGGTTGGATATTAGGGGAACCC 
G47A-R GGGTTCCCCTAATATCCAACCATCTGCTTTATCTATTACATATAATCC G47A point mutation; (190) 
D48A-F GGATTATATGTAATAGATAAAGGAGCTGGTTGGATATTAGGGGAACCC 
D48A-R GGGTTCCCCTAATATCCAACCAGCTCCTTTATCTATTACATATAATCC D48A point mutation; (190) 
G49A-F GATTATATGTAATAGATAAAGGAGATGCTTGGATATTAGGGGAAC 
G49A-R GTTCCCCTAATATCCAAGCATCTCCTTTATCTATTACATATAATC G49A point mutation; (190) 
W50A-F GTAATAGATAAAGGAGATGGTGCGATATTAGGGGAACCCTCAG 
W50A-R CTGAGGGTTCCCCTAATATCGCACCATCTCCTTTATCTATTAC W50A point mutation; (190) 
I51A-F GTAATAGATAAAGGAGATGGTTGGGCATTAGGGGAACCCTCAG 
I51A-R CTGAGGGTTCCCCTAATGCCCAACCATCTCCTTTATCTATTAC I51A point mutation; (190) 
L52A-F GATAAAGGAGATGGTTGGATAGCAGGGGAACCCTCAGTAGTTTC 
L52A-R GAAACTACTGAGGGTTCCCCTGCTATCCAACCATCTCCTTTATC L52A point mutation; (190) 
G53A-F GGAGATGGTTGGATATTAGCGGAACCCTCAGTAGTTTC 
G53A-R GAAACTACTGAGGGTTCCGCTAATATCCAACCATCTCC G53A point mutation; (190) 
E54A-F GGAGATGGTTGGATATTAGGGGCACCCTCAGTAGTTTC 
E54A-R GAAACTACTGAGGGTGCCCCTAATATCCAACCATCTCC E54A point mutation; (190) 
D48E-F GGATTATATGTAATAGATAAAGGAGAGGGTTGGATATTAGGGGAACCC 
D48E-R GGGTTCCCCTAATATCCAACCCTCTCCTTTATCTATTACATATAATCC D48E point mutation; (190) 
D48N-F TTATATGTAATAGATAAAGGAAATGGTTGGATATTAGGGGAACCC 
D48N-R GGGTTCCCCTAATATCCAACCATTTCCTTTATCTATTACATATAA D48N point mutation; (190) 
W50Y-F GTAATAGATAAAGGAGATGGTTACATATTAGGGGAACCCTCAG 
W50Y-R CTGAGGGTTCCCCTAATATGTAACCATCTCCTTTATCTATTAC W50Y point mutation; (190) 
W50F-F GTAATAGATAAAGGAGATGGTTTTATATTAGGGGAACCCTCAG 
W50F-R CTGAGGGTTCCCCTAATATAAAACCATCTCCTTTATCTATTAC W50F point mutation; (190) 
I51L-F GTAATAGATAAAGGAGATGGTTGGCTATTAGGGGAACCCTCAG 
I51L-R CTGAGGGTTCCCCTAATAGCCAACCATCTCCTTTATCTATTAC I51L point mutation; (190) 
I51V-F GTAATAGATAAAGGAGATGGTTGGGTATTAGGGGAACCCTCAG 
I51V-R CTGAGGGTTCCCCTAATACCCAACCATCTCCTTTATCTATTAC I51V point mutation; (190) 
TM1-A-F CGCGGATCCGGCGATGTTAATTATAATATGCTTAGTAAC TM1 deletion; (191) 
TM1-D-R CCGGAATTCTATATGGAAGGAGAAATTAATGC TM1 deletion; (191) 
TM1-B-R TTGTTCTCCTATAGTTTCTTTAGATTTAGTTAATGATTGGCTAAA TM1 deletion; (191) 
TM1-C-F ACTAAATCTAAAGAAACTATAGGAGAACAAAATACAATAGAAAG TM1 deletion; (191) 
TrcSeq-1F GGACAGCAAATCGGTCGG Sequencing; (191) 
2-F GGTACCTTAAGCCAATCA Sequencing; (191) 
6-R CCGGAATTCTATATGGAAGGAGAAATTAATGC Sequencing; (191) 
PH-309-R TGATCAATATTCCTAAGCTATCTGCAG Sequencing; (191) 
PH-310-F GATTTAGCTGCTACAGAAAGA Sequencing; (191) 
* nucleotides incorporating mutations are bold and underlined 
 
 49 
2.3 PROTEIN BIOCHEMISTRY AND CHROMATOGRAPHY 
 
 
2.3.1 Preparation of CPE 
 
Native CPE was purified from C. perfringens strain NCTC8239 as described previously (127).  
All recombinant CPE constructs were affinity-enriched (via their vector-encoded N-terminal 
(His)6-tags from lysates of E. coli transformed with the indicated construct (Table 2.1).  One liter 
of SOB media was inoculated with 20 ml of an overnight SOB culture of the desired rCPE-
expressing E. coli strain.  After vigorous shaking for 3 h at 37°C, rCPE expression was induced 
by adding isopropyl-beta-D-thiogalactopyranoside to 5 mM.  After an additional 4 h of shaking at 
37°C, the bacteria were harvested by centrifugation.  Final pellets were resuspended in HiTrap 
binding buffer (20 mM NaH2PO4, 500 mM NaCl, 10 mM imidazole, pH 7.4) and then stored at  
-80°C overnight.  After thawing the bacterial suspension, a Heat Systems Ultrasonic Sonicator 
(Misonix, Farmingdale, NJ) was used to lyse the bacteria.  Cell debris was pelleted by 
centrifugation at 7,500 × g and supernatant containing the (His)6-tagged rCPE was passed 
through a MILLEX®HV 0.45 µm PVDF Filter (Millipore, Billerica, MA).  This supernatant was 
then loaded on a cobalt-charged HiTrap Chelating affinity column (Amersham Biosciences, 
Piscataway, NJ).  The column was washed with HiTrap binding buffer and rCPE was then 
eluted with a linear imidazole gradient from 10-500 mM.  Protein-containing fractions from the 
elution were pooled and dialyzed overnight against sterile deI H2O, pH 7.0.  Toxins were stored 
in aliquots at -80°C until use. 
Toxin yield was calculated by quantitative Western blotting, as described previously 
(190).  Briefly, known amounts of native CPE were separated on a 10% acrylamide SDS-PAG 
along with 10-fold serial dilutions of each the affinity-enriched rCPE to be quantitated.  After 
Western blotting for CPE with rabbit polyclonal anti-CPE antiserum, densitometric imaging was 
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performed with the Gel Doc imaging system and Quantity One software (Bio-Rad) to generate a 
standard curve from which the concentration of the rCPE dilutions was estimated. 
 
2.3.2 Enterokinase digestion of rCPE37-319 
 
For use in the heteromeric shift experiments described below, it was necessary to cleave the 
(His)6-tag from the rCPE37-319 construct.  To this end, 200 µg of rCPE37-319 was incubated with 10 
units of EKMax (Invitrogen, Carlsbad, CA) overnight at 37°C.  This digestion mixture was then 
incubated for 20 min at 4°C with the EKAway resin (Invitrogen) to remove the enterokinase from 
the toxin.  This slurry was added to a disposable plastic gravity column, and the flow through 
(containing the (His)6-tagless rCPE37-319) was again quantitated using the Western blot method 
described above, before aliquotting and storage at -80°C. This EKMax-treated rCPE37-319 will 
hereafter be referred to as EK-rCPE37-319. 
 
2.3.3 Limited trypsin proteolysis assay 
 
For site-directed mutagenesis studies, a limited proteolysis assay was used to assess rCPE 
variants for gross conformational changes induced by the introduced mutation.  In these assays, 
400 ng aliquots of each affinity-enriched rCPE species were brought to a final volume of 100 µl 
with phosphate-buffered saline containing Ca2+ and Mg2+ (PBS2+; Mediatech, Herndon, VA).  
Reactions were prepared in quadruplicate and digested at 25°C for 0, 5, 15, or 30 min with 4 ng 
of trypsin (Sigma, St. Louis, MO).  Immediately after completion of the digestion period, 100 µl 
of 2X Laemmli buffer w/ 5% β-mercaptoethanol (β-ME) was added to each reaction before 
sample boiling (5 min) to terminate the reaction.  A 50 µl aliquot of each sample was then 
loaded onto a 10% acrylamide SDS-PAG, followed by Western blotting using anti-CPE antibody 
as described above for the rCPE quantitation. 
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2.3.4 Size exclusion chromatography 
 
To estimate the native molecular masses of the two CPE large complexes, a Sephacryl S400 
HR (Amersham) size exclusion column (76 × 1.5 cm internal diameter) was poured and 
equilibrated with S400-TX buffer (50 mM sodium phosphate, 150 mM NaCl, 0.1% Triton-X 100, 
pH 7.2).  Using the method of Whitaker (226), the column was calibrated by calculating the 
elution volumes of the following standards from Sigma: bovine thyroglobulin (669 kDa), horse 
spleen apoferritin (443 kDa), bovine liver catalase (232 kDa), and aldoase (158 kDa).  Column 
runs were performed overnight at 4°C with a 0.5 ml/min flow rate.   
When performing gel filtration of the CPE large complexes, confluent Caco-2 cells were 
harvested by gentle scraping, washed, and then treated (with inversion) with 10.0 µg/ml native 
CPE in 10 ml Hank’s balanced salt solution lacking Ca2+ or Mg2+ (HBSS, Mediatech) for 20 min 
at 37°C.  Cells were then washed once with HBSS and lysed in S400-TX containing 1% Triton 
X-100 for 30 min at RT with inversion.  Insoluble debris was pelleted by centrifugation, and 5.0 
ml of the lysate supernatant was filtered with a Millex®HV 0.45 µm syringe filter.  This filtrate 
was then loaded on the calibrated Sephacryl S400 HR column and run overnight at 4°C at 0.5 
ml/min, collecting 0.8 ml fractions between 200 and 250 ml of column flow-through.  To assess 
the fractions for the presence of CPE complexes, 100 µl samples were taken from desired 
fractions and brought to 1X Laemmli buffer.  Those samples were then separated on a 4% 
acrylamide SDS-PAG and Western immunoblotted with rabbit polyclonal anti-CPE antiserum.  
Densitometric scanning of autorad films using the Gel Doc imaging system and the 
accompanying Quantity One software (Bio-Rad) was used to quantitate the amount of each 
complex located in each fraction.  Molecular mass estimations were calculated by correlating 
the elution volumes of peak Western blot fractions to the standard curve generated from the 
aforementioned standards. 
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2.3.5 Ferguson plot analysis 
 
Ferguson plots were used in this study to analyze the molecular mass of the CPE large 
complexes.  To perform these experiments, large complex or standards were separated on 4, 5, 
6, and 7% acrylamide PAGs (16 cm), each poured with a 4% acrylamide stacking gel.  Samples 
were electrophoresed at 15 mA per gel until the dye front had reached the bottom of the gels.  
Lanes containing the native molecular mass standards were excised and stained with 
Coomassie Brilliant Blue G-250 (Bio-Rad), while lanes containing CPE-treated cell lysates were 
electrotransferred onto Immobilon™ –P PVDF membranes (Millipore) for 60 min at 1.0 A with 
Gershoni’s transfer buffer (52).  Membranes were then Western blotted with rabbit polyclonal 
anti-CPE antiserum to detect the CPE complexes.  Molecular mass calculations were performed 
as described elsewhere (39, 75).  Briefly, relative migrations of the standards on each 
percentage gel were plotted versus the gel concentration.  Negative slopes from best fit lines 
generated for each standard were then plotted, in a separate graph, versus the known 
molecular masses of the standards.  The line equation of the best fit line from this second plot 
was used to extrapolate the molecular masses of each CPE-containing complex. 
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2.4 CPE ACTIVITY CHARACTERIZATION 
 
 
2.4.1 Morphologic Damage Assay 
 
Caco-2 cells were cultured using minimal essential medium Eagle (Sigma) with 10% fetal 
bovine serum (Mediatech), 1% minimal essential medium non-essential amino acids (Sigma), 
100 units/ml penicillin G (Invitrogen), 100 µg/ml streptomycin (Invitrogen), and 2 mM L-
glutamine (Invitrogen).  Cells were kept in 5% atmospheric CO2 at 37°C throughout culturing.  
To perform the morphologic damage assays, Caco-2 cells grown to confluency in 100 mm 
dishes were washed once with pre-warmed Hank’s balanced salt solution containing Ca2+ and 
Mg2+ (HBSS2+; Mediatech), and then treated with 2.5 µg/ml of toxin in 2 ml of HBSS2+.  Cellular 
morphologic damage (nuclear condensation, cell rounding, detachment from well bottom) was 
assayed at the indicated time points using a Zeiss Axiovert 25 inverted microscope at 10× 
magnification (Zeiss, Thornwood, NY).  A Canon Powershot G5 digital camera and Canon 
Utilities RemoteCapture software (Canon, Inc., Lake Success, NY) were used to capture images 
of cells at each time point, and subsequent image processing was performed with Adobe 
Photoshop software (Adobe Systems, Inc., San Jose, CA). 
 
2.4.2 Competitive binding analysis 
 
Small intestinal BBMs were isolated from female New Zealand White rabbits, as described 
previously (184).  125I-CPE was prepared using IODO-GEN® Pre-Coated Iodination tubes 
(Pierce, Rockford, IL), with 2.5 mCi of Na125I (specific activity - 17.0 mCi/mg, ICN) for 1 mg of 
native CPE.  As described previously (92), BBMs (100 µg) were preincubated for 20 min in 200 
µl of PBS2+ containing various concentrations (0.01-50 µg/ml) of each competing rCPE species. 
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125I-CPE (0.5 µg) was then added to each sample for an additional 20 min at RT. After washing, 
125I-CPE bound to the BBMs was quantitated using a Cobra Quantum gamma counter.  Data 
are expressed as percent of total binding, where total (100%) binding was determined by 
incubating BBMs with 125I-CPE in the absence of any competing rCPE species. The previously 
described rCPE random point variant W226Stop (Table 2.1; (92)) was affinity-enriched (as 
above) and used as a negative control in binding experiments. 
 
2.4.3 Small complex formation 
 
The ability of rCPE variants to form small complex was measured as previously described (92).  
Briefly, BBMs (200 µg) were treated for 15 min at 4°C (to inhibit formation of CPE large 
complexes (117)) with 5 µg of rCPE dissolved in 500 µl of PBS2+. Those BBMs were then 
pelleted, washed, and extracted for 30 min at 4°C with 40 µl of PBS2+ containing 1% Triton X-
100 (Sigma). After microcentrifugation, 10 µl of 5X native loading buffer (5 mM Tris-HCl, 38 mM 
glycine, 33% glycerol, 0.25 mg bromophenol blue) was added to the extraction supernatants.  
These samples were electrophoresed at 5 mA on a 6% acrylamide native PAG and small 
complexes were electrotransferred onto Immobilon–P PVDF membrane (Millipore) using 
Gershoni’s transfer buffer. Western blotting to detect the CPE-containing small complex was 
then performed as described for affinity-enrichment quantitation. 
 
2.4.4 Large complex formation 
 
Large complex formation by each rCPE species was assayed as described previously (190) 
using confluent 100 mm dish cultures of Caco-2 cells. Briefly, cells were washed once with 
HBSS, gently dislodged from the plate with a cell scraper, and harvested by centrifugation.  
After one additional wash with HBSS, 2.5 x 106 harvested cells were resuspended in 200 µl of 
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HBSS.  An rCPE species was then added at a final concentration of 2.5 µg/ml, and samples 
were incubated for 45 min at 37°C with shaking.  After microcentrifugation at 4°C, pelleted cells 
were washed with HBSS containing the Complete® protease inhibitor cocktail (Roche; HBSS-PI) 
at 2X concentration and then finally resuspended in 45 µl of ice cold HBSS-PI.  Benzonase® 
Nuclease (12.5 units; Novagen, Inc., Darmstadt, Germany) was added to each sample for 10 
min at RT.  Samples were brought to 1X Laemmli buffer and then loaded onto a 4% acrylamide 
SDS-PAG that was run overnight for ~19 h at 5 mA before electrotransfer and CPE Western 
immunoblotting as described above. 
For Ferguson plot experiments, it was necessary to form each of the ~155 kDa and ~200 
kDa large complexes in the absence of one another.  To accomplish this, we utilized previous 
findings from our laboratory that short, apical treatment of Caco-2 cell cultures grown to 
confluency on  Transwell® permeable supports (Corning, Corning, NY) results in the formation of 
only the “~155 kDa”  large complex (185).  In order to form the “~200 kDa”  large complex in the 
absence of any “~155 kDa” large complex, a Caco-2 variant cell line was used that only 
produces the “~200 kDa” large CPE complex when confluent monolayers are treated for 30 min.   
After CPE treatment, all cells were washed once with HBSS and then lysed with HBSS 
containing 1% Triton X-100 for 30 min at RT with constant inversion.  Insoluble material was 
pelleted by centrifugation, and the supernatant lysate was prepared for native PAGE by the 
addition of an appropriate amount of 5X native loading buffer.  
 
2.4.5 Heteromer gel shift assay with CPE large complexes 
 
To generate heteromeric CPE large complexes, various ratios of rCPE and EK-rCPE37-319 were 
used to treat 2.5 × 106 Caco-2 cells suspended in HBSS for 20 min at 37°C with constant 
inversion, keeping the total toxin concentration constant at 2.5 µg/ml.  Samples were 
electrophoresed on a 4% acrylamide SDS-PAG cast in a 20 cm Protean II gel electrophoresis 
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system (Bio-Rad) with current kept constant at 50 mA per gel.  After the gels were Western 
blotted as described above, blots were scored qualitatively for the number of resolvable 
individual bands in all lanes.  Densitometric scanning of each lane was performed using the Gel 
Doc imaging system and the accompanying Quantity One software (Bio-Rad). 
 
2.4.6 86Rb release experiments 
 
Formation of CPE pores was determined by measuring 86Rb release from Caco-2 cells, as 
described previously (190).  Briefly, confluent Caco-2 cell monolayers were pre-loaded with 4 
µCi/well of 86RbCl (specific activity, 6.4 mCi/mg; Perkin Elmer) for 4-5 h at 37°C.  After two 
washes with pre-warmed HBSS2+, the radiolabeled cultures were treated with toxin at the 
indicated concentrations for 15 min at 37°C.  86Rb released into the culture supernatant was 
collected and counted with a Cobra Quantum gamma counter (Perkin Elmer).  Spontaneous 
release of 86Rb from cells was measured by incubation of radiolabeled monolayers with HBSS2+ 
alone and maximal release was determined by treating monolayers with 1 ml each of 0.5% 
saponin and 1.0 M citric acid.  Data from 86Rb release experiments were converted and plotted 
as percent maximal release using the following equation: [(experimental release − spontaneous 
release) / (maximal release − spontaneous release)] ? 100. 
 
2.4.7 Pronase resistance of large complex 
 
Experiments used to analyze the pronase susceptibility of large complexes formed by rCPE (or 
its variants) were adapted from a previously published procedure (228).  BBMs (100 µg) were 
treated for 20 min at RT with 1.5 µg of rCPE or 4.5 µg of TM1 (Table 2.1) in 100 µl of PBS2+.  
The BBMs were then washed once with 100 µl of ice-cold PBS2+,  before treatment for 5 or 60 
min in 50 µl of PBS2+ containing the indicated concentration of pronase.  BBMs were then 
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washed three times with ice-cold PBS2+ containing the Complete® protease inhibitor cocktail 
(Roche Applied Science, Penzberg, Germany).  Final pellets were resuspended in Laemmli 
buffer without β-ME, and loaded on a 6% acrylamide SDS-PAG and subsequently treated as a 
CPE Western blot detailed above. 
 
2.4.8 Dissociation of CPE large complex from membranes 
 
rCPE or its variants were added to 100 µg of BBMs at a final concentration of 2.5 µg/ml.  Large 
complex formation was allowed to occur at 37°C for 20 min, followed by a washing step with 
phosphate buffered saline without Ca2+ or Mg2+ (PBS; Mediatech) containing the Complete® 
protease inhibitor cocktail at 2X concentration (PBS-PI; Roche).  After this wash, toxin-treated 
BBMs were resuspended in 200 µl of PBS-PI and inverted gently at 4°C for the indicated time 
periods.  At the end of this incubation, the toxin-treated BBMs were pelleted by centrifugation, 
and both the supernatants and pellets from this spin were separated on an SDS-containing, 4% 
acrylamide gel and Western immunoblotted for CPE as described above.   
 
2.4.9 Heat denaturation of CPE large complex 
 
rCPE or TM1 was added to 100 µg of BBMs for 20 min at 37°C in PBS-PI.  After centrifugation 
and washing once with 200 µl of PBS-PI, BBMs containing large complex were extracted with 
Laemmli buffer containing β-ME then heated at 90°C in a dry bath for the indicated time period.  
After this incubation, samples were separated on a 4% acrylamide SDS-PAG and Western 
immunoblotted for CPE as described above. 
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2.5 IN VIVO ANALYSIS OF CPE ACTIVITY 
 
 
2.5.1 Fluid accumulation in rabbit ileal loops 
 
Adult male New Zealand White rabbits (Charles River) were fasted overnight and then 
tranquilized by an intramuscular injection of xylazine and acepromazine.  Analgesia was 
produced with burprenorphine, and anesthesia was induced with intravenous ketamine 
hydrochloride and maintained with inhalatory isofluorhane.  A laparotomy was performed and 
the small intestine was exposed.  Several lengths (approximately 20 mm) of ileum were isolated 
by ligation, avoiding interference with the blood supply and leaving an empty segment of gut 
between consecutive loops.  Toxin preparations or Ringer's solution (control) were  injected into 
one of each of the ileal loops.  Care was taken to avoid over-distension of loops.  The 
abdominal incision was closed by separate muscle and skin sutures and the animals were kept 
deeply anaesthetized.  After a designated incubation period, the abdominal cavity was 
reopened, and intestinal loops were excised sequentially, in the same order that they had been 
inoculated.  The volume of accumulated fluid and the length of the loops were measured and 
the ratio volume/length was calculated for each loop.  
 
2.5.2 Histopathological analysis of CPE-treated ileal tissues 
 
Selected sections from loops treated for 30 min with 300 µg/ml of rCPE or its mutants were cut 
and embedded.  Mouse monoclonal anti-CPE antibody was used to detect the location of CPE, 
while an anti-mouse streptavidin peroxidase conjugate was used as the secondary antibody.  
Sections were counterstained with hematoxylin, then photomicrographed at total magnification 
of 100X. 
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3.0 RESULTS 
 
 
3.1 FINE-MAPPING OF THE N-TERMINAL CYTOTOXICITY REGION OF CPE 
 
 
3.1.1 Alanine-scanning mutagenesis 
 
3.1.1.1  Introduction of amino acid substitutions 
 
As detailed above, previous rCPE deletion mutagenesis studies (93) have implicated the region 
between residues D45 and G53 of the full length rCPE as being important for cytotoxicity.  For 
that reason, the current study targeted this region for site-directed mutagenesis (Fig. 3.1).  
Because the single methyl group of alanine is small in size and only slightly non-polar, this 
amino acid was chosen for mutagenesis of the N-terminal cytotoxicity region of CPE since it 
would be least likely to induce gross conformational changes.  Therefore, in order to evaluate 
the contribution of each individual amino acid in the N-terminal cytotoxicity region of rCPE, 
single alanine substitutions were introduced into residues D45 to E54 in the fully-toxic rCPE 
background using the QuikChange® Kit (see Section 2.2.1).  All mutations were confirmed by 
nucleotide sequencing of both strands of the mutated cpe gene, and affinity enrichments of the 
resultant variants were assayed for their CPE activities. 
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Figure 3.1  Map of the N-terminal cytotoxicity region targeted for  
site-directed mutagenesis in this study.  Copyright © 2007, the 
American Society for Microbiology.  All rights reserved. 
 
 
3.1.1.2  Morphologic damage of Caco-2 cells by alanine variants of rCPE 
 
Because Caco-2 cells express several CPE-binding claudins (166), they quickly develop cellular 
morphologic alterations (membrane blebbing, nuclear condensation, detachment from plating 
surface) when treated with rCPE.  Thus, these cells were utilized in the present study to screen 
the generated rCPE alanine variants for cytotoxicity.  Caco-2 monolayers treated for 1 h with 
rCPE developed typical changes in cell morphology (Fig. 3.2).  In contrast, no detectable 
damage was observed in monolayers treated for 1 h with HBSS2+ alone or HBSS2+ containing 
the pTrcHis A mock affinity enrichment negative control.  Damage to Caco-2 cell monolayers 
was readily apparent when all affinity-enriched, alanine-substituted rCPE variants were used 
except for D48A and I51A (Fig. 3.2).  This observation gave early indications that these two N-
terminal CPE residues are critical for cytotoxicity. 
 
 
 61 
 
Figure 3.2  Caco-2 morphologic damage assay.  Inset boxes represent toxin preparation 
used to treat Caco-2 monolayers for 1 h at 37°C.  Final magnification of 
photomicrographs is 200×.  Copyright © 2007, the American Society for Microbiology.  All 
rights reserved. 
 
 
3.1.1.3  Analysis of pore-formation by the alanine-substituted rCPE variants   
 
Amino acids 45-53 in CPE have been previously demonstrated to be required for inducing the 
plasma membrane permeability alterations responsible for CPE-mediated cytotoxicity (93).  
Therefore, it was appropriate to assay our collection of single alanine variants of this region for 
their abilities to induce pore-formation in Caco-2 cells with 86Rb-release experiments.  
Consistent with the morphologic damage screening results (Fig. 3.2), D48A and I51A were the 
only rCPE alanine variants that exhibited substantially reduced abilities to cause 86Rb-release 
from Caco-2 cells (Fig. 3.3A, Table 3.1).  Even at 50 µg/ml, D48A elicited no detectable 86Rb 
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release from Caco-2 cells, while I51A induced only slight quantities of release (~35% of 
maximal release) at this very high toxin concentration (Fig. 3.3A).  These findings indicate that 
the D48A and I51A variants are >160-fold less active than rCPE in this assay.  All remaining 
rCPE alanine variants were able to elicit wild-type levels of 86Rb release from cells (Table 3.1), 
consistent with the Caco-2 morphologic damage results (Fig. 3.2).   
 
 
 
Figure 3.3  Assessment of pore-formation by rCPE variants using the 86Rb-release assay.  
Caco-2 cells labeled with 86Rb were treated with the indicated concentration of toxin.  Efflux of 
86Rb is expressed in this figure as percent maximal 86Rb release.  Toxin preparations depicted 
in A are: rCPE (?), D45A (?), D48A (?), I51A (?), L52A (?).  Depicted in B are 86Rb-release 
experiments with rCPE saturation variants including: rCPE (?), D48A (?), D48E (?), D48N 
(?), I51A (?), I51L (?), I51V (?). All data points represent means of three independent 
experiments and error bars represent the standard deviation.  Copyright © 2007, the American 
Society for Microbiology.  All rights reserved. 
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Table 3.1  Summary of rCPE variant phenotypes 
rCPE 
species 
Concentration needed 
for 50% Maximal 
 86Rb release (µg/ml) 
Concentration needed for 
50% 125I-CPE binding 
inhibition (µg/ml) 
Small 
complex 
formation 
Large complex 
formation 
rCPE 0.57 ± 0.19 3.69 ± 0.52 + + 
D45A 0.24 ± 0.04 1.83 ± 0.54 + + 
K46A 0.82 ± 0.07 2.89 ± 0.86 + + 
G47A 0.92 ± 0.63 5.52 ± 0.52 + + 
D48A >50 3.31 ± 0.78 + - 
G49A 0.83 ± 0.23 2.45 ± 0.59 + + 
W50A 1.35 ± 0.64 4.13 ± 0.90 + * 
I51A >50 2.59 ± 0.16 + - 
L52A 0.68 ± 0.21 1.45 ± 0.04 + + 
G53A 0.52 ± 0.15 3.20 ± 0.74 + + 
E54A 0.38 ± 0.19 2.47 ± 0.56 + + 
D48E >50 1.92 ± 0.05 + - 
D48N >50 2.21 ± 0.16 + - 
W50Y 0.65 ± 0.4 2.68 ± 0.45 + + 
W50F 0.9 ± 0.2 2.60 ± 1.41 + + 
I51L 0.9 ± 0.3 3.23 ± 0.18 + + 
I51V 1.6 ± 1.2 2.82 ± 0.57 + + 
 *The W50A variant produces an atypical large complex (Fig. 3.6) 
 
 
3.1.1.4  Competitive binding ability of the rCPE alanine variants 
 
To determine why the D48A and I51A rCPE variants exhibit attenuated cytotoxicity, the ability of 
the rCPE alanine variants to perform early steps in CPE action was assessed.  Initial 
interactions between CPE and claudins represent the first step in CPE action, receptor binding 
(reviewed in Section 1.3.3.1).  Since previous structure-function analyses have mapped 
receptor binding activity of CPE to its C-terminal domain (Fig. 1.12; (93)), the introduction of 
alanine substitutions in the N-terminal amino acids 45-54 was not expected to affect binding 
activity.  Using a well-established BBM competitive binding assay (92, 93, 117, 136, 190, 232, 
233) that measures the ability of an rCPE species to inhibit binding of 125I-labeled native CPE to 
BBMs, this expectation was confirmed.  As can be seen in Table 3.1, all alanine-substituted 
rCPE variants generated in this study had similar ability as rCPE to inhibit 125I-CPE binding to 
BBMs, including the attenuated variants D48A and I51A (Fig. 3.4).  The previously-identified 
W226Stop point variant of rCPE (92) failed to inhibit 125I-CPE binding to BBMs as expected (Fig. 
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3.4),  further verifying the functionality of the BBM competitive binding assay.  Collectively, these 
binding activity results support previous studies of the enterotoxin indicating that its N-terminus 
is not involved in binding (57, 65-68, 78, 93, 113, 136).  This implies that D48 and I51 of the 
CPE are important for some post-binding step in CPE action. 
 
 
 
Figure 3.4  Competitive binding analysis of rCPE variants.  BBMs were pre-
incubated with the indicated concentrations of each rCPE species before 
incubating with 125I-CPE.  rCPE species depicted above are: rCPE (?), D48A 
(?), D48E (?), D48N (?), I51A (?), W226Stop (?), pTrcHis A empty vector 
(?).  Data points represent the average of duplicate independent 
experiments run in triplicate, and error bars represent the standard deviation.  
Copyright © 2007, the American Society for Microbiology.  All rights reserved. 
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3.1.1.5  Small complex formation by the rCPE alanine variants   
 
Upon binding to sensitive cells, CPE can initially be localized in an SDS-sensitive complex of 
~90 kDa (229, 231) that likely represents CPE bound to its receptor (reviewed in Section 
1.3.3.2).  It was expected, therefore, that the ability of the alanine rCPE variants to form small 
complex would parallel their binding activities (Fig. 3.4, Table 3.1).  When each rCPE variant 
species generated in this study was used to treat BBMs at 4°C (to prevent formation of large 
complex (117)), all variants were able to form the small complex (see Fig. 3.5 for a 
representative experiment).  Although the temperature used in these experiments is typically 
inhibitory for large complex formation, limited amounts of the large complex was still observed 
using active rCPE species (note the immunoreactive material migrating above the small 
complex in the rCPE lane of the blot in Fig. 3.5).  Interestingly, no large complex formation was 
apparent in lanes containing extracts from BBMs similarly treated with the D48A or I51A 
variants (Fig. 3.5). 
 
 
Figure 3.5  Small complex formation by rCPE variants.  BBMs were treated with 2.5 µg/ml of the 
indicated rCPE species before washing and extraction with Triton X-100.  Complexes were then 
separated on a 6% acrylamide native PAG and Western blotted for CPE.  Copyright © 2007, the 
American Society for Microbiology.  All rights reserved. 
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3.1.1.6  Large complex formation by the rCPE alanine variants 
 
As described in detail above, CPE treatment of cells at physiological temperatures results in the 
formation of two large, SDS-resistant complexes in Caco-2 cells (186, 232) which are likely CPE 
pores (or subunits thereof).  When experiments were performed to analyze the large complex 
forming ability of each alanine rCPE variant prepared in this study, several intriguing 
observations were made.  The most significant result was that the completely non-cytotoxic 
D48A variant (Fig. 3.2 & 3.3) forms no detectable amount of SDS-resistant, high molecular 
mass material, while the highly attenuated I51A variant forms only small amounts of the classic 
~155 and ~200 kDa CPE complexes (Fig. 3.6).  These observations extend previous findings 
(117) that development of cytotoxicity (Fig. 3.2) and pore-formation (Fig. 3.3) correlates with 
(and is proportional to) the ability to form the large complexes (Fig. 3.6).  Agreeing with this idea 
were the observations that all rCPE alanine variants eliciting 86Rb-release levels comparable to 
rCPE (Table 3.1, Fig. 3.3A) could also form SDS-resistant, large complexes (Fig. 3.6).   
The large complex phenotypes of several active rCPE alanine variants differed 
qualitatively and quantitatively from the classical ~155 and ~200 kDa CPE complexes formed by 
rCPE.  For example, rCPE variants G47A and G49A produced appreciable levels of the 
standard ~155 and ~200 kDa CPE complexes, but each formed additional immunoreactive 
material even higher in molecular mass (Fig. 3.6).  In contrast, W50A (which is only slightly 
attenuated in 86Rb-release experiments (Table 3.1)), made very little ~155 kDa CPE complex 
despite forming some immunoreactive material of roughly similar size as the ~200 kDa large 
complex produced by rCPE (Fig. 3.6).  Also, substantially greater amounts of immunoreactive 
material were present at (or near) the dye front of lanes of W50A-treated Caco-2 cells compared 
with rCPE-treated cells (Fig. 3.6). 
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Figure 3.6  Formation of the SDS-resistant large complexes by rCPE variants.  Isolated Caco-2 cells 
were treated with the indicated toxin for 45 min at 37°C.  After washing, cells were lysed with Laemmli 
buffer and separated on a 4% acrylamide SDS-PAG before Western blotting for CPE.  Copyright © 
2007, the American Society for Microbiology.  All rights reserved. 
 
 
3.1.1.7  Analysis of gross conformational changes in rCPE alanine variants   
 
The above results indicated that the D48A and I51A rCPE variants are highly attenuated at 
cytotoxicity due to an impaired ability to form the large complexes.  To address whether these 
variants lost their activity because of gross conformational changes induced by the alanine 
substitutions, limited trypsin proteolysis was performed.  As described previously (92), the rCPE 
protein normally exposes only a few of the 24 trypsin digestion sites present in its primary amino 
acid structure.  Misfolded rCPE variants have more sites exposed and thus are more sensitive 
to limited digestion with trypsin. 
With the exception of an initial affinity-enrichment batch of W50A, all rCPE variants 
prepared in this study displayed similar trypsin digestion patterns as rCPE (a representative blot 
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is shown in Fig. 3.7).  These results suggest that the attenuation of the D48A and I51A rCPE 
variants is specifically due to the loss of the native amino acid at D48 and I51, rather than from 
gross conformational changes occurring in those two rCPE variants. As mentioned, the first 
affinity-enrichment preparation of the W50A rCPE variant was nontoxic and displayed a trypsin 
digestion pattern suggestive of a substantially misfolded protein (Fig. 3.7, W50A1). Therefore, 
this inactive batch of W50A served as a control, verifying the ability of the trypsin proteolysis 
assay to detect misfolded rCPE.  Note that all subsequent affinity-enrichment preparations of 
W50A displayed a trypsin digestion pattern similar to that of rCPE (Fig. 3.7.; W50A2).  Those 
later W50A preparations were also active for receptor binding, small and large complex 
formation, morphologic damage and 86Rb release (Table 3.1).   
 
 
 
Figure 3.7  Limited trypsin proteolysis of rCPE variants.  Four hundred ng 
of the indicated toxin preparation was digested with trypsin for the 
indicated time period at 37°C.  Reactions were heat-terminated and then 
separated on a 10% acrylamide SDS-PAG and Western blotted for CPE.  
Copyright © 2007, the American Society for Microbiology.  All rights 
reserved. 
 
 
 
3.1.2 Saturation mutagenesis of residues important for CPE action 
 
Alanine-scanning mutagenesis above identified that CPE residues D48 and I51 were important 
for CPE toxicity (Figs. 3.2 & 3.3).  In addition, the W50 residue of CPE appears to play a 
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structural role for the protein, given the batch-to-batch variation in protein folding and activity 
observed with the W50A rCPE variant (Figs. 3.6 & 3.7). Therefore, these three CPE residues 
were subjected to saturation mutagenesis to evaluate which biochemical properties are 
important at these positions for CPE function.  These additional studies involved introducing 
more conservative substitutions at each of the three amino acids using the QuikChange® kit 
(see Section 2.2.1) to produce the rCPE variants D48E, D48N, W50F, W50V, I51L, and I51V 
(Table 3.1).  All saturation mutations were confirmed by nucleotide sequencing, and each 
saturation rCPE variant was expressed in E. coli for subsequent affinity-enrichment as 
described earlier. 
 
3.1.2.1  Non-alanine substitutions at D48 
 
The D48A rCPE variant was the only alanine-substituted rCPE lacking any detectable cytotoxic 
activity, even using extremely high concentrations (Table 3.1, Figs. 3.2, 3.3A, & 3.6).  In 
addition, this variant exhibited no gross conformational changes (Fig. 3.7) and had wild-type 
binding and small complex activities (Figs. 3.4 & 3.5), indicating some property of this aspartic 
acid residue is specifically important for formation of the SDS-resistant, large CPE complexes.  
To determine whether side chain size or charge was important for toxicity at CPE amino acid 
48, the rCPE variants D48E and D48N were engineered and tested for cytotoxicity.  These 
rCPE saturation variants both failed to elicit any morphologic damage (Fig. 3.2) or 86Rb release 
from Caco-2 cells even at 50 µg/ml (Fig. 3.3B), matching earlier results observed with the D48A 
rCPE variant.  Also resembling the D48A rCPE variant, the D48E and D48N rCPE variants 
could bind and form the SDS-sensitive small complexes in Caco-2 cells (Figs. 3.4 & 3.5), but 
both variants were unable to form either of the two SDS-resistant large complexes made by 
rCPE (Fig. 3.6), explaining their lack of cytotoxicity in the Fig. 3.3B 86Rb-release experiments. 
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3.1.2.2  Non-alanine substitutions at I51 
 
Activity characterization studies above show that the I51A rCPE variant is highly attenuated, but 
maintains a small amount of cytotoxic activity (Table 3.1, Figs. 3.3A & 3.6A).  Therefore, 
conservative mutations were engineered into rCPE at this amino acid residue to determine 
whether restoring the aliphatic hydrocarbon side chains at this residue would be sufficient to 
regain wild-type levels of toxicity.  The resulting variant rCPE species, I51L and I51V, displayed 
the same cytotoxicity as rCPE in the Caco-2 cell morphology and 86Rb release assays (Figs. 3.2 
& 3.3B).  Consistent with that observation, both rCPE saturation variants also had unimpaired 
receptor binding activity (Table 3.1), formed small complex (Fig 3.5 & Table 3.1), and formed 
the classic ~155 and ~200 kDa large complexes (Fig. 3.6).  In addition, both I51L and I51V 
displayed normal trypsin digestion patterns indicating that they, like I51A, lack gross 
conformational changes. 
 
3.1.2.3  Non-alanine substitutions at W50 
 
Because the W50A variant displayed several interesting phenotypes (Figs. 3.6 & 3.7), 
conservative substitutions more closely resembling the tryptophan residue were engineered at 
CPE amino acid 50.  CPE activity characterization revealed that the resulting W50Y and W50F 
variants were fully active.  Not only did W50Y and W50F bind and form normal amounts of small 
complex, these rCPE variants were highly toxic toward Caco-2 cells and could form functional 
pores (Table 3.1).  While the W50A rCPE variant formed an atypical large complex species 
similar in size to the ~200 kDa complex made by rCPE, the rCPE saturation variants W50Y and 
W50F both formed the classic ~155 and ~200 kDa large complexes (Fig. 3.6).   
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3.1.3 Correlation between in vitro cytotoxicity and in vivo enterotoxicity 
 
The results described above, as well as several previous studies (65-68, 92, 93, 190), have 
analyzed structure-function relationships largely using in vitro models for CPE action.  While 
insights gained from these works have greatly aided understanding the early molecular events 
of CPE action against mammalian cells, it remains unknown whether these same structure-
function relationships also extend to in vivo gastrointestinal disease.  For example, it is possible 
that structural elements of CPE found to be important for cytotoxicity for Caco-2 cells may be 
irrelevant for action at the enterotoxic level.  In efforts to establish a correlation between findings 
made in our in vitro models of CPE action and an in vivo model of CPE gastrointestinal disease, 
the rabbit ileal loop model was used to test the activities of several rCPE constructs generated 
in the present and previous studies. 
 
3.1.3.1  Fluid accumulation in the rabbit ileal loop model 
 
The rCPE point variant D48A was clearly shown in the above experiments to completely lack 
cytotoxic activity (Figs. 3.2, 3.3, & 3.6), despite maintaining full ability to bind (Fig. 3.4) and form 
small complex (Fig. 3.5).  In addition, a previously-described rCPE fragment containing only 
residues 168-319 (rCPE168-319) has been shown to fully maintain binding activity but lack the 
ability to form large complex or be cytotoxic (93).  These two constructs were affinity-enriched 
and assayed for their ability to elicit fluid accumulation in rabbit ileal loops.  In these same 
experiments, native CPE and full length wild-type rCPE served as positive controls, while 
pTrcHis empty vector mock affinity enrichments served as a negative control. 
When affinity-enriched samples of these constructs were injected into rabbit ileal loops 
and incubated for 6 h, a large degree of fluid accumulation was observed in loops treated with 
rCPE or CPE (Fig. 3.8).  Histopathological scoring of rCPE or CPE-treated tissue demonstrated 
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severe mucosal damage involving necrosis and destruction of the superficial epithelium and 
lamina propria (Table 3.2 & Fig. 3.9). Villus blunting and fusion was also noted with rCPE or 
CPE-treated loops, along with hemorrhaging and minimal neutrophilic infiltrate.  On the contrary, 
rabbit ileal loops treated with affinity enrichments of D48A or rCPE168-319 lacked any significant 
fluid accumulation and resembled loops treated with the pTrcHis or Ringer’s only negative 
controls (Fig 3.8).  In addition, these rCPE variant constructs were unable to cause the 
histopathologic response seen with treatment with CPE or rCPE (Table 3.2 & Fig. 3.9). 
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Figure 3.8  Fluid accumulation in rabbit ileal loops treated with rCPE constructs.  
White bars for each construct are the averages of experimental duplicates in one 
rabbit, while black bars for each construct represent averages of all biological 
replicates. * represents p = <0.05, ** represents p = <0.005. 
** **
* * 
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Table 3.2  Gross histology scores of rabbit ileal loops treated with the indicated constructs. 
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CPE (1) +++++ +++++ +++++ +++ ++ +++ - +++++ ++ 
CPE (2) +++++ +++++ +++++ +++ ++ +++ - +++++ ++ 
rCPE (1) +++++ +++++ +++++ +++ ++ +++ - +++++ ++ 
rCPE (2) +++++ +++++ +++++ +++ ++ +++ - +++++ ++ 
pTrcHis (1) - - - - ++ - - - - 
pTrcHis (2) - - - - ++ - - - - 
168-319 (1) - - - - ++ - - - - 
168-319 (2) - - - - ++ - - - - 
D48A (1) - - - - ++ - - - - 
D48A (2) - - - - ++ - - - - 
Ringers (1) - - - - ++ - - - - 
Ringers (2) - - - - ++ - - - - 
Ringers (3) - - - - ++ - - - - 
Untreated loop - - - - ++ - - - - 
 
No significant histological lesions observed the following examined tissues: ileum, colon, kidney, 
lung, spleen, liver, heart, and brain. 
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Figure 3.9  Rabbit intestinal loops were treated with 300 µg/ml of the indicated construct (bottom 
of panels) for 6 h. The loops were then examined grossly and immersed for 24 h in 10% buffered 
formalin, pH 7.2.  The tissue was processed routinely to produce 4 µm thick histological sections 
which were stained with hematoxylin and eosin, followed by photomicroscopy at the indicated 
magnification.  Location of lamina propria is denoted with “LP”, while lumen of intestine is denoted 
with “L” in each photomicrograph.  Total magnification is 40×. 
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3.2 SEARCH FOR A MEMBRANE INSERTION DOMAIN IN CPE 
 
 
3.2.1 Amino acids 81-106 of CPE: a transmembrane stem domain? 
 
As mentioned in the Introduction, CPE shares several structural similarities with pore-forming 
toxins of the β-PFT family including the presence of a 25 amino acid region (residues 81-106) 
that strikingly alternates in side chain hydrophobicity (Fig. 3.10).  Because similar regions serve 
as the TMDs for β-PFTs (Fig 1.15-1.17; (158, 207, 214)), and since no CPE region has yet been 
identified that is involved with membrane penetration, these amino acids were targeted for 
deletion mutagenesis.   
 
 
 
Figure 3.10  A structure-function map of CPE depicting the alternating 
pattern of hydrophobic (asterisk) and hydrophilic amino acids between 
residues 81-106.  The D48 residue in the N-terminal cytotoxicity region 
(inverted triangle) is demonstrated in Section 3.1 to be essential for 
cytotoxicity.  Copyright © 2007, the American Society for Microbiology.  All 
rights reserved. 
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3.2.1.1  Deletion mutagenesis of the putative TMD of CPE 
 
A complete deletion of amino acids 81-106 in CPE was generated using “splicing by overlap 
extension” PCR (80), which amplifies sequences upstream and downstream from the intended 
deletion and splices these two products together in a third reaction (see Section 2.2.2).  This 
methodology has also been helpful with other β-PFTs to identify and characterize TMDs (22, 
131, 138).  The rCPE internal deletion variant generated in this study, named TM1, had a 100% 
deletion of the CPE 81-106 region (Fig. 3.11A).  After DNA sequencing confirmed this mutation, 
the TM1 variant was affinity-enriched via the N-terminal (His)6-tag contributed by the pTrcHis A 
vector.  When enriched samples of TM1 were subjected to a CPE Western blot, the variant 
migrated to its expected molecular mass (Fig. 3.11B). 
 
 
Figure 3.11  A, Constructs used in this study to investigate 
membrane insertion.  B, Fifty ng of the indicated toxin 
preparations were separated on a 12% acrylamide SDS-
PAG and Western blotted for CPE.  Copyright © 2007, the 
American Society for Microbiology.  All rights reserved. 
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3.2.1.2  Competitive binding analysis of the TM1 deletion variant 
 
Since the receptor binding activity of CPE has been previously mapped to the toxin’s C-terminus 
(57, 65-68, 78, 93, 113, 136), it was expected that the rCPE variants produced in this study 
should be unimpaired for their binding activity.  To confirm this, a competitive binding assay was 
performed similar to that found in Section 3.1.1.4 that measured the ability of the TM1 deletion 
variant to inhibit 125I-CPE binding to BBMs.  Table 3.3 contains a calculated binding inhibition 
index for each rCPE variant from this Section.  Since TM1 had a similar binding index to rCPE, 
this analysis demonstrated that deletion of amino acids 81-106 does not exert a major effect on 
receptor binding, and that this TM1 variant can complete the first step in CPE action. 
 
 
 Table 3.3  Binding analysis of constructs in this study 
Construct Inhibition Index* 
Standard 
Deviation 
rCPE 330 ± 80 
pTrcHis A >20,000 - 
W266Stop >20,000 - 
D48A 240 ± 30 
TM1 410   ± 120 
TM1-D48A 650 ± 40 
 
*ng required to cause a 50% inhibition of 125I-CPE 
specific binding 
 
 
3.2.1.3  Cytotoxicity of the TM1 deletion variant 
 
To assess whether deletion of the putative transmembrane stem region affects the ability of an 
rCPE variant to cause cytotoxicity, the Caco-2 morphological damage assay described in 
Section 3.1.1.2 was used.  Treatment of Caco-2 cells with 2.5 µg/ml of rCPE for 1 h caused the 
development of typical CPE cytopathology, including nuclear condensation, membrane 
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blebbing, and cellular detachment from the plate (Fig. 3.12).  No morphologic damage was 
observed if Caco-2 cells were treated with HBSS2+ alone, an affinity-enriched lysate of empty 
vector transformants negative control, or (consistent with previous studies (190)) the D48A point 
variant.   Caco-2 monolayers also showed no observable morphologic damage after 1 h of 
treatment with 2.5 µg/ml of TM1 (Fig. 3.12).  These results, along with the competitive binding 
data in Table 3.3, provided an initial indication that the TM1 variant is deficient in some post-
binding CPE activity. 
 
 
 
Figure 3.12  Caco-2 morphologic damage assay.  Inset boxes indicate which toxin 
preparation used to treat Caco-2 monolayers for 1 h at 37°C.  Final magnification of 
photomicrographs is 200×.  Copyright © 2007, the American Society for Microbiology.  
All rights reserved. 
 
 
3.2.1.4  Pore-formation of the TM1 variants   
 
The TM1 deletion variant was next assayed for its ability to elicit 86Rb release from Caco-2 cells 
via formation of a CPE pore, as performed in Section 3.1.1.3.  As expected, rCPE was 
measured to elicit 50% maximal 86Rb release at a concentration of ~1.0 µg/ml, while the empty 
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vector negative control and D48A point variant predictably did not elicit any 86Rb release (Fig. 
3.13).  When TM1 was similarly tested, it was not able to elicit any appreciable 86Rb release, 
even at artificially high toxin concentrations (up to 50 µg/ml).  These results indicate that TM1 is 
non-cytotoxic to Caco-2 cells because it cannot alter plasma membrane permeability. 
 
 
 
Figure 3.13  Assessment of pore-formation by rCPE variants 
using the 86Rb-release assay.  Caco-2 cells labeled with 86Rb 
were treated with the indicated concentration of toxin.  Efflux of 
86Rb is expressed in this figure as percent maximal 86Rb 
release.  All data points represent means of three independent 
experiments and error bars represent the standard deviation.  
Copyright © 2007, the American Society for Microbiology.  All 
rights reserved. 
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3.2.1.5  Formation of SDS-resistant large complexes by the TM1 variant 
 
The data presented above indicated that, despite maintaining receptor binding activity (Table 
3.3), TM1 is deficient at inducing cytotoxicity (Figs 3.12 & 3.13).  Since CPE cytotoxicity requires 
the formation of an ~155 kDa, SDS-resistant complex in the membranes of sensitive cells (117), 
we next to determined whether TM1 can form this complex.  Treatment of isolated Caco-2 cells 
with 2.5 µg/ml of rCPE resulted in the formation of the ~155 kDa large complex, as well as a 
second ~200 kDa CPE complex (Fig. 3.14), as reported previously (186, 190).  Also as shown 
in Section 3.1, the D48A variant of rCPE did not form either of the two large CPE complexes, 
although this rCPE variant remains membrane-associated (note the immunoreactivity at the dye 
front in Fig. 3.14).  Interestingly, the TM1 variant was able to form the ~155 kDa large complex, 
despite its complete loss of cytotoxicity as depicted in earlier figures.  The TM1 variant did not, 
however, form any detectable ~200 kDa complex. 
 
 
 
Figure 3.14  Formation of the SDS-resistant large complexes by rCPE variants.  Isolated  
Caco-2 cells were treated with the indicated toxin for 45 min at 37°C.  After washing, cells were 
lysed with Laemmli buffer and separated on a 4% acrylamide SDS-PAG before Western 
blotting for CPE.  Copyright © 2007, the American Society for Microbiology.  All rights reserved. 
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3.2.1.6  Analysis of the TM1 pre-pore large complex  
 
The ability of the TM1 deletion variant to form the ~155 kDa complex (Fig. 3.14) in the complete 
absence of cytotoxicity (Fig. 3.12) or pore-formation (Fig. 3.13) led us to investigate whether the 
TM1 large complex could represent a previously-unidentified pre-pore step in the mechanism of 
action of CPE.  To this end, we examined the integrity of the TM1 large complex in membranes 
via resistance of the TM1 large complex to proteolytic degradation, dissociation of this complex 
from membranes, and heat-induced disassembly. 
 
3.2.1.6.1  Pronase resistance of the TM1 large complex 
 
As detailed above in Section 1.3.3.3, CPE in the large complex appears to gain pronase 
resistance by inserting into the membrane (228).  We hypothesized, therefore, that the TM1 
large complex might be trapped in a pre-pore stage because it cannot insert into membranes.  
To test this hypothesis, a pronase resistance assay was performed with TM1 large complex.  
When isolated BBMs containing ~155 kDa large complex formed by rCPE were digested with 
600, 60, or 6 µg/ml of pronase for 5 or 60 min, significant amounts of rCPE large complex 
remained present in BBMs even after a 60 min treatment with 600 µg/ml of pronase (Fig. 3.15).  
In contrast, pronase treatment of membranes containing the TM1 large complex caused a 
nearly complete disappearance of this complex after only a 5 min treatment with 60 µg/ml of 
pronase.  Enhancing these findings is the fact that TM1 samples in Fig. 3.15 deliberately 
contained ~3-fold more TM1 large complex at the start of the experiment compared to rCPE 
large complex.  These results indicate that the ~155 kDa large complex formed by TM1 is 
between 10-100 fold more sensitive to pronase digestion than the ~155 kDa large complex 
formed by wild-type rCPE.  This finding is consistent with the TM1 variant forming the ~155 kDa 
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large complex, but without the putative TMS, the membrane insertion step required for 
development of pronase resistance is blocked. 
 
 
 
Figure 3.15  Comparative pronase susceptibility of large complexes formed by rCPE and TM1.  
Large complex formed by rCPE or TM1 was treated with indicated concentration of pronase for 
the indicated time period.  Samples of these reactions were separated on a 6% acrylamide SDS-
PAG and Western blotted for CPE.  Copyright © 2007, the American Society for Microbiology.  All 
rights reserved. 
 
 
3.2.1.6.2 Membrane dissociation of the TM1 large complex 
 
Once sequestered in CPE large complexes, only limited dissociation of CPE from membranes is 
observed (228).  If the ~155 kDa large complex made by TM1 remains trapped on the 
membrane surface in a pre-pore state, it might be anticipated that this TM1 variant large 
complex would exhibit faster dissociation from membranes compared to large complex formed 
by rCPE.  To test this hypothesis, isolated BBMs containing the ~155 kDa large complex formed 
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by either rCPE or TM1 were harvested by centrifugation at the indicated time intervals, and 
samples from both the supernatants and pellets were Western blotted for CPE.  These studies 
showed that the ~155 kDa large complex formed by rCPE remained largely membrane-
associated even after 20 h (Fig. 3.16).  In contrast, little of the ~155 kDa large complex formed 
by TM1 remained membrane-associated after a similar 20 h incubation.  A steady kinetic 
increase in lower molecular mass material accompanied the loss of large complex 
immunoreactivity in the pellet lanes of the TM1-treated membranes (Fig. 3.16).  This smaller 
complex may be an intermediate from the break-up of the TM1 large complex and is noticeably 
absent from rCPE-treated membranes.   
Overnight film exposures of these blots also allowed the visualization of intact TM1 large 
complex that had dissociated from the membrane (Fig. 3.16, lanes marked “OE”).  Very little (if 
any) large complex could be detected in similarly overexposed lanes containing rCPE-treated 
membranes.  Because these reactions were performed at 4°C and constantly in the presence of 
a strong protease inhibitor cocktail, the TM1 large complex instability noted in Fig. 3.16 is 
unlikely to be the result of proteolytic activity.  In support of this, we observed no differences in 
total protein content between rCPE-, TM1-, or control-treated BBMs after overnight dissociation 
experiments.  Taken together, results from these experiments appear to indicate that the TM1 
large complex is overall less stable and more likely to dissociate from membranes compared 
with large complex formed by rCPE.   
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Figure 3.16  Dissociation of the large complexes formed by rCPE and TM1.  BBMs were 
treated with 2.5 µg/ml of the indicated toxin then were incubated at 4°C with constant inversion 
for the indicated time periods.  Reactions were then microcentrifuged and samples of the 
supernatants and pellets were separated on a 6% acrylamide SDS-PAG and Western blotted 
for CPE.  Copyright © 2007, the American Society for Microbiology.  All rights reserved. 
 
 
3.2.1.6.3  Heat Denaturation of the TM1 Large Complex 
 
Since the ~155 kDa large complex formed by TM1 appeared from Fig. 3.16 experiments to be 
less stable and more likely to disassemble, a heat denaturation experiment was performed to 
test the stability of the TM1 large complex after extraction from membranes.  Heating of 
samples from large complex experiments prior to SDS-PAGE is typically avoided since previous 
studies have shown that boiling of samples promotes higher order aggregation CPE complexes 
(232).  However, it was of interest to assess the ability of the TM1 large complex to resist 
disassembly as a result of heating.  To perform these experiments, large complex formed by 
rCPE and TM1 was extracted from BBMs and then heated for 0 sec, 20 sec, 1 min, 5 min, 10 
min, or 20 min (Fig. 3.17).  While no obvious decrease in rCPE large complex could be seen at 
1 min of heating, the TM1 large complex began to show obvious decreases after only 1 min of 
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heating and was undetectable as a complex past this time point (Fig. 3.17).  A qualitative 
change of the rCPE large complex started to appear at the 5 min time point, however, this 
immunoreactivity remains as an intact complex in striking contrast to the presence of only free 
toxin in TM1 lanes at these times (Fig. 3.17).  Urea was also included in similar heat 
denaturation experiments but had no discernable effect on the large complexes formed by either 
rCPE or TM1. 
 
 
 
Figure 3.17  Heat denaturation of the CPE large complex.  Large complex formed by 
rCPE and TM1 in BBMs was extracted using Laemmli buffer then heated at 90°C for 
the indicated time.  Samples were then separated on a 4% acrylamide SDS-PAG 
and Western blotted for CPE.  Copyright © 2007, the American Society for 
Microbiology.  All rights reserved. 
 
 
3.2.2 Temporal questions regarding functional regions of CPE 
 
The non-cytotoxic, pre-pore phenotype of the TM1 deletion variant described above has 
provided evidence for the importance of amino acids 81-106 in membrane insertion/pore-
formation.  Still unclear, however, is whether these residues are important before or after other 
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functional regions of CPE.  To aid in identifying the order of involvement of known functional 
regions of CPE, an additional variant was generated by introducing a point mutation into the 
TM1 deletion variant background.  As demonstrated above in Section 3.1.1, D48 of CPE is a 
critical residue for forming large complex and cytotoxicity.  While the CPE point variant D48A is 
functional for receptor binding (Fig. 3.4), it does not form large complex (Fig. 3.6) and is unable 
to alter plasma membrane permeability of Caco-2 cells (Fig. 3.3).  Therefore, to determine 
whether the D48 residue is important before or after the involvement of the putative TMS in 
CPE, a D48A mutation was introduced into TM1, producing the combination variant TM1-D48A 
(Fig. 3.11). 
 
3.2.2.1  Activity characterization of TM1-D48A 
 
Both the TM1 and D48A single variants have been shown to be non-cytotoxic for Caco-2 cells, 
despite being unaltered in receptor binding activities (Fig. 3.4 & Table 3.3).  Thus, it was not 
surprising that the TM1-D48A combination variant mirrored this phenotype by failing to elicit 
morphological damage to Caco-2 cells (Fig. 3.12) but at the same time maintaining the ability to 
compete with 125I-CPE for binding (Table 3.3).  Also like the single variants, TM1-D48A was 
unable to cause permeability alterations of Caco-2 cells (Fig. 3.13) indicating it is also deficient 
at pore-formation.  A divergence in the phenotypic similarities with TM1 and D48A single 
variants appeared when the ability to form large complex was examined.  Although the TM1 
variant could form the ~155 kDa large complex, the TM1-D48A combination variant was 
completely deficient at formation of either of the two SDS-resistant large complexes (Fig. 3.14).  
Since the TM1-D48A large complex phenotype resembles the D48A phenotype, this seems to 
indicate that formation of the ~155 kDa large complex is directly dependent on the presence of 
D48, and is independent on amino acids 81-106. 
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3.3 INVESTIGATING THE OLIGOMERIZATION OF CPE IN THE LARGE COMPLEXES 
 
 
As mentioned above in Section 1.6.3, several indirect lines of evidence imply that CPE acts as 
an oligomer.  Briefly restated, i.) CPE contains several structural attributes similar to the 
oligomeric β-PFTs (high β-sheet content (58, 173) and presence of putative TMS (Section 3.2)), 
ii.) CPE can form functional pores in artificial membranes devoid of other proteins (72), and iii.) 
large complexes formed by CPE and rCPE differ in apparent molecular mass than the ~5 kDa 
which separate the two toxins alone (186).  Contained within this Section is an analysis of 
oligomerization of CPE in the two large complexes formed by Caco-2 cells.  Information gained 
from CPE’s stoichiometry in these complexes prompted the reevaluation of their molecular 
masses, and additional evidence for CPE’s oligomeric nature during action came from the 
identification of several dominant negative variants of rCPE. 
 
3.3.1 Generation of rCPE molecular mass variants 
 
In order to determine the stoichiometry of CPE in the large complexes, it was first necessary to 
have two cytotoxic rCPE variants differing significantly in molecular mass.  The largest 
biologically-active construct that currently exists is the full length recombinant CPE (rCPE), 
which contains all 319 native amino acids of native CPE preceded by a 42 amino acid (His)6-tag 
(total molecular mass = 40.0 kDa; Fig. 3.18; (93)).  For a small rCPE construct, we used the N-
terminal deletion variant, rCPE37-319, which was generated during a previous CPE structure-
function study (Figs. 1.12 & 3.18; (93)).  Despite the absence of the first 36 amino acids, this 
rCPE variant has similar binding activity but is 2-3 fold more active than the full-length rCPE 
(93).  To further enhance the molecular mass difference between these two rCPE variants, the 
36 amino acid (His)6-tag on rCPE37-319 was removed with enterokinase (see Section 2.3.2).  This 
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resulted in an rCPE variant (EK-rCPE37-319; total molecular mass = 31.3 kDa; Fig. 3.18) that 
differed from rCPE by a total of 8.7 kDa.   
 
 
 
Figure 3.18  Constructs used in this study to investigate the oligomerization of CPE. 
 
 
3.3.2 Characterization of large complexes made by rCPE molecular mass variants 
 
While the difference in molecular mass between rCPE and EK-rCPE37-319 is readily apparent on 
a 10% acrylamide SDS-PAG Western blotted for CPE (Fig. 3.19A), the large complex 
phenotype of each of these rCPE variants is also strikingly different.  When isolated Caco-2 
cells were treated with either rCPE or EK-rCPE37-319, both toxin variants formed each of the two 
CPE large complexes (Fig. 3.19A).  The complexes formed by these variants were expected to 
differ in molecular mass (since the toxins alone differ by ~9 kDa), but the observed degree to 
which the complexes differed in migration during SDS-PAGE was noteworthy.  Compared to the 
migration of marker proteins on these gels, the “~200 kDa” large complexes formed by the 
variants had an apparent molecular mass difference of ~38.4 kDa, whereas an ~34.9 kDa 
difference was calculated for the “~155 kDa” large complexes made by rCPE versus EK-rCPE37-
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319.  Since large complexes containing a single copy of each CPE variant should only differ by 
~9 kDa (the mass difference between the variants alone), the sizable differences in relative 
migration shown in Fig. 3.19B provided early indication that CPE is present as some kind of an 
oligomer in these two complexes. This observation, along with the aforementioned earlier 
evidence implying CPE may form an oligomeric pore, provided the impetus for pursuing detailed 
studies of the stoichiometry of CPE in the two large complexes. 
 
 
 
Figure 3.19  A, Fifty ng of the indicated toxin preparations were separated on 
a 12% acrylamide SDS-PAG and Western blotted for CPE.  B, The large 
complexes formed by rCPE and EK-rCPE37-319 have drastically different 
relative migrations when separated on a 4% acrylamide SDS-PAG and 
Western blotted for CPE. 
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3.3.3 Heteromeric CPE large complex gel shift analysis 
 
In order to quantitate the number of CPE subunits present in each of the two large CPE 
complexes, a heteromer gel shift assay was used.  This methodology involves forming 
heteromeric oligomers with varying ratios of two variants of the same toxin and separating these 
heteromers electrophoretically.  By quantitating the number of different heteromers observed in 
these gels, the toxin stoichiometry in each oligomer can be deduced.  This technique has been 
successfully used to demonstrate that the pore oligomers of both S. aureus alpha hemolysin 
and C. perfringens epsilon toxin have heptameric stoichiometries (56, 143, 144), while the pore 
oligomers of V. cholerae cytolysin have a pentameric conformation (240).  The conclusion from 
heteromer gel shift analysis that S. aureus alpha hemolysin pore is a heptamer was later 
confirmed when the toxin was crystallized as a heptamer (Fig. 1.16; (192)). 
A similar heteromer gel shift analysis was performed with CPE by treating isolated Caco-
2 cells with different ratios of rCPE and EK-rCPE37-319 and then analyzing the heteromeric CPE 
complexes by Western blotting.  When using conditions optimal for the formation of the “~155 
kDa” large complex, seven individually resolvable complexes were observed (Fig. 3.20A), 
corresponding to seven different CPE oligomers containing a varying composition of rCPE and 
EK-rCPE37-319 subunits.  This conclusion was confirmed by performing densitometry of these 
lanes, where seven distinct, individual peaks can clearly be seen among the tracings (Fig. 
3.20B).  Since five heteromers were observed in Fig. 3.20 (along with two homomers formed by 
rCPE and EK-rCPE37-319 in the absence of each other), CPE must be in six copies in the “~155 
kDa”  large complex to account for these results. 
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Figure 3.20  Heteromer gel shift analysis of the “~155 kDa”  CPE large complex.  A, 
treatment of Caco-2 cells with the indicated ratios of rCPE and EK-rCPE37-319 (tops of 
lanes) resulted in the formation of seven different oligomeric complexes.  B, 
Densitometric tracings of lanes from the blot in A depicting seven individual peaks. 
 
 
A similar approach was then used to analyze the stoichiometry of CPE in the “~200 kDa” 
large CPE complex.  Using heteromeric gel shift analysis with conditions optimized for the 
formation of this complex, seven distinct heteromeric large complex bands were resolved by 
Western blotting (Fig. 3.21A).  Densitometric analysis was also performed on these Western 
blots, which confirmed the presence of seven individual peaks on these tracings (Fig. 3.21B).  
Taken together, these data indicate that are also six copies of CPE in the “~200 kDa”  large 
complex. 
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Figure 3.21  Heteromer gel shift analysis of the “~200 kDa”  CPE large complex.  A, treatment 
of Caco-2 cells with the indicated ratios of rCPE and EK-rCPE37-319 (tops of lanes) resulted in 
the formation of seven different oligomeric complexes.  B, Densitometric tracings of lanes from 
the blot in A depicting seven individual peaks. 
 
 
3.3.4 Reassessment of the molecular mass of the CPE large complexes 
 
Previous studies have suggested the presence of claudin-4 (~20 kDa) in high molecular mass, 
CPE-containing complexes formed in membranes of CPE-sensitive cells (88).  Recent results 
from our laboratory have conclusively demonstrated the presence of both receptor and non-
receptor claudins in the “~155 kDa” and “~200 kDa” large complexes (166). Also, we have 
previously shown that occludin, an ~65 kDa tight junction protein, is present in the “~200 kDa” 
large complex (186).  The presence of these host proteins in CPE complexes (88, 166, 186), 
along with the heteromer gel shift results presented above indicating CPE’s hexamerization 
(Figs. 3.20 & 3.21), made it readily apparent that the ~155 and ~200 kDa molecular masses 
previously assigned to these two large CPE complexes must be underestimates.  The “~155 
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kDa” large complex must have a molecular mass of at least ~230 kDa (six CPE molecules plus 
at least one claudin) while the “~200 kDa” large complex must have a molecular mass of at 
least ~300 kDa (six CPE molecules plus at least one molecule each of claudin and occludin).  It 
is also possible that multiple copies of claudin and/or occludin are present in these complexes, 
which would even further increase their molecular masses. 
Since a discrepancy clearly existed between the predicted molecular masses of the CPE 
large complexes and their apparent molecular masses when analyzed on SDS-containing, low 
percentage PAGs (186, 232), we reevaluated the molecular mass of the CPE complexes by 
altering the acrylamide concentration of SDS-PAGs used for the separation of the CPE large 
complexes.  When SDS lysates of CPE-treated Caco-2 cells were separated using either a 4% 
or 6% PAG containing SDS, migration of the “~155” and “~200 kDa”  large complexes were very 
different (Fig. 3.22).  On the 4% gel, the “~200 kDa” large complex had a relative migration 
corresponding to a mass of ~180 kDa, while the same complex on the 6% gel migrated with a 
mass of ~215 kDa.  Similarly, the “~155 kDa”  large complex was observed to have a relative 
mass of ~140 kDa on the 4% gel, but exhibited a mass of ~160 kDa on the 6% gel.  If the CPE 
complexes migrated through these gels solely by their molecular masses, their relative 
migration should not change as the acrylamide percentage of the gels was increased.  Since, 
however, the apparent molecular mass of these complexes was dependent on the gel 
concentration in Fig. 3.22 experiments, we hypothesized that these complexes were migrating 
through the acrylamide matrix as tightly compacted, oligomeric structures that mask their actual 
molecular masses.  In efforts to address the discrepancy between the predicted molecular 
masses calculations versus the apparent molecular masses on SDS-PAG, two alternative 
approaches were used to reevaluate the molecular masses of these large protein complexes. 
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Figure 3.22  Demonstration of the effect of altering acrylamide concentration on 
the electrophoretic migration of CPE large complexes.  Isolated Caco-2 cells 
were treated with CPE, lysed with Laemmli buffer, then separated on a 4% (left 
panel) or 6% (right panel) acrylamide SDS-PAG before Western blotting for CPE.  
Numbers in parentheses above each complex represent the calculated relative 
molecular mass in kDa. 
 
 
3.3.4.1 Ferguson plot analysis of the large CPE complexes 
 
Based on the Fig. 3.22 findings indicating that the relative migration of CPE large complexes 
demonstrate a dependence on the percentage of acrylamide present in gels, Ferguson plot 
analysis was employed.  By using this methodology, a retardation factor (RF) is calculated from 
the degree by which migration of a protein (or protein complex) is retarded as a function of the 
acrylamide content in a series of native PAGs.  By calculating RF values from known molecular 
mass standards run through these same gels, a standard curve can be generated and used to 
calculate the molecular mass of the unknown protein or complex.  Relative migrations of the 
native molecular mass standards from these experiments were determined after Coomassie 
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brilliant blue staining (Fig. 3.23A, left panel), whereas migration of CPE or CPE large complexes 
were measured after Western blotting with anti-CPE antibodies (Fig. 3.23A, right panel).  This 
analysis was first performed to calculate the molecular mass of free CPE as verification of the 
technique.  These Ferguson plots yielded a calculated molecular mass of 37.7 kDa for free CPE 
(Fig. 3.23B & C), which is close to CPE’s actual molecular mass of 35.3 kDa. 
 
 
 
Figure 3.23  Ferguson plot analysis of CPE.  A, A representative example of the native PAGs 
used for Ferguson analysis in this study where lanes containing standards are stained with 
Coomassie blue (left panel), whereas lanes containing CPE or its complexes are Western blotted 
(right panel).  B, Molecular mass standards and free CPE were separated in a series of native 
PAGs in this indicated concentrations.  C, Negative slopes from curves in B are plotted versus the 
molecular mass to estimate the molecular mass of free CPE. 
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The native gel conditions used in Ferguson plot analysis failed to provide adequate 
electrophoretic separation between the “155 kDa” or the “200 kDa” large complexes (Fig. 3.23A, 
right panel).  Therefore, cell culturing conditions were used to form each of the complexes in the 
absence of the other (see Section 2.4.4).  Using conditions that allowed for exclusive formation 
of either the “155 kDa” or the “200 kDa” large complex in Caco-2 cells (Fig. 3.24A), Triton-X 100 
lysates of the large complex-containing Caco-2 cells were separated on 4, 5, 6, and 7% PAGs 
(note: the large CPE complexes did not enter 8, 9, 10, or 12% acrylamide separating gels, 
therefore these gel concentrations could not be used for this analysis).  When the relative 
migrations of the resultant CPE complexes were calculated on the subsequent CPE Western 
blots, the “~155 kDa” large complex was determined to have a molecular mass of ~430 kDa, 
whereas the “~200 kDa” large complex displayed a molecular mass of ~550 kDa (Table 3.4, Fig. 
3.24B & C).   
 
 
Table 3.4  Ferguson plot calculations for CPE large complexes.   
  
Actual Molecular 
Mass (Da) 
 
Line Equations  
from Fig. 7B 
Calculated Molecular 
Mass from Fig. 7C  
Line Equation (Da) 
Thyroglobulin 669,000 y = -19.896x + 241.77 654,483 
Ferritin 440,000 y = -15.52x + 245.53 425,191 
Catalase 232,000 y = -11.85x + 232.95 266,148 
Lactase dehydrogenase 140,000 y = -7.7891x + 222.41 128,435 
"~155 kDa" Large Complex ? y = -15.536x + 200.48 425,953 
"~200 kDa" Large Complex ? y = -17.934x +200.98 546,520 
 
 
 97 
 
 
 
 
 
Figure 3.24  Ferguson plot analysis of CPE large complexes.  A, Cell culture conditions were 
manipulated to achieve the formation of both of the large complexes (lane 1), only the “~155 kDa” 
large complex (lane 2), or only the “~200 kDa” large complex (lane 3).  RF values were calculated for 
these complexes along with molecular mass standards by their migrations in 4, 5, 6, and 7% 
acrylamide native PAGs. C, Negative slopes from curves in B are plotted versus the molecular mass 
to estimate the molecular masses of the CPE large complexes.  
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3.3.4.2  Analysis of the large CPE complexes by size exclusion chromatography 
 
In order to confirm the Ferguson plot analysis, size exclusion chromatography of the CPE large 
complexes was performed.  Caco-2 cells treated in suspension with CPE were lysed with 1% 
Triton-X 100 and loaded onto a Sephacryl-400 HR column calibrated with several molecular 
mass standards (Fig. 3.25A; see Section 2.3.4).  Column fractions were then analyzed on a 4% 
acrylamide SDS-PAG and subjected to CPE Western blotting (Fig. 3.25B).  Densitometric 
analysis of exposed Western blot films was then used to determine the relative intensities of the 
“~155” and “~200 kDa” large complexes in each fraction (Fig. 3.25C).  The peak intensity for the 
“~155 kDa” large complex occurred at fraction 50, which corresponded to a molecular mass of 
~500 kDa.  Similar analysis of the “~200 kDa” large complex peak intensity (fraction 29) had a 
corresponding molecular mass of ~660 kDa (Fig. 3.25C). 
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Figure 3.25  Size exclusion chromatography of the CPE large complexes.  A, Molecular mass 
standards (see Section 2.3.4) were used to calibrate an Sephacryl-400 HR column.  The Kav value for 
each standard was calculated and plotted versus their known molecular masses.  B, Isolated Caco-2 
cells treated with CPE were lysed with 1% Triton-X 100 and loaded on the calibrated Sephacryl-400 HR 
column.  Samples from collected fractions were separated on a 4% acrylamide SDS-PAG and Western 
blotted to detect the presence of the CPE large complexes (denoted with arrows to left of blot).  C, 
Relative intensity of the immunoreactivity corresponding to each complex (from B) was quantitated and 
then plotted versus the fraction number.  The solid line represents relative signal intensity of the “~155 
kDa” large complex, while the dashed line depicts the “~200 kDa” large complex relative signal 
intensity.  Shown in parentheses at the top of each signal intensity peak are molecular masses 
calculated using the standard curve generated in A.   
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3.3.5 Exploration of dominant negative phenotypes from rCPE variants 
 
The data presented above provide robust evidence that the large complexes formed by CPE are 
in fact oligomers of CPE and represent the oligomeric pore that causes membrane permeability 
alterations of cells.  Several groups studying bacterial toxins have described mutants which are 
capable of exerting a dominant negative effect on wild-type toxin when added in combination 
(178, 210, 220, 221, 237).  Since many variants of rCPE have been generated both by the 
present and previous studies which are blocked for different stages of CPE action, it was 
interesting to examine the effect rCPE variants might have on rCPE oligomerization.   
For example, work presented in Section 3.1 shows that the D48A point variant of rCPE 
is non-cytotoxic because it cannot form large complex (Fig. 3.6).  Since the D48 residue 
appears to be essential for the formation of SDS-resistant CPE oligomers, it could easily be 
imagined that if D48A variant monomers were incorporated into a growing oligomer of wild-type 
rCPE monomers, the inability of the D48A to co-oligomerize might have a dominant negative 
effect by blocking the formation of a hexamer (dominant negative by ‘chain termination’).  In 
addition, dominant negative mutants of the B. anthracis protective antigen all have mutations 
that map to the TMD of these pore-forming heptamers (147).  Because removal of the putative 
TMD of CPE results in a similar phenotype of a non-cytotoxic pre-pore oligomer (see Section 
3.2), perhaps TM1 variant monomers incorporated into a wild-type rCPE oligomer could block 
membrane insertion of rCPE monomers (dominant negative by membrane insertion inhibition).  
Lastly, since the rCPE168-319 fragment lacks both the N-terminal cytotoxicity region and the 
putative transmembrane stem domain but is binding-capable, it was of interest to determine if 
this fragment could also have a dominant negative effect.  Each of these three variants of rCPE 
were evaluated for their potential inhibitory effects on rCPE action. 
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3.3.5.1  Dominant negative effects on CPE oligomerization 
 
Since oligomerization of CPE precedes pore-formation, the ability of the aforementioned rCPE 
variants to inhibit oligomerization of rCPE was measured.  To accomplish this, a standard large 
complex assay was performed by treating isolated Caco-2 cells with various pre-mixed ratios of 
variant:rCPE.  After treatment, lysates of these Caco-2 cells were separated on 4% acrylamide 
SDS-PAGs and Western blotted for CPE.  In the absence of any variant, rCPE formed the 
standard two SDS-resistant large complexes of ~155 and ~200 kDa in all three experiments 
performed (Fig. 3.26).  Since the TM1 variant was previously shown to form the ~155 kDa large 
complex (Fig. 3.14), it was expected that all ratios of TM1:rCPE would result in the formation of 
some large complex as seen in Fig. 3.26.  It was interesting to note a decrease in the amount of 
~200 kDa large complex present as the amount of TM1 included was increased.  In addition, the 
apparent molecular mass of the ~155 kDa large complex seems to decrease as more TM1 is 
added, an observation similar to Figs. 3.20 & 3.21 indicating that heteromeric large complexes 
are probably being formed. 
The D48A and rCPE168-319 variants each had a dramatic effect on the formation of large 
complex by rCPE.  At ratios of only 1:1, a nearly complete loss of both complexes was noted in 
experiments where either D48A or the rCPE168-319 variants were used in combination with rCPE 
(Fig. 3.26).  Overexposed films of each of these blots could detect some of the large complexes 
at the 2:1 ratio, however it is clear that D48A and rCPE168-319 have a powerfully dominant 
negative effect on rCPE oligomerization. 
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Figure 3.26  Dominant negative effects of rCPE variants on rCPE large complex formation.  
Isolated Caco-2 cells were treated with the indicated ratios (top of figure) of variant:rCPE, then 
lysed with Laemmli buffer, separated on a 4% acrylamide SDS-PAG, then Western blotted for 
CPE.  Values and arrows to left of blot represent migration of molecular mass markers on each 
blot.  rCPE variant used in each experiment is indicated to the right of the blot. 
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3.3.5.2  Blocking of pore-formation by dominant negative variants 
 
Since the above experiments demonstrated that some variants of rCPE could inhibit the 
oligomerization of rCPE, it was next appropriate to determine whether or not they also exhibited 
a similar effect on pore-formation.  In order to evaluate inhibition of pore-formation, the standard 
86Rb release assay was used (as performed in Figs. 3.3 & 3.13), except that pre-mixed ratios of 
variant:rCPE were added to Caco-2 cell monolayers instead of a single toxin.  When confluent 
monolayers of 86Rb-labeled Caco-2 cells were treated with rCPE alone (the 0:1 ratio of all 
variant:rCPE data series), large amounts of 86Rb were effluxed from these cells (Fig. 3.27).  
However, it was readily apparent that as the ratio of variant:rCPE for each variant tested was 
increased, the amount of 86Rb released from these cells decreased.    Since D48A and rCPE168-
319 appeared to strongly inhibit oligomerization of rCPE when added in combination (Fig. 3.26), it 
was expected that these variants would also have a similar inhibitory effect on pore-formation as 
depicted in Fig. 3.27.  However, it was interesting to note the TM1 variant also could inhibit the 
release of 86Rb from cells, though not as robustly as D48A and rCPE168-319.  As noted in earlier 
experiments (Figs. 3.3 & 3.13), neither D48A nor TM1 alone were able to elicit an 86Rb 
response from Caco-2 cells even at the highest concentration tested (Fig. 3.27).  Though not 
included in Fig. 3.26, the rCPE168-319 has been conclusively shown to not elicit 86Rb release from 
cells (93). 
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Figure 3.27  Dominant negative effects on rCPE pore formation by rCPE 
variants.  Caco-2 cells pre-loaded with 86Rb were treated with the indicated ratio 
of variant:rCPE.  86Rb effluxed from the cells was quantitated and is expressed 
as percent maximal 86Rb release. 
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4.0 DISCUSSION  
 
 
As reviewed above, there have been several investigations into the mechanism of action of CPE 
which have greatly contributed to the understanding of how this toxin causes disease.  
However, Section 1.6 highlighted three specific and important questions that still remained prior 
to this thesis dissertation.  First, why is the N-terminal cytotoxicity region essential for post-
binding cytotoxic activity of CPE?  Second, is there a region of CPE that is important for 
membrane insertion or pore formation?  Third, what is the oligomeric state of CPE within the 
large complexes?  The work presented above has helped to answer each of those three 
questions and has also generated additional unexpected insights into the molecular events 
leading to CPE-induced killing of enterocytes.  What follows is a detailed interpretation of the 
results generated from this study, along with their relevancies to each specific question asked in 
this thesis dissertation. 
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Figure 4.1  Current structure-function map of CPE (top) with a secondary structure prediction of CPE 
(bottom) by the PROF method (170).  Highlighted above the map are locations of known and putative 
functional regions of CPE, as well as the N-terminals amino acids of several C-terminal fragments of CPE 
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4.1 WHY IS THE N-TERMINAL CYTOTOXICITY REGION ESSENTIAL FOR POST-
BINDING CYTOTOXIC ACTIVITY OF CPE? 
 
 
4.1.1 Explanation of mutagenesis and rCPE variant phenotypes 
 
4.1.1.1  D48 and I51: crucial for CPE cytotoxicity 
 
Alanine-scanning mutagenesis is a useful tool for deciphering the contribution of individual 
amino acids in a linear protein region.  Since deletion mutagenesis performed earlier had 
identified that amino acids 45-53 in CPE were essential for cytotoxicity (93), this small stretch of 
amino acids was ideal for an alanine-scanning approach.  Two alanine substitution mutants of 
rCPE, D48A and I51A, were found to be completely or strongly (respectively) attenuated for 
cytotoxicity (Figs. 3.2 & 3.3).  The nontoxic phenotype of these two rCPE variants appears 
specifically attributable to their inability to form the large CPE complexes (Fig. 3.6) since both 
variants exhibited normal binding and small complex activities (Figs. 3.4 & 3.5) and neither 
variant appeared to had undergone gross conformational distortions (Fig. 3.7).  With regard to 
D48, more conservative mutations were engineered that restored the side chain charge (D48E) 
or length (D48N).  Each of these saturation variants mirrored the D48A phenotype in that they 
were completely deficient in large complex formation and toxicity, despite being properly folded 
and maintaining binding and small complex activity (Figs. 3.4 & 3.5).  These observations 
suggest that both the negative charge and chain length supplied the aspartic acid at amino acid 
48 is essential for the formation of CPE large complex.  Regarding the alanine variant at I51 in 
CPE, saturation mutagenesis at this residue (variants I51L and I51V) completely restored wild-
type levels of large complex formation and cytotoxicity (Figs. 3.2, 3.3, & 3.6).  It was also 
interesting that, though highly attenuated, the I51A variant could form some residual large 
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complex (Fig 3.6).  Taken in total, the data from the alanine and saturation mutagenesis at this 
residue implies that aliphatic hydrocarbon chain length is important at this position and may be 
roughly proportional to activity. 
 
4.1.1.2  Glycine to alanine: loss of flexibility 
 
Other interesting findings from the alanine-scanning studies include the distinct large complex 
phenotype of the G47A and G49A variants.  In addition to the two standard large complexes of 
~155 and ~200 kDa, both formed some immunoreactive material of even higher molecular mass 
than the 200 kDa large complex (Fig. 3.6).  However, this odd large complex phenotype did not 
have any detectable effect on any other CPE activity, as levels of binding, small complex, and 
pore-formation were all similar to wild-type rCPE (Table 3.1).  It is unclear from what this largest 
complex is derived since the presence or absence of occludin was not assessed in these 
experiments.  It is interesting to note that both G47A and G49A (in the absence of any Caco-2 
lysates) displayed an unusual propensity to aggregate on SDS-PAGE gels even after heating 
and reduction with β-ME.  Therefore, it is possible that the material seen above the 200 kDa 
large complex in Fig. 3.6 could be simply represent anomalous aggregation.  While the mutation 
from glycine to alanine only represents the addition of a single methyl group, this also has the 
effect of greatly restraining the freedom of rotation about the Φ and Ψ angles.  The loss of 
protein flexibility in this region could be the cause of the aggregation seen in large complex 
experiments, however, it appears to be dependent on location since a glycine to alanine 
substitution at position 53 did not have a similar aggregation effect (Fig. 3.6).  Since the G47 
and G49 residues directly flank the D48 residue demonstrated in this study to be essential, it is 
possible (if not likely) that the flexibility provided by these two glycines properly frames the D48 
residue for protein-protein interactions required for the formation of large complex.  This 
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explanation would also be consistent with G53A mutation not affecting activity since it is not 
proximal to the D48 amino acid determined in this study to be so functionally important. 
It is also interesting to consider results from a previous mutagenesis study of rCPE 
which isolated the point variant G49D by random mutagenesis (92).  It was demonstrated in this 
work that the G49D variant was proficient at binding and small complex formation, however it 
resembled the D48 variants of the present study in that it could not form the large complexes or 
elicit 86Rb-release from cells.  Taking into account information learned from the present study, 
two possible explanations exist for the G49D phenotype seen earlier.  First, even though the 
G49D variant contained the native aspartic acid at residue 48, it is apparent that rCPE can only 
tolerate one of these aspartic acids in this crucial stretch of amino acids.  A D48A/G49D double 
point variant might be useful in determining if this is the case.  Second, it is possible that a 
glycine to aspartic acid switch at position 49 may too severely constrain the Φ and Ψ angle 
rotation proposed here to be important for large complex formation.  Perhaps the relatively 
conservative mutations to alanine by the G47A and G49A variant from the present study may be 
more easily tolerated by rCPE. 
 
4.1.1.3  W50 is plays a structural role for CPE  
 
As noted in the Section 3.1.1.7, our first W50A rCPE variant preparation was inactive and 
appeared to be improperly folded.  Despite this, subsequent preparations of this variant 
produced active toxin lacking gross conformational changes, as measured by limited trypsin 
proteolysis (Fig. 3.7).  However, even active W50A rCPE variant preparations formed little or no 
detectable ~155 kDa complex, although they did produce the atypical high molecular mass 
material also seen with the G47A and G49A rCPE variants (Fig. 3.6).  In addition, substantially 
greater amounts of immunoreactive material were present at/near the dye front of large complex 
gel lanes loaded with extracts of W50A-treated Caco-2 cells.  This finding probably represents 
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free W50A dissociated from large complexes (Fig. 3.6).  Although it appears that the W50A 
rCPE variant is structurally-compromised, the large complex formed by this variant may be 
functional but more sensitive to the SDS used for extraction in large complex experiments.  
Since the W50Y and W50F saturation variants formed large complexes resembling those of 
wild-type rCPE (Fig. 3.6), these observations collectively suggest that an aromatic amino acid is 
preferred at CPE residue 50 to maintain normal structural integrity. 
 
4.1.2  N-terminal core cytotoxicity sequence: the latch hypothesis 
 
Considering the G47, D48, G49, W50, and I51 rCPE variant data together, it becomes notable 
that at least one substitution introduced at each of these five amino acid residues produced an 
atypical phenotype.  Although the active phenotypes of G47A, G49A, and W50A differed from 
attenuated D48A and I51A variants, each of the three former variants displayed large complex 
activity distinct from rCPE (Fig. 3.6).  Taken together, these observations suggest that N-
terminal CPE residues G47 to I51 (Fig. 4.1) represent a minimal critical ‘core’ sequence 
important for the development of cytotoxicity.  Since this sequence appears to mediate large 
complex formation, and since experiments in Section 3.3 have shown that these large 
complexes are CPE hexamers, it can be therefore deduced that this N-terminal core cytotoxicity 
sequence (NTCCS) is important because it facilitates oligomerization.   
It is detailed above that CPE is similar in many ways to the β-PFT family of toxins 
(Section 1.6.2).  One of these toxins, S. aureus alpha hemolysin, contains a latch domain at its 
N-terminus (Fig. 1.15) that specifically functions to link monomers together in an oligomer (156, 
192, 215, 222, 223).  Several aspartic acids and isoleucines are present in the latch domain of 
this toxin, and ionic and hydrophobic interactions have been predicted to mediate the monomer-
monomer interactions necessary for oligomerization (192).  The data presented in this study are 
consistent with the possibility that the NTCCS of CPE act in similar fashion to the S. aureus 
 111 
alpha hemolysin latch as a region responsible for the protein:protein interactions required for 
oligomerization.  The size and charge requirement of CPE residue 48, along with the aliphatic 
hydrocarbon preference at position 51, could permit ionic and/or hydrophobic interactions 
between the NTCCS latch and a latching site on another CPE monomer.  As mentioned, the 
glycines at 47 and 49 flanking the critical D48 residue may provide flexibility that properly 
frames this latch, enabling interaction with its binding partner. 
Prior to beginning this study, we noted the presence of a KGD motif at CPE amino acids 
46-48 (Fig. 3.1) and hypothesized that this three amino acid sequence might explain large 
complex formation since RGD and KGD sequences are known protein binding motifs (4, 85, 
129, 171, 198).  However, the unimpaired cytotoxic activity observed for rCPE variants K46A 
and G47A now precludes CPE amino acids 46-48 (as a complete KGD motif) as being 
important for CPE action.  Additionally, a GXXXG sequence also exists in the CPE N-terminal 
cytotoxicity region, extending from G49 to G53 (Fig. 3.1).  This was interesting given that 
GXXXG motifs have been implicated in dimerization of the Helicobacter pylori vacuolating toxin 
(109, 110).  However the GXXXG motif of the CPE N-terminal region does not appear important 
for toxicity, since glycine to alanine mutations did not alter the pore-forming ability of rCPE 
(Table 3.1), in contrast to the attenuation of oligomerization and membrane channel formation 
observed following some glycine to alanine mutations in VacA (110). 
It is notable that none of the rCPE variants generated in the present study could form the 
~155 kDa CPE complex without forming the ~200 kDa complex, or vise versa.  That observation 
suggests the NTCCS latch is important for formation of both CPE large complexes.   This leaves 
one of two possibilities: i) the ~155 kDa complex formation is a precursor for ~200 kDa 
formation, or that ii) formation of both CPE large complexes is independent but involves similar 
protein:protein interactions.  Support for the latter possibility comes from Section 3.3 studies 
which have demonstrated CPE’s existence as a hexamer in both the ~155 and ~200 kDa large 
complexes.  If the NTCCS latch facilitates oligomerization, it would conceivably be required for 
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the formation both of these hexamers, and as a result, the formation of the ~155 and ~200 kDa 
large complexes would parallel each other according to this model. 
 
4.1.3 In vivo validation of in vitro phenotypes 
 
The rabbit ileal loop model of CPE-mediated intestinal disease has been invaluable in 
establishing an impressive knowledgebase about enteric CPE action (111).  While the 
numerous technical advantages of immortal cell culture lines has no doubt accelerated the 
advancement of CPE structure-function relationships and CPE action, the danger of ‘losing the 
forest for the trees’ is real if efforts are not made to validate experimental findings in vitro with in 
vivo models.  By using the two rCPE variants D48A and rCPE168-319 in the rabbit ileal loop assay, 
we were able to demonstrate a very good correlation between our in vitro and in vivo models for 
CPE action.  Neither of these two variants could elicit fluid accumulation or histopathological 
damage (Figs. 3.8 & 3.9, Table 3.2), observations consistent with the lack of cytotoxicity seen 
with the D48A and rCPE168-319 variants seen previously (Table 3.1 and (93)).  The fact that our in 
vitro and in vivo models parallel each other illustrates two important points.  First, it is clear from 
this work that the cytotoxic consequences of CPE treatment are a necessary first step in the 
development of enteropathogenic effects caused by this toxin.  Second, analysis of CPE activity 
with the use of Caco-2 cells is an accurate and valid model to predict the enteropathogenic 
phenotypes of CPE (or its variants).   
It is interesting to note that the C-CPE fragment of CPE (Fig. 1.14) was found in several 
studies to increase intestinal absorption by removing/rearranging claudins resulting from 
CPE:claudin interactions (88, 105, 195, 204).  Since these effects only appeared after several 
hours of treatment with C-CPE, it would be interesting to determine whether the D48A and/or 
the rCPE168-319 variant could have a similar effect on rabbit ileal loops after longer treatment 
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times.  Experiments testing the long-term effects of these rCPE variants on the tight junctions of 
the rabbit intestinal epithelium are currently underway. 
 
 
 
4.2 SEARCH FOR A REGION OF CPE INVOLVED IN MEMBRANE INSERTION 
 
 
4.2.1 Identification of a pre-pore large complex state 
 
Since CPE has been definitively shown to have pore-forming activity (70, 72, 112), and since 
CPE in the large complex appears to insert (at least partially) into membranes (94, 228), the 
initial goal of the Section 2.0 studies was to define a region of CPE involved with membrane 
insertion.  Complete deletion of amino acids 81-106 (which resembles the TMDs of the β-PFTs; 
Fig. 1.17) led to a novel CPE variant phenotype: formation of the ~155 kDa large complex in the 
absence of cytotoxicity.  In addition to not being toxic for Caco-2 cells (Fig. 3.12), this TM1 
deletion variant was defective in the 86Rb release assay for pore-formation (Fig. 3.13).  
Biochemical analysis of this non-cytotoxic large complex revealed several differences from the 
large complex formed by wild-type rCPE.  The TM1 large complex appeared to not insert into 
membranes (Fig. 3.15), and was more likely to both dissociate from membranes and 
disassemble (Fig. 3.16), especially in the presence of heat (Fig. 3.17).  These observations 
collectively suggest that the TM1 large complex is trapped in a pre-pore state, capable of 
forming an SDS-resistant ~155 kDa complex on the surface of cells, yet unable to complete the 
final step in CPE action: membrane insertion to form a pore. 
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4.2.2 Possible functions of CPE amino acids 81-106 
 
4.2.2.1 Transmembrane stem domain 
 
While several possibilities exist to explain why amino acids 81-106 in CPE are important for 
pore formation, a strong case can be made for this region acting as a TMD.  By simply scanning 
the primary amino acid structure of CPE, it was found that amino acids 81-106 have remarkable 
resemblance to the transmembrane β-hairpins of the β-PFTs (Fig. 1.17; (158, 207, 214)).  
Amino acids in these TMDs alternate in side chain hydrophobicity for ~12 residues, are 
interrupted briefly for 2-7 resides of no particular character, then the alternating pattern resumes 
for another ~12 residues (Fig. 1.17).  Numerous fluorescence spectroscopy studies (reviewed 
(1)) in have determined that the alternating hydrophobic residues in these beta hairpins interact 
with the non-polar hydrocarbon chains of membrane phospholipids, whereas the hydrophilic 
amino acids face the water-filled channel made by the oligomeric pore.  While the alignment 
shown in Fig. 1.17 depicts how well amino acids 81-106 of CPE adhere to this same pattern, 
Fig. 4.2 additionally demonstrates how easily this region in CPE fits the membrane topology 
model frequently used to represent TMDs of other β-PFTs. 
 
 
 115 
110K
E
Y
M
S
T
L
T
Y
G
F
N
G
N
V
T
G
D
D
T
G
K
I
K
L
T
H
G
I
S
V
N
A
G
I
L
G
G
Y148
203K
I
G
V
K
T
S
F
K
V
G
L
E
A
I
A
S K
V
E
233Q
E
A
N
F
E
F
S
T
80E
V
S
I
N
V
N
F
S
V
G
F
T
S E
F
I
Q
A
S
G109
I
T
I
G
F
G
Y
E
V
Staphylococcus aureus       
alpha hemolysin
Clostridium septicum
alpha toxin
Clostridium perfringens
enterotoxin  
Figure 4.2  Membrane topology model of the TMDs of S. aureus alpha hemolysin, C. 
septicum alpha toxin, and the putative TMD of CPE.  Circled in the putative TMD of 
CPE are residues substituted with Cys and labeled with NBD. 
 
 
Additional information in support of amino acids 81-106 functioning as a TMD comes 
from hydrophobicity analysis of CPE.  As mentioned in Section 1.4.1, amino acids 81-106 in 
CPE represent the only major hydrophobic patch in the protein according to Kyte-Doolittle 
analysis (Fig 1.9; (97)).  The TMDs of β-PFTs, including those of S. aureus alpha hemolysin and 
C. perfringens epsilon toxin, are frequently found in distinct hydrophobic patches (Fig. 4.3).  
Further, secondary structure predictions of CPE are also consistent with a TMD existing 
between amino acids 81-106 of CPE.  Several prediction methods project two beta strands 
between roughly V81 and T92 and again between approximately F95 and I106 (Double 
Prediction Method (30), Protein Sequence Analysis Server (200, 201, 227), PROF (170)).  In an 
interesting deviation from other predictions, the PROF program actually projects a strong alpha 
helical structure between amino acids 90-100 flanked on each side by two shorter beta strands 
(Fig 4.1).  While this prediction seems to argue against amino acids 81-106 forming a 
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transmembrane stem β-hairpin, it is important to mention that the crystal structure of monomeric 
perfringolysin O revealed that both of its TMDs are folded as short alpha helices (Fig. 4.4; 
(169)).  It was subsequently demonstrated that only after oligomerization do these TMDs 
transition into complete beta hairpins allowing penetration of the phospholipid bilayer (181).  It is 
entirely possible, therefore, that similar secondary structure rearrangements could take place 
within in CPE after to hexamerization and prior to insertion into the membrane. 
 
 
 
Figure 4.3  Kyte-Doolittle hydrophobicity analysis of two β-PFTs, S. aureus alpha 
hemolysin (left) and C. perfringens epsilon toxin (right).  Dashed boxes represent 
location of the TMDs of these toxins. 
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Figure 4.4  A, Ribbon rendering of the crystal structure of the C. perfringens perfringolysin 
O (169).  B, Backbone carbon tracing of the same protein structure.  The two TMDs and 
membrane-anchoring rim loops are indicated with arrows in each rendering.  Images were 
created using the KiNG molecular modeling program. 
 
 
It is prudent to note that the mere presence of a structural element does not necessitate 
its function as such.  For example, the KGD and GXXXG motifs located in the N-terminal 
cytotoxicity region of CPE (Fig. 3.1) do not appear to be distinct protein-protein interaction 
domains in CPE, despite several examples in the literature of this being the case for both of 
these sequences (4, 109, 110, 171).  Identification of putative functional domains must be 
followed by experiments testing the proposed functionality. 
When the transmembrane stem domains from the S. aureus alpha hemolysin, B. 
anthracis protective antigen, and C. septicum alpha toxin were deleted in previous studies, all 
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resultant variant toxins were unaffected in binding activity and oligomerization, but were 
impaired at membrane insertion/pore-formation (22, 131, 138).  In yet another similarity with this 
toxin family, the TM1 deletion variant of CPE maintained wild-type levels of binding activity, but 
formed a non-cytotoxic oligomer incapable of inserting into the membrane (Table 3.3 & 3.12-
15).  When these observations are combined with i.) the similar distinctive alternating amino 
acid pattern, ii.) the Kyte-Doolittle hydrophobicity analysis, iii.) and the secondary structure 
predictions, a scenario in which amino acids 81-106 in CPE acts as a TMD becomes more 
likely. 
 
4.2.2.1.1  Probing the environment of residues in the putative TMD of CPE 
 
While the indirect evidence noted above seems to implicate amino acids 81-106 in CPE action 
as a membrane-spanning β-hairpin, a more direct approach will be required to conclusively 
demonstrate transmembrane functionality from this region.  As mentioned, the literature 
contains several examples of investigators making cysteine substitutions at proposed 
transmembrane residues, then using sulfhydryl labeling techniques to attach an 
environmentally-sensitive fluorescent dye molecule at each residue in question.  Because some 
fluorescent dyes (such as (7-nitrobenz-2-oxa-1,3,-diazoyl)ethylenediamine, or NBD) are 
quenched by water, they undergo a significant increase in fluorescence intensity when inserted 
into the membrane.  Such a shift is usually noted where hydrophobic residues have been Cys-
substituted and labeled.  A similar shift, however is not typically observed for Cys-substituted 
hydrophilic positions which face the water-filled channel.  The TMDs of many β-PFTs have been 
identified in this manner, including perfringolysin O (180, 181) and C. septicum alpha toxin 
(131).   
A small-scale version of this approach was attempted in the present study with CPE, 
unfortunately with only limited success.  Six residues within the putative TMD of CPE (V85, N86, 
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F87, E101, Y102,  and G103; Fig. 4.2) were each mutated to cysteines using site-directed 
mutagenesis in the fully-active C186A background of CPE.  While the G103C mutant 
demonstrated substantially reduced amounts of large complex formation, the remaining five 
Cys-variants maintained activity similar to their C186A background construct (Fig. 4.5A).  When 
the five active Cys-variants were labeled with NBD and tested in fluorescence intensity shift 
experiments, the findings were somewhat ambiguous.  Of the three variants which were 
expected to undergo a fluorescence intensity shift (V85C, F87C, Y102C), only F87C had a 
significant increase when associated with membranes (Fig. 4.5B).  In addition, of the two 
variants expected to lack a fluorescence intensity shift (E101C, N86C), N86C demonstrated an 
increase of fluorescence intensity after inserting into membranes (Fig. 4.5B).  To summarize, 
two of the five residues tested displayed the predicted result, while the other three did not. 
 120 
 
Figure 4.5  A, Large complex formation by six Cys-substitution 
variants in the putative TMD of rCPE.  B, Relative fluorescence 
observed from indicated NBD-labeled Cys variants of rCPE before 
and after the addition of membranes. 
 
 
While the data from this preliminary study are not particularly encouraging, several 
things must be considered before dismissing the possibility that amino acids 81-106 function as 
a transmembrane β-hairpin.  First, it is entirely possible that this pilot study of CPE TMD 
insertion suffered from sampling error.  Examples in the literature of fluorescence spectroscopic 
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studies of β-PFT TMDs define these domains by observing an alternating pattern of 
fluorescence intensity shifts over a span of 30+ residues, usually at hydrophobic amino acids.  
However, it is not uncommon for hydrophilic residues to undergo a shift, while neighboring 
hydrophobic residues remain quenched.  For example, if the five consecutive residues of Q191, 
I192, S193, S194, and A195 of perfringolysin O were chosen for a pilot study similar to the one 
performed here for CPE, ambiguous findings would also have resulted.  While Shepard et al. 
have conclusively shown with more exhaustive fluorescence methodologies that these residues 
in perfringolysin O are part of the first TMD, only two of the residues would have displayed the 
predicted fluorescence pattern while three would not have (181).  A similar situation can be 
seen with fluorimetric analysis of the TMD of C. septicum alpha toxin.  If only residues K211, 
V212, G213, L214, and E215 were examined, an equally unimpressive two of five these 
residues would have resulted in the predicted fluorescence intensity pattern (131).  These 
examples make it clear that one must use caution confirming or rejecting the presence of a TMD 
by only assaying a few amino acids for their performance in fluorescence spectroscopy 
experiments. 
Another possible contributor to the ambiguous results from the fluorescence study CPE’s 
putative TMD could be the protein preparations.  In nearly every experiment included in this 
dissertation, affinity-enrichments of rCPE (or its variants) are used.  Since the sulfhydryl labeling 
involved in this pilot study required relatively pure protein, efforts were made to separate the 
Cys-variants from contaminating E. coli proteins.  Despite these efforts, some background 
proteins were still observed in affinity “purifications” of these variants, and some of these 
contaminants were unintentionally fluorescently labeled with NBD during labeling of the CPE 
cysteine.  Background fluorescence contributed by these labeled contaminants could have 
unquestionably clouded the interpretation of the data.  If this fluorescence spectroscopy 
approach will be later revisited to examine the putative TMD of CPE, it will of utmost importance 
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to first establish and develop a purification protocol for the Cys-variants of rCPE which can 
achieve 90-95% purity before performing labeling experiments. 
It would also be important to chose longer consecutive stretches of amino acids to test 
for insertion.  In the preliminary study described above, three consecutive residues were chosen 
from each side of the predicted β-hairpin, representing three residues projected to insert into the 
membrane (V85, F87, Y102) and three residues projected to face the channel (N86, E101, 
G103).  A better strategy for a follow up study might be to pick five to ten consecutive residues 
in one side of a predicted β-hairpin possibly allowing for a clearer identification of an alternating 
pattern of fluorescence intensity shifts. 
While the alternating hydrophobic amino acids of residues 81-106 are the best candidate 
in CPE for TMD, there is also a second stretch of amino acids which may roughly resemble the 
β-PFT TMD pattern.  Located between amino acids 238-265 (Fig. 1.8), the first half of the 
putative β-hairpin aptly alternates in hydrophobicity while the second half does not so clearly 
alternate.  Although all of the small-pore β-PFTs only have one TMD per monomer, it is 
appropriate to point out that the cholesterol-dependent cytolysins all use two TMDs to penetrate 
the phospholipid bilayer.  Whether amino acids 238-265 actually serve as the only or a second 
TMD awaits investigation, though it is unlikely that each CPE monomer would contribute two 
independent TMDs to an only hexameric CPE pore. 
 
4.2.2.2  Rim interactions with the membrane 
   
Besides a TMD, another possible function for amino acids 81-106 of CPE could be a role in 
mediating some protein:membrane interactions other than direct membrane penetration.  
Several pore-forming toxins are thought to contain regions in their rim domains (S. aureus alpha 
hemolysin Figs. 1.15 and 1.16) which interact peripherally with the plasma membrane.  In 
addition, perfringolysin O contains several small loops at the bottom of its domain 4 (Fig. 4.4) 
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that have been shown to only shallowly insert into the membrane and participate in membrane-
anchoring of the oligomer (77, 169).  Several hydrophobic residues are located in these small 
loops of PFO, similar to the many hydrophobic residues found between amino acids 81-106 of 
CPE (Fig. 1.9).  Additionally the preliminary fluorescence studies described above appear (at 
face value) to be consistent with this idea, since two consecutive residues (F87 and N86) did 
undergo a fluorescence intensity shift when membranes were added (Fig. 4.5B).  Therefore, the 
large complex formed by the TM1 variant could be deficient at the membrane anchoring 
necessary for subsequent insertion of CPE into the membrane.   
 
4.2.2.3  Protein-protein interactions 
 
A final possibility for the function of amino acids 81-106 is that this CPE region mediates critical 
protein:protein interactions between CPE monomers or between CPE and other proteins 
required for membrane insertion/pore formation.  Data presented in Section 3.2.1.6 appear to be 
consistent with this interpretation since it is clear that the ~155 kDa large complex formed by 
TM1 is structurally-compromised.  Loss of crucial contact points between CPE monomers 
and/or other proteins could result in the increased rate of membrane dissociation (Fig. 3.20) 
compared to rCPE large complex.  Also, the  kinetic increase in a lower molecular mass 
complex in these dissociation experiments (Fig. 3.16), along with the sensitivity to heat 
denaturation (Fig. 3.17) both could lend support to the idea of the TM1 large complex lacking 
some important structural associations as a result of the deletion of amino acids 81-106.   
 
4.2.3 Order of involvement of CPE functional regions 
 
Introduction of a D48A mutation into the TM1 background helped assign a temporal order to the 
contributions of known CPE functional regions for cytotoxicity.  Interestingly, the TM1-D48A 
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combination mutant paralleled the attenuated phenotype of the TM1 variant except that it could 
not form the ~155 kDa large complex (Fig. 3.14).  This result indicates that the D48 residue in 
CPE’s NTCCS acts prior to the involvement of the amino acids 81-106 in CPE, which is in 
agreement with a model for CPE action where NTCCS-mediated oligomerization precedes 
membrane insertion by the putative TMD.  It also demonstrates that the NTCCS is not directly 
involved in membrane penetration or pore formation since the TM1 variant (containing a native 
D48), formed the ~155 kDa large complex, but could not insert into the membrane or form a 
pore (Figs. 3.13-15). 
 
 
 
4.3 EXAMININATION OF THE OLIGOMERIC STATE OF CPE IN THE 
 LARGE COMPLEXES 
 
 
Identification of an ~155 kDa, SDS-resistant complex early in CPE investigations led to a 
preliminary model (232) where one CPE protein, one unidentified ~50 kDa protein, and one 
unidentified ~70 kDa protein interacted to form a complex critical for CPE action (117).  Later 
studies identified a second, “~200 kDa” large complex in Caco-2 cells and demonstrated that it 
contained the tight junction protein occludin (186).  As detailed above, claudins have been 
identified as receptors for CPE (47, 88), and it has been demonstrated only recently that 
claudins are present within these same large complexes (166).  However, the question of CPE 
oligomerization within the CPE large complexes has never been vigorously evaluated, despite 
several pieces of indirect evidence supporting this possibility as described earlier.  The work in 
Section 3.3, therefore, directly evaluated whether CPE is an oligomer in the two large 
complexes and then determined the CPE stoichiometry in each complex. 
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4.3.1 Determination the stoichiometry of CPE in the large complexes 
 
Heteromer gel shift analysis has previously been used to identify the toxin stoichiometries of 
several β-PFTs (56, 137, 143, 144, 240).  Using this same approach, we demonstrated that 
CPE exists as a hexamer in both the “~155 kDa” (Fig. 3.20) and “~200 kDa” (Fig. 3.21) large 
complexes formed by Caco-2 cells.  This result seems to align CPE with the β-PFTs which form 
pores containing pentameric (V. cholerae cytolysin (240)), heptameric (S. aureus alpha 
hemolysin (56, 192)), or octomeric (S. aureus Panton-Valentine leukocidin (86, 137)) toxin 
stoichiometries.  Interestingly, CPE appears to be the first pore-forming toxin in this family 
confirmed to form functional hexamers.  The hexamerization of C. perfringens beta toxin has 
been previously reported but was not described as being functional (unlike the heptamer also 
formed by this toxin) (150).  In addition, Nguyen et al. observed a hexameric conformation of the 
S. aureus gamma hemolysin using a FRET microscopy technique (152), however it was stated 
in this work that this same FRET data was also consistent with a heptameric conformation.  The 
precise subunit stoichiometry of the bicomponent leucocidins is an area of ongoing research in 
the field. 
A hexameric CPE oligomer is also consistent with previously reported sizes of the pore 
formed by CPE.  Osmotic stabilizer studies have demonstrated the CPE pore to be very 
permeable to molecules of ~100 Da early in CPE treatment of cells (114, 118), while other work 
showed that only molecules over ~200 Da were able to osmotically protect cells from CPE 
toxicity (107).  The CPE pore size estimation of 0.5 to 1.0 nm (70) is similar to the sizes seen 
with the small-pore β-PFTs (Table 1.2), including the 1.2-1.6 nm V. cholerae cytolysin 
pentameric pore (83), the 1.4 nm (minimum diameter) S. aureus alpha hemolysin heptameric 
pore (192), and the 1.7 nm A. hydrophilia aerolysin heptameric pore (157, 213).  The CPE pore 
appears to be quite different in stoichiometry and internal diameter from the pores formed by 
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cholesterol-dependent cytolysin family members (such as perfringolysin O), which form large 
24-48 nm pores with up to 50 toxin subunits to each oligomer (158). 
 
4.3.2 Molecular mass and composition of the “~155 kDa” large complex 
 
Determining that six copies of CPE are present in the “~155 kDa”  large complex was in conflict 
with previous molecular mass estimates of this complex (186, 232).  To address this 
discrepancy, we reevaluated the molecular mass of the “~155 kDa”  large complex by Ferguson 
plot analysis and size exclusion chromatography.  Results from these two methods gave a 
molecular mass range of ~430-500 kDa for the “~155 kDa” large complex.  Since six copies of 
CPE equal a molecular mass of only ~210 kDa (Fig. 4.6), this finding strongly supports the 
presence of eukaryotic proteins in this complex.  Consistent with this idea, it has recently been 
demonstrated that both receptor and non-receptor claudins can be present in the two large 
complexes formed by CPE in Caco-2 cells (166).   
If one assumes the simplest possible stoichiometry for this “~155 kDa” large complex 
(six CPE molecules each bound to one claudin receptor), this configuration would result in a 
molecular mass of ~330 kDa (Fig. 4.6).  However, since the “~155 kDa” large complex was 
estimated in this study to have a molecular mass range of ~430-500 kDa, a scenario where 
multiple claudins associate with each CPE subunit becomes more probable.  The demonstration 
that non-receptor claudins can localize with the large complexes (166) suggests that additional 
claudins not directly bound to CPE become localized with the CPE complexes via claudin-
claudin interactions.  Several studies have shown that these tight junction proteins can self-
associate both within and in between adjacent cells (49, 106, 176, 217), so it is highly likely that 
CPE binding and oligomerizing with the initial receptor claudin would likely itself already be 
bound to another (or multiple) ‘carrier’ claudin(s).  This could serve as an explanation as to how 
non-receptor claudins can be found in these complexes.  Moreover, the association of two 
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claudins for each CPE molecule in the “~155 kDa” large complex would yield a projected 
molecular mass of ~450 kDa which is well within the range of estimates reported in the present 
study (Fig. 4.6).   
 
 
 
Figure 4.6  Possible configurations for the CH-1 (depicted in A) or CH-2 (depicted in 
B) complexes.  CPE is represented as white circles, receptor claudins (black 
rectangles), carrier claudins (speckled rectangles), and occludin (hatched hexagons).  
Predicted molecular masses (in kDa) of these configurations are located below each 
in parentheses. 
 
 
4.3.3 Molecular mass and composition of the “~200 kDa” large complex 
 
The more recently discovered “~200 kDa” large complex is distinguishable from its “~155 kDa” 
counterpart because it contains occludin, a protein proposed to interact with claudin in tight 
junctions (48, 154).  Occludin is physically present in the “~200 kDa” large complex based upon 
Western blot, electroelution, and co-immunoprecipitation analyses, yet naturally CPE-resistant 
fibroblasts transfected with occludin cDNA do not gain the ability to bind the toxin or become 
CPE-sensitive (186).  Collectively, these observations suggests that CPE does not directly 
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interact with occludin (at least initially) and that the presence of occludin in the “~200 kDa” large 
complex may be a result of still incompletely characterized occludin:claudin interactions.   
Reevaluation of the size of this complex by gel filtration estimated a molecular mass of 
~660 kDa (Fig. 3.25), whereas Ferguson plot studies calculated a molecular mass of ~550 kDa 
for this complex (Fig. 3.24).  If, similar to the “~155 kDa” large complex above, the “~200 kDa” 
large complex consisted of six CPE molecules and 12 claudins, it would have a molecular mass 
of ~515 kDa after the addition of one occludin molecule (Fig. 4.6), within range of our size 
estimations for this complex.  Association of additional occludins would place this hypothetical 
conformation even closer to the mass estimations presented here within (Fig. 4.6). 
 
4.3.4 Nomenclature change 
 
Since results from this study have shown that the “~155 kDa” and “~200 kDa” large complexes 
have actual molecular masses much greater than those by which they were previously 
identified, it is necessary to propose a new nomenclature unrelated to molecular mass.  Such a 
change is particularly important since the present mass estimations of these large complexes 
are still not very precise.  We propose that the “~155 kDa” and “~200 kDa” large complexes 
hereafter be referred to as CPE Hexamer 1 (CH-1) and CPE Hexamer 2 (CH-2), respectively.  
These designations are not only more accurate descriptions, but should avoid any future need 
to change the nomenclature as the exact size and composition of the complexes become more 
precisely determined.  In addition, the number value after the ‘CPE Hexamer’ can easily be 
extended to accommodate any forthcoming discoveries of new complexes (i.e., “CH-3”). 
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4.3.5 Dominant negative variants of rCPE 
 
4.3.5.1  Inhibition by blocking membrane insertion 
 
Additional confirmation of CPE’s oligomeric state came from the finding that several variants of 
rCPE from present or previous studies have an inhibitory effect on the action of rCPE when 
added in combination.  It was expected that all ratios of TM1:rCPE would form CH-1, since TM1 
has been shown in Section 3.2 studies to be proficient for the formation of CH-1 but not CH-2 
(Fig. 3.14).  Nonetheless, it was interesting to see the amount of CH-2 formed by rCPE 
decrease as the TM1:rCPE ratio increased (Fig. 3.26).  Since the amount of rCPE in all of these 
lanes remains constant, this finding seems to support a scenario where an abundance of 
growing TM1 oligomers incorporate rCPE and exert a dominant negative effect on the formation 
of CH-2.  As seen in Fig. 3.14, this result may be indicating that formation of CH-2 requires 
membrane insertion, a step for which a heteromer consisting mostly of TM1 variants may be 
deficient. 
Since the TM1 deletion variant of rCPE is able to form the CH-1, it was not surprising 
that this variant had an inhibitory effect on rCPE when added in combination in 86Rb release 
experiments.  A 5:1 ratio of TM1:rCPE was required to maximize this effect, giving implications 
that several copies of TM1 must be incorporated into a mostly rCPE oligomer in order to block 
pore formation.  Studies examining the dominant negative effects of TMD mutants of B. 
anthracis protective antigen have demonstrated a similar effects but at much lower variant:wild-
type ratios (147, 178).  It is important to point out, though, that while the 86Rb release 
experiments directly measure pore formation  by CPE, the dominant negative variants of 
protective antigen in these studies are blocked for translocation of unfolded peptides through 
the protective antigen pore and subsequent toxic activity of that translocated peptide (147, 178).  
The dominant negative protective antigen system is probably very sensitive to small distortions 
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of pore conformation, whereas one might imagine that a rCPE oligomer with only 1 or 2 copies 
of TM1 might still partially insert the plasma membrane causing leakage (albeit less efficient) of 
86Rb from cells in this experiment. 
 
4.3.5.1  Inhibition by chain termination 
 
It was very interesting to find that both the D48A point variant of rCPE (generated by Section 3.1 
studies) and the rCPE168-319 fragment (93) were also both dominant negative.  Both of these 
variants dramatically decreased 86Rb release of Caco-2 cells even at a ratio of only 1:1 (Fig 
3.27), and each variant completely inhibited the formation of both CH-1 and CH-2 at the same 
ratio (Fig 3.26).  These effects, particularly in the 86Rb release experiments, seemed to be even 
more severe than the TM1’s dominant negative phenotype.  The potent dominant negative 
phenotypes of D48A and rCPE168-319 were especially interesting because both variants alone 
clearly lack the ability to form CH-1 or CH-2, as seen in Fig. 3.26.  One possible explanation for 
this result is that these variants are inhibitory by chain termination.  Described in detail above 
and in Section 3.1, the NTCCS in CPE is proposed to mediate the protein-protein interactions 
required for oligomerization.  According to this proposal, this region of CPE would need to 
interact with second CPE region to complete this ‘latching’ step.  While the D48A would not be 
able to provide a functional latch for oligomerization, it is possible that D48A can receive a latch 
from a wild-type rCPE monomer alone or one in a growing oligomer.  Since the D48A mutation 
precludes this variant from extending the oligomer, rCPE would be perilously trapped in an 
partial oligomer and thus inactivated. 
Valuable insights regarding the location of a potential latch ‘binding site’ can be gained 
from similar phenotype of the rCPE168-319 fragment of CPE.  Since the large complex 
experiments in Fig. 3.26 indicate that rCPE168-319 is also dominant negative by chain termination, 
this implies that the latch binding site would exist between amino acids 168-319 of CPE.  This 
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finding greatly narrows the search for the this additional functional region in CPE to less than 
half of the protein.  While genetic and biochemical approaches will be required to define a 
region in this CPE fragment functioning as a latch binding site, it is interesting to recount results 
from a recent study of the C-CPE fragment of CPE (Figs. 1.14 & 4.1).  It was determined that 
when amino acids 184-220 were deleted from C-CPE, this smaller fragment could bind claudin 
but was unable to modulate tight junctions and increase intestinal absorption (105).  This result 
seems to assign some functionality to residues 184-220, and represents a reasonable starting 
point in the search for the latch binding site.  
 
 
 
4.4 UPDATING STRUCTURE-FUNCTION RELATIONSHIPS OF CPE 
 
 
Given the contributions of the present study, it is appropriate at this time to consolidate all 
known and putative functional regions of CPE to date.  While the absence of a crystal structure 
adds great difficulty in analyzing precise structure-function relationships, several interesting 
insights can be gained by aligning an updated structure-function map of CPE with a prediction 
of secondary structure elements of the protein, as depicted in Fig. 4.1.  Therefore, what follows 
is a synopsis of the current functional regions CPE, along with consideration given to elements 
of its predicted secondary structure (170). 
 
4.4.1 N-terminal activation region 
 
As described in Section 1.4.2.1, the first ~40 amino acids of CPE have an inhibitory effect on 
activity since truncation of the N-terminus using enzymatic (59, 60, 67) or molecular cloning (93) 
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methods doubles or triples its cytotoxicity.  Analysis of secondary structure predictions reveals a 
large alpha helical structure followed by a unstructured loop section in this location (Fig 4.1).  It 
is likely that this region is inhibitory because is slows or interferes with oligomerization, mediated 
by the adjacent NTCCS.   
 
4.4.2 N-terminal core cytotoxicity sequence 
 
Initially discovered by deletion mutagenesis (93), then fine-mapped by present Section 3.1 
studies (190), this region contains five amino acids essential for the oligomerization of the toxin.  
Of the residues in this region, the aspartic acid at position 48 appears to be absolutely essential 
for formation of the CPE oligomer, whereas aliphatic hydrocarbons chains are preferred at 
position 51.  Interestingly, all the amino acids of the NTCCS appear to be contained in a single 
beta strand (Fig. 4.1).  Despite the proposed comparative functionality with the N-terminal latch 
of S. aureus alpha hemolysin, the latch in this toxin consists of mostly of an unstructured loop 
with N-terminal 5-7 amino acids having slight alpha helical structure (Fig 1.15). 
 
4.4.3 Putative transmembrane domain 
   
As the subject of Section 3.2 studies, amino acids 81-106 are essential for the insertion of the 
CPE oligomer into membranes and the formation of a pore.  Though other potential functions do 
exist (including mediating protein-membrane or protein-protein interactions), it is likely that this 
region serves to form a beta hairpin structure during pore-formation.  According to this model, 
the TMD beta hairpins from six CPE molecules would combine to form a membrane-penetrating 
beta barrel pore.  Detailed above in Section 4.2, the putative TMD appears in this prediction to 
be alpha helical flanked by two beta strands, a pattern shared by both TMDs of perfringolysin O 
(Figs. 4.1 & 4.4). 
 133 
4.4.4 Tight junction modulator region 
 
While the C-CPE fragment of CPE (amino acids 184-319) has been shown to disrupt tight 
junctions and modulate paracellular permeability, the 220-319 fragment of C-CPE lacks this 
specific activity (105).  Thus, amino acids 184-220 have been proposed to be responsible for 
this intestinal absorption enhancement activity.  Secondary structure predictions of CPE project 
a large alpha helical structure between amino acids 190-220 to which the intestinal absorption 
activity could possibly be attributed (Fig. 4.1).  
 
4.4.5 C-terminal binding domain 
 
The 30 C-terminal amino acids of CPE have been conclusively demonstrated to fully contain the 
receptor binding activity of the toxin.  Even a synthetic peptide corresponding to these 30 
residues can compete for CPE-binding, possibly indicating that strict secondary structure 
requirements are probably not present in this domain.  Correlating with this idea is the 
secondary structure predictions that project no dominant structural elements at the C-terminus 
of CPE (Fig. 4.1). 
 
4.4.6 Latch binding site  
 
The identification the NTCCS and proposal that it acts as a latch to join together monomers in 
an oligomer necessitates that separate region of CPE functions to receive this latch.  The 
dominant negative studies highlighted in Section 3.3.5 demostrate that rCPE168-319 fragment of 
CPE can act as a chain terminator, implying that the binding site for the NTCCS latch might 
exist between amino acids 168-319.  While the identification of latch binding site remains to be 
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elucidated, it is nonetheless interesting to consider the alpha helical structure in the 
aforementioned tight junction modulator region as a potential candidate for such a site. 
 
 
 
4.5 UPDATED MODEL FOR THE MOLECULAR MECHANISM OF ACTION OF CPE 
 
 
The structure-function and oligomeric analyses of CPE in the present study has made several 
advances in the understanding of the molecular mechanism of action of CPE.  It is clear from 
these studies that three distinct steps now exist within CPE action.  Found below is a succinct 
description of these steps, each of which is graphically represented in Fig. 4.7. 
 
4.5.1 Step 1 – Receptor binding and formation of the small complex 
 
Mediated by its extreme C-terminus, CPE interacts with the second extracellular loop of 
receptor-claudins located within tight junctions.  Claudins serving as CPE-receptors are likely to 
associate with (or already be associated with) other tight junction proteins, namely, additional 
receptor- or non-receptor claudins.  This collection of proteins results in what has been 
described as the CPE small complex and is sensitive to denaturation with SDS (Fig. 4.7A). 
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4.5.2 Step 2 – Oligomerization of CPE and formation of the pre-pore 
 
Six CPE small complexes self-assemble in an oligomerization event directly involving an 
interaction between the NTCCS latch and a latch binding pocket in C-terminal half of CPE.  This 
association results in the formation of an SDS-resistant hexamer of CPE and contains several 
other copies of claudin (Fig. 4.7B).  The CPE hexamer at this pre-pore stage is not resistant to 
soluble proteases and is subject to dissociation from the membrane as well as heat 
denaturation. 
 
4.5.3 Step 3 – Pore-formation by membrane insertion 
 
Conformational changes in CPE structure allow the coordinated insertion of a TMD from each 
monomer forming a beta barrel pore structure, resulting in the CH-1 complex (Fig. 4.7C).  
Should occludin be present, it may also associate with the CPE hexamer and form the CH-2 
complex (Fig. 4.7D).  Accompanying this insertion event is the protection of this oligomeric 
complex from proteolytic degradation as well the achievement of oligomer stability.  Membrane 
penetration of the CH-1 and CH-2 complexes event permits an intracellular Ca2+  influx, causing 
the beginning of the cytotoxic and enteropathic effects of CPE action. 
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Figure 4.7  Model for the molecular mechanism of action of CPE.  A, Binding of CPE to a receptor claudin 
(dark green) itself already associated with a carrier claudin (light green) results in the formation of the 
small complex.  B, Oligomerization of small complexes mediated by the N-terminal cytotoxicity sequence 
results in the formation of a pre-pore, SDS-resistant hexamer uninserted into the membranes.  C, In the 
absence of occludin, this hexamer (CH-1) penetrates the phospholipid bilayer with a beta barrel formed 
with six TMDs, allowing Ca2+ to penetrate the cell.  D, If occludin is present during membrane insertion, it 
can also associate with this hexamer via an interaction with claudin, also resulting a CPE pore (CH-2). 
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4.6 FUTURE INVESTIGATIONS 
 
 
4.6.1 NTCCS latch and binding site 
 
Both the site-directed mutagenesis study in Section 3.1 and the dominant negative work in 
Section 3.3.4 illustrate that a crucial interaction takes place between the NTCCS of one CPE 
molecule to the latch binding site of a neighboring CPE molecule.  There are several ways in 
which this interaction can be further evaluated.  First, amino acids 184-220 is an appealing 
candidate for the latch binding site for the reasons delineated in Section 4.3.5.1.  Attainment of 
a 220-319 deletion construct either as a gift from Masuyama et al. or by PCR cloning would be 
helpful in this regard (105).  It would be predicted that if this 184-220 region contained the latch 
binding site, the 220-319 fragment would maintain binding activity but would not be dominant 
negative since it cannot receive a latch domain.   
Another way to determine where the NTCCS binds would be to possibly use label-
transfer reagents.  These experiments would involve labeling CPE with a label-transfer tag near 
the NTCCS, then after allowing oligomerization to occur, performing a cross-linking step which 
would transfer the label near the putative latch binding site.  Defining the specific location of 
label transfer could occur via several different methods, however, mass spectrometry of tryptic 
peptides of the oligomers would probably be the most precise method. 
 
4.6.2 Confirming the putative TMD of CPE 
 
Although Section 3.2 studies provide evidence consistent with amino acids 81-106 acting as a 
TMD, more direct analysis must now follow to formerly establish that this region functions as 
predicted.  Section 4.2.2.1.1 highlighted the fluorescence spectroscopic approach that will 
 138 
probably be required to definitively show transmembrane status.  Large initial strides have 
already been made for this strategy, including creating a cysteine-less background construct 
(C186A) and generation of the six Cys-variants V85C, N86C, F87C, E101C, Y102C, G103C.  
As mentioned above, follow-up studies of this strategy will probably have to involve making 
more single cysteine variants as well as better purification techniques to achieve 90-95% purity 
before labeling. 
Another potential method to shown that amino acids 81-106 serve as a transmembrane 
beta hairpin would be to swap this region with a bona fide TMD from another β-PFT.  For 
example, restoring full pore-forming functionality to the TM1 deletion variant by cloning in the 
TMD of S. aureus alpha hemolysin would provide very strong evidence for the proposed 
functionality.  While protein-folding issues may prohibit such an approach, this may be a 
worthwhile alternative should the fluorescence spectroscopy be unfruitful or ambiguous. 
It is also worth mentioning that the second putative TMD of CPE between amino acids 
238-265 could be investigated identically to the first putative TMD.  Initial deletion mutagenesis 
by PCR splicing would rapidly should whether this region is specifically important and whether it 
also would form the pre-pore large complex similar to TM1.  Additionally, fluorescence 
spectroscopy or TMD swapping could also be applied to this region if necessary. 
 
4.6.3 Additional dominant negative analysis 
 
The initial dominant negative studies described in Section 3.3.5 have yielded promising results 
regarding the inhibitive nature of some rCPE variants.  This preliminary work must be followed 
up with more detailed analysis.  For example, it is crucial to determine the extent of which (if 
any) binding inhibition contributes to the dominant negative effect seen by these variants.  While 
it is unlikely that the dramatic inhibitory effects seen in these experiments result merely from 
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binding competition, this needs to be evaluated by performing careful binding competition 
experiments with a labeled toxin (possibly 125I-CPE). 
It would also be interesting to explore the protective effect of a co-incubation with one of 
these dominant negative variants.  The 86Rb release experiments in Section 3.3.5 demonstrate 
that pore formation in Caco-2 cells can be blocked nearly 100% after incubation of only a 1:1 
ratio of rCPE168-319:rCPE.  Perhaps a co-treatment of Caco-2 cells with similar ratios of these two 
toxins would be able to provide extensive protection from morphologic damage.  If such a 
protective effect is offered by co-treatment of rCPE with rCPE168-319, it is conceivable that similar 
co-treatments could inhibit fluid accumulation in the rabbit ileal loop model, thus providing in 
vivo promise for a potential therapeutic for CPE.   
 
4.6.4 Solving the three-dimensional structure of CPE 
 
Impressive strides have recently been made in structure-function analysis of CPE, all in the 
absence of any three-dimensional information.  Nonetheless, having detailed knowledge of 
secondary, tertiary and even quaternary elements of the structure of CPE and/or its oligomer 
would greatly propel investigations of how functional regions of the toxin contribute in the 
mechanism of action.  An ongoing collaboration between our laboratory and Dr. Ajit Basak in the 
Department of Crystallography at Birkbeck College has generated several crystallized forms of 
native CPE as seen in Fig. 4.8.  However, all crystals formed to date they have been either of 
poor quality or of heterogeneous unit cell to generate any meaningful structural information.  
While efforts are currently underway to grow crystals from highly-purified recombinant fragments 
of CPE (such as rCPE168-319), it is critical that work geared towards solving the three-dimensional 
structure of CPE continue and be completed.  This may involve using non-crystallographic 
means to generate structural information (NMR-based structure-mapping), however the end 
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result will greatly increase the pace at which knowledge of structure-function relationships can 
be attained. 
 
 
Figure 4.8  Montage of various crystal morphologies formed by CPE 
(Briggs, D. & Basak, A., unpublished observations).  
 
 141 
4.7 FINAL SUMMATION 
 
 
The research contained within this thesis dissertation has directly built upon previous 
investigations of the mechanism of action of CPE, the causative toxin of C. perfringens type A 
gastrointestinal diseases suffered by hundreds of thousands of people each year.  Investigation 
of a distinct region at the N-terminus of the CPE resulted in identification of specific residues 
involved in toxin oligomerization.  In addition, a novel pre-pore step in the molecular mechanism 
of action was discovered when a second CPE region was deleted that may potentially act as a 
transmembrane domain.  Lastly, examination of the stoichiometry of CPE in its large SDS-
resistant complexes resulted in the discovery that six copies of CPE are found within both of 
these complexes.  Collectively these findings have uncovered new aspects of the mechanism of 
action of CPE and have demanded a reevaluation of molecular interactions that occur between 
CPE, host cell proteins, and the plasma membrane.  Just as this present work has benefited 
greatly from the important studies performed earlier, the contributions here within can (and 
should) be extended to continue answering both fundamental and advanced questions 
regarding the role of CPE in C. perfringens type A gastrointestinal diseases. 
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